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Abstract 
Synthesis of Novel Glycosylidene-Based Quinolines 
Peter H. Dobbelaar 
Doctor of Philosophy in Chemistry 
Seton Hall University 
Dr. Cecilia H. Marzabadi, Advisor 
Carbohydrates and their derivatives are involved in a wide array of biological 
processes and are crucial for the survival of living entities. As a result, sugar-based 
compounds have become attractive scaffolds for drug design. In addition, quinoline 
derivatives have shown promise in the treatment of numerous health conditions such as 
cancer and life-threatening infections and are therefore of interest from a therapeutic 
point of view. Consequently, we desired to prepare molecules that contained 
carbohydrates conjugated to these heterocycles. Such novel sugar-derived quinoline 
compounds were anticipated to have pharmacological activity as anticancer DNA 
intercalating agents. Based upon common structural features, we surmised that they may 
also possess glycosidase inhibitory activity. 
The focal point of our research was to determine a synthetic route for the 
preparation of novel sugar-based quinolines. We have developed a facile, one-pot 
method based upon the Povarov reaction to prepare C-glycosylated quinolines. We have 
determined that this reaction proceeds through sugar-spiroanellated tetrahydroquinoline 
intermediates. These compounds subsequently oxidize and undergo sugar ring opening 
to form the fully aromatized quinolines. Extensive catalyst screening and reaction 
optimization studies were conducted, and NMR experiments have confirmed the 
structures of both the spiro and open-ring sugar-linked quinolines. This one-pot 
methodology has been efficiently employed with several sugar exo-glycals and a series of 
para-substituted benzanilines to prepare novel open-ring, glycosylidene-derived 
quinolines. Deprotection experiments were carried out in order to determine conditions 
to remove the benzyl protective groups. The successful debenzylation chemistry 
demonstrates that this one-pot, scandium triflate-catalyzed Povarov reaction followed by 
manganese dioxide oxidation is an expeditious way to obtain novel C-glysosylated 
quinolines. 
The physiochemical and anticancer properties of several carbon-linked sugar- 
derived quinolines have been assessed. Results from computer calculations lead us to 
predict that the debenzylated compounds should exhibit favorable bioavailability. Some 
of the glucose analogues have been tested in the NCI60 human tumor cell line anticancer 
screen. Although several cell lines experienced modest growth inhibition, the 
glycosylidene-based quinolines do not possess sufXcient anticancer activity to warrant 
dose titration studies. 
xvi 
Chapter 1 
The Properties and Biological Significance of Carbohydrates 
I .  I .  Overview and Historical Perspective 
Carbohydrates are the most abundant biomolecules on Earth. Saccharides and 
their derivatives are involved in a wide array of biological processes and are therefore 
crucial for the survival of living entities. Carbohydrates are a unique family of 
polyfunctional molecules, and the chemistry of these compounds can be enormously 
complex. They exist as monosaccharide building blocks that are linked together in 
almost limitless ways to form oligosaccharides and polysaccharides. Most 
monosaccharides are predominately cyclized polyhydroxy aldehydes and ketones with 
the general formula C,(HzO),. Even the simplest monosaccharides possess multiple 
asymmetric carbons, resulting in a variety of isomers.' Although the stereoisomeric 
diversity and oftentimes problematic chemistry of carbohydrates present numerous 
challenges, their widespread presence in biological systems makes them attractive targets 
for continued research, especially in the field of therapeutics.2 In addition, carbohydrate 
products are utilized in the food, clothing, and agrochemical ind~stries.~ Today a 
renewed focus on carbohydrates is necessary to understand the relevance of the. 
interrelationships among many disciplines of science, including organic chemistry, 
cellular and molecular biology, and biochemistry. 
The significance of carbohydrates has been recognized for hundreds of years, 
dating back to the times of the Persians and Arabians. These ancient civilizations were 
familiar with grape sugar, which centuries later was given its current name, glucose, by 
Dumas in 1838. Despite methodical studies by both Dumas and Kekule, it was the 
pioneering work of the German scientist Emil Fischer in the late 19& and early 20" 
centuries that rapidly advanced the ever-growing field of carbohydrate chemistry.3 
Emil Fischer was the key figure in the development of carbohydrate chemistry 
because he was instrumental in the transformation of the field from a study of syrups and 
gums to an accepted scientific discipline. Fischer established the fundamental 
groundwork that provides the basis of carbohydrate chemistry. He successfully 
elucidated the structure of D-(+)-glucose by utilizing both chemical reactivity 
observations as well as polarimetric methods. Several depictions of the structure of 
glucose4 are illustrated in Figure 1 .O. One such structural representation, the Fischer 
projection, is named in his honor. In recognition of his achievement for the structural 
work surrounding glucose, Fischer was award4 the second Nobel Prize for Chemistry in 
1902.~ 
Figure 1 .O. Structural representations of D-glucose. 
Fischer Projection Haworth Ring 
6 H 2 0 H  a-form p-form 
Chair Perspective 
a-form p-form 
The knowledge associated with the field of carbohydrates has expanded rapidly 
since Fischer's early studies. Other scientists, such as Hudson and Haworth, have also 
made key contributions to this area of chemistry. Prior to the 1970s, carbohydrate 
chemistry was considered to be an isolated field of study practiced by specialists. Since 
that time, this discipline has been mainstreamed into the realm of organic chemistry, and 
many of the resulting developments have been the work of organic chemi~ts.~ 
1.2. Physical and Chemical Properties 
Carbohydrates possess several unique physical and chemical properties that 
differentiate them from other types of organic compounds. One such property is the 
phenomenon of mutarotation, which was first observed by Fischer's students, Deidi and 
Heinz, in 1891 .5 Mutarotation is the change in optical rotation of a monosaccharide 
solution over time as an equilibrium is reached between the cyclic hemiacetal or 
hemiketal form and the linear aldose or ketose containing the free carbonyl group. Six- 
membered cyclic pyranoses and five-membered furanoses usually predominate over their 
linear form counterparts in solution. In addition, cyclic pyranose and furanose anomers 
also exist, and these isomers differ by the configuration of the hydroxyl group at the 
anomeric carbon. Each isomer has its own characteristic optical rotation, and the rotation 
of the solution therefore changes until equilibrium is established between the 
interconverting f o r r n ~ . ~  Figure 1.1 illustrates the process of mutarotation with D- 
glucose.6 
Figure 1.1. Mutarotation of glucose in water at 3 1 OC. 
Another equilibrium process that is characteristic of sugars is the conformational 
conversion of the cyclic ring. Much like cyclohexane, monosaccharides can undergo an 
equilibrium between chair conformations. Figure 1.2 illustrates the process with P-D- 
glucose. The preferred 4~~ conformation has all of the hydroxyl substituents in the 
equitorial position. Upon conversion via a boat conformation, the ' ~ 4  form has all of the 
hydroxyl groups in the axial position. From an energetics perspective, the 4~~ 
conformation is significantly more stable.' However, a stereoselective effect exists that 
causes a heteroatomic substituent to favor the axial orientation instead of the equatorial 
orientation. This tendency for the formation of the a-anomer is known as the anomeric 
effect. This effect, originally noted by ~dward' and later extensively studied by 
~emieux,' virtually ensures that an electronegative atom at the anomeric carbon will take 
the axial position as illustrated in Figure 1.3. Although the anomeric effect has many 
potential theoretical explanations, its influence is important for determining the 
energetics as well as the three-dimensional shape of many polysaccharides. Therefore, 
the anomeric effect impacts both the molecular configuration and biological function of 
sugar derivatives.' 
Figure 1.2. Equilibrium chair conversions of glucose. 
4c1 boat 'c4 
Figure 1.3. Practical illustration of the anomeric effect. 
AcO 
OAC 
AcO 
AcO 
known unknown 
Several monosaccharides are readily obtainable from the environment, but many 
carbohydrates are not available in bulk quantities from natural sources. This requires that 
chemists must turn to synthesis as an alternate means of supply. However, the reactivity 
of the functional groups of carbohydrates renders their synthetic manipulations 
particularly challenging. The free hydroxyl groups help to make the sugar water soluble 
and frequently have an undesired effect on the intended rea~tion.~ As a consequence, 
protecting groups are often introduced to mask particular functionalities during a 
reaction. The use of protective groups is essential to ensure that the desired chemical 
reaction occurs at the desired atom. Commonly, hydroxyl groups are protected as esters 
and acetates as well as benzyl and silyl ethers. The appropriate protecting group is 
usually chosen based upon the subsequent reaction sequence, and includes such 
considerations as sterics, robustness, and removal  condition^.^ The site or location of 
transformation is also an issue that needs to be considered, especially since sugars contain 
numerous stereocenters. Although the utilization of protecting groups is necessary to 
carry out chemistry on carbohydrates, it adds extra steps to the synthetic sequence. 
Common problems associated with protection and deprotection chemistry also include 
additional purifications and the potential for loss of material. As a direct result of the 
challenges posed by both stereochemistry and protection/deprotection chemistry, the 
development of the field of carbohydrate chemistry was slower than other scientific 
disciplines. 
The chemistry of sugars is exceedingly complex, and carbohydrate chemists need 
to evaluate a variety of properties when designing syntheses and conducting structural 
analyses. In addition to potential conformational changes, chemists must carefully 
consider protection strategies to mask hydrophilic hydroxyl groups. Reaction conditions 
must preserve stereochemistry while avoiding epimerization and unwanted side reactions 
such as ring opening events. In addition, carbohydrate chemists have come to realize that 
the three dimensional properties of sugars are essential from a biochemical perspective. 
Modem analytical methods can determine the position and configuration of linkages 
between monosaccharide units while glycosylation chemistry exists to synthesize 
oligosaccharides in a stereoselective manner. These techniques now permit a laboratory 
synthesis that produces the same compound as the natural preparation. This crucial 
development allows for a more systematic study of the biological properties of sugars.6 
1.3. Biological Relevance 
Carbohydrates are a diverse and versatile class of functional natural products, and 
their primary significance is attributed to their major importance in numerous, crucial 
biological functions. Many processes required to maintain life, such as biochemical 
reactions, involve carbohydrates and their derivatives. D-glucose is central to several of 
these pathways. For example, it is the major fuel of most organisms and occupies an 
essential position in both anabolic and catabolic reactions. Glucose is relatively rich in 
energy, and it is a remarkably versatile building block for more complex biomolecules. 
Glucose is the key product of photosynthesis carried out by plants in which energy from 
the sunlight is converted into chemical bonds (Scheme 1 .Oa). It is also the essential 
starting material for respiration, the process by which energy stored in chemical bonds is 
extracted by animals (Scheme 1.0b). These complimentary metabolic pathways required 
for living organisms to sustain life are therefore dependent upon glucose.' 
Scheme 1 .O. Chemical equations for the processes of (a) photosynthesis and (b) 
respiration. 
(a) light + 6H20 + 6C02 - C~H1206 (glucose) + 602 
(b) C6Hj206 (glucose) + 602 - 6H20 + 6C02 + energy 
In addition to catabolic processes that break down compounds, glucose is also 
involved in anabolic pathways responsible for the synthesis of important biomolecules. 
For instance, glucose may be stored as sucrose 1 or more complex polysaccharides in 
both higher plants and animals (Figure 1.4)' Sucrose, commonly known as table sugar, 
is the most abundant disaccharide in the biological world.1° Starch, a mixture of the a- 
amylose 2 and amylopectin 3 polysaccharides, is used in plants for energy storage and is 
concentrated in roots, tubers, rhizomes, fruits, and seeds. Glycogen 4 is a non-linear 
polymer of D-glucose that is the mammalian counterpart to starch. It is primarily stored 
in the muscle and liver.' Compounds such as sucrose, starch, and glycogen are examples 
of abundant energy storage carbohydrates, and their widespread presence in nature 
indicates that glucose storage is an important strategy for both plants and animals. 
Figure 1.4. Glucose-based storage carbohydrates. 
HO HO 
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The regulation of blood glucose levels in humans is a significant physiological 
process required to properly maintain carbohydrate homeostasis. In addition to its role as 
the principle source of energy for the cells and tissues of the body, glucose is also the 
primary energy source for the brain. The human body is dependent upon glucose 
availability for both physical and psychological processes. The uptake of glucose from 
the blood is regulated by the hormone insulin. This polypeptide is produced by 
pancreatic p-cells and is released into the bloodstream in response to rising glucose 
concentrations. Insulin also triggers the conversion of glucose into the polysaccharide 
glycogen. Glucagon is a polypeptide hormone produced by the a-cells of the pancreas, 
and it acts in a manner opposite to that of insulin. When low blood concentrations of 
glucose and insulin are detected, glucagon stimulates hepatic glucose output via the 
breakdown of glycogen. An individual's inability to regulate glucose levels may result in 
diabetes mellitus, a globally prevalent health condition. Diabetes is a chronic metabolic 
disorder characterized by high blood glucose levels, and it is usually the result of 
defective insulin secretion or function. Both insulin and glucagon hold crucial functions 
as hormones involved in feedback loops responsible for the regulation of glucose in the 
bloodstream through the modulation of its metabolic pathways.' 
Aside from their involvement in energetic pathways necessary for the 
maintenance of homeostasis in living entities, carbohydrates also play a key role in 
providing structural support for viable organisms (Figure 1 S). For instance, cellulose 5 
is the main component of the cell wall of plants and is the most abundant polymer on 
Earth. Cellulose is a linear polysaccharide that consists of D-glucose units joined by P- 
1,4-glycoside bonds. Although humans do not have the enzyme required for the 
digestion of cellulose, many bacteria have the P-glycosidases necessary to break down 
the cellulose in wood and other plant material. Chitin 6, on the other hand, is the 
cellulose of the animal world. Chitin is a polymer of N-acetyl-D-glucosamine that is 
present in the hard exoskeletons of insects, the shells of crustaceans, and the cell walls of 
many mushrooms. The cell wall of many bacteria consists of murein 7, an aminosugar 
polymer commonly called peptidoglycan. It contains N-acetyl-D-glucosamine and N- 
acetyl-D-muraminic acid polysaccharide units cross-linked by short peptide chains. In 
multicellular animals, the extracellular matrix holds together cells and provides a medium 
for the diffusion of substances. It is composed of an interlocking network of 
heteropolysaccharides known as glycosaminoglycans. Hyaluronic acid 8 is a key 
component of the extracellular matrix as well as cartilage and tendons6 From these 
examples, it is apparent that many organisms synthesize functional carbohydrate-based 
polymers not only to provide structural support, but also to create a barrier from the 
external environment. 
Figure 1.5. Repeating units of polysaccharide polymers used by organisms for structural 
support. 
~ ~ ~ ~ o ~ o & o i  HO HO HO %-o&o&oy- HO NHAc HO NHAc 
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Sugars are also key structural components of nucleic acids, a class of 
biomolecules that serve to carry out a diverse set of functions in the cell. These 
nucleotide polymers consist of three types of monomer units: a pentose sugar, a 
phosphoric acid functionality component, and a heterocyclic aromatic amine base derived 
from either purine or pyrimidine (Figure 1.6a). The sugar for deoxyribonucleic acids 
(DNA) is 2-deoxy-D-ribose 9 while D-ribose 10 is the sugar for ribonucleic acids (RNA) 
(Figure 1.6b). DNA is the biopolymer that functions as the carrier of genetic 
information, and messenger RNA is the intermediate that conveys this coded genetic 
information from DNA to the ribosomes for protein synthesis. In addition, nucleotides 
also are incorporated into enzyme cofactors, serve as cellular secondary messengers, and 
store chemical energy in the form of adenosine triphosphate (ATP).' There is 
considerable overlap in both the roles and functions of the different classes of 
biomolecules, as sugars are integrated into the structure of nucleic acids which are, in 
turn, directly linked to proteins. 
Figure 1.6. Structural representations of (a) a generic nucleotide and (b) nucleotide 
sugars. 
R = H o r O H  
X = aromatic base 
Many carbohydrates in the cell are covalently bound to a protein or lipid, and 
these carbohydrate containing biomolecules are located primarily on the cell surfaces. 
Such hydrid molecules, known as glycoconjugates, are the subject of a field of study now 
referred to as glycobiology. The importance of glycobiology has been established only in 
the last quarter century after scientists have studied the role that these molecules play in 
cellular processes. However, glycobiology has quickly become an active and exciting 
area of biochemistry, despite the fact that the biological advantages to linking 
oligosaccharides to proteins and lipids are still not fully understood. Although many 
theories have been proposed, it is evident that oligosaccharides mediate specific events 
and modulate biological processes." 
Glycoproteins and glycolipids are crucial to a variety of diverse roles, including 
cell signal transduction, cellular recognition, and the initiation of both bacterial and viral 
infections. For instance, oligosaccharide labels on glycoconjugates influence levels of 
circulating hormones and blood cells as well as the rate of peptide hormone degradation.' 
Many cell surface and extracellular proteins contain oligosaccharides that are recognized 
by lectins. These plasma membrane lectins, commonly referred to as selectins, bind to 
carbohydrate chains in the extracellular matrix or on the surface of other cells in order to 
mediate recognition, communication, and adhesion. In addition, the binding of both 
bacterial and viral pathogens to their desired cellular targets occurs via lectins.I2 This is 
true for such pathogens as Vibrio cholera and Bordetellapertussis. The sugar coatings of 
plasma membrane bound proteins are for self-recognition purposes, and they act as 
biochemical markers, or antigenic determinants, in the blood group substances. The 
lipopolysaccharides on the outer membranes of Escherichia coli and Salmonella 
typhimurium are the targets of the vertebrate immune system in response to bacterial 
infections.' These diverse and varied examples indicate that organisms are reliant upon 
oligosaccharides and glycoconjugates to conduct the essential cellular processes of 
recognition, adhesion, and communication. 
The growing appreciation for the importance of oligosaccharides and their 
derivatives has resulted in a vast amount of information that suggests they are involved in 
processes that are both trivial and crucial for the survival of organisms. Carbohydrate 
functions include energy regulation and homeostasis, structural support, and cellular 
communication. These important findings have led to the elucidation of biosynthetic 
reactions and enzyme control mechanisms. Numerous fundamental discoveries by 
primary investigators have resulted in many significant developments in medicinal 
chemistry. As the roles that carbohydrates play in biological processes and diseases 
become better understood, tremendous opportunities exist for the development of new 
carbohydrate therapeutics." Areas of focus include, but are not limited to, bacterial and 
viral infections, cancer, immunity, and metabolic disorders such as diabetes and 
obesity.'' 
1.4. Therapeutic Applications 
The pharmacokinetic properties of absorption, distribution, biotransformation, and 
excretion are important areas of focus in the field of drug discovery, especially when 
dealing with sugar-based compounds.14 Incorporation of a sugar moiety onto a drug 
candidate often impacts the compound's physiochemical properties.'5 Futhermore, many 
natural products, including those with a saccharide moiety, can typically be modified into 
drug-like molecules with favorable absorption and metabolic properties. In fact, the 
biological prevalence and favorable bioavailability of carbohydrates make stable sugar 
derivatives attractive scaffolds for drug design2 
The ability to generate structure activity relationship (SAR) data while balancing 
stability, solubility, molecular weight, lipophilicity, and metabolism is extremely 
important in the hit to lead process. Although high throughput methodology and 
combinatorial libraries hold many advantages for drug discovery, natural product 
modification has the potential to provide improved structural diversity. Often, sugar- 
based compounds have enhanced activity against the specified target. In many cases, this 
can be attributed to structural similarities to endogenous ligands, especially if the ligand 
possesses a carbohydrate moiety.' Therefore, molecules with a carbohydrate scaffold are 
excellent targets for new chemical entities with potentially favorable pharmacological 
properties. 
A variety of natural products and derivatives of natural products that contain a 
carbohydrate moiety have shown utility in the treatment of human medical conditions. 
Several therapeutically beneficial compounds (Figure 1.7) can be classified as derivatives 
of structurally simple carbohydrates. For instance, one such example is the physiological 
antioxidant, ascorbic acid 11. This monosaccharide, also known as vitamin C, is an 
important dietary supplement that is necessary to prevent the deficiency syndrome 
scurvy.16 The sulfamate substituted monosaccharide, topiramate 12, is a structurally 
distinct antiepileptic that is also used to treat migraine headaches.I7 Yet another 
illustration of a structurally simple carbohydrate-based therapeutic compound is the 
synthetic disaccharide, lactulose 13. This compound is composed of lactose and glucose 
and has been used as a treatment for both hepatic coma and chronic c~ns t i~a t ion .~  
Figure 1.7. Several carbohydrate-based therapeutics. 
Natural products that contain a carbohydrate component also serve as important 
antibiotics. Macrolide antibiotics (Figure I .@,  produced as secondary metabolites of soil 
microorganisms, are polyfunctional molecules that contain at least one aminosugar. The 
natural product erythromycin 14 is one of the first known macrolides and has been an 
effective treatment for a variety of bacterial infections." The semisynthetic macrolide 
clarithromycin 15 is a well-tolerated derivative of erythromycin that exhibits similar 
activity against pathogenic bacteria.I9 These representative macrolides are just a 
sampling of the diversity of carbohydrate-based antibiotics and illustrate the potential 
benefit of natural product modification. Other examples of antibiotic classes that consist 
of a carbohydrate-based scaffold include aminoglycosamides, avermectins, and analogues 
of streptomycin.13 
Figure 1.8. Macrolide antibiotics. 
Carbohydrate-based natural products and their synthetic derivatives are also 
useful in the treatment of potentially fatal diseases such as cancer and HIV (Figure 1.9). 
Streptozocin 16 is a glucose derivative isolated from the fermentation broth of 
Streptomyces achromogenes. This compound is an antineoplastic and diabetogenic 
agent.'' Azidothymidine 17, commonly referred to as AZT, is a pyrimidine nucleoside 
analogue. This synthetic pentose derivative is a reverse transcriptase inhibitor that is 
prescribed as an antiretrovira~.~' The functional specialization of these and other 
biologically active carbohydrate derivatives has brought about improved treatments for 
both cancer and life-threatening viral infections. 
Figure 1.9. Anticancer and antiviral carbohydrate-based drugs. 
Carbohydrate-based therapeutics are well known for their ability to successfully 
treat human disease. The provided examples illustrate the fact that carbohydrate 
derivatives possess the biological activity as well as the pharmacokinetic properties 
necessary to be beneficial drugs. The study of natural products and their synthetic 
derivatives has been crucial for the development of novel antibacterial, antiviral, and 
anticancer agents. Sugar-based compounds must be utilized in the exploitation of both 
new and existing targets in order to discover future novel medicines. 
1.5. Glycosidase Inhibitors 
Perhaps one of the most promising areas of research involving carbohydrates is 
the study of glycosidase inhibitors. Both pharmaceutical companies and academic 
laboratories have recognized the importance of glycosidase inhibitors because of their 
biological relevance. Glycosidases are enzymes which catalyze glycosidic bond 
hydrolysis (Figure 1 .lo). A glycoside bond is a covalent linkage between two 
monosaccharide units that results in the formation of an acetal from the hemiacetal of one 
sugar and the hydroxyl group of another sugar molecule.' Currently there are more than 
2,000 identified glycoside hydrolases which are classified into 97 different fa mi lie^.^' 
The sheer number of presently known glycosidases indicates that these enzymes impact 
numerous, crucial biological functions and thus warrant further study. 
Figure 1 .lo. Generic illustration of the activity of a glycosidase enzyme. 
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Glycosidases are central to a wide variety of biological anabolic and catabolic 
processes, such as digestion, the synthesis of glycoproteins, the catabolism of 
glycoconjugates, quality control of the endoplasmic reticulum (ER), and ER-associated 
degradation of glycoproteins. The blockade or modulation of these functions may prove 
beneficial from a therapeutic point of view.23 Small molecules designed as reversible or 
irreversible inhibitors could slow down or prevent glycoside bond hydrolysis and thus 
modify a specific biochemical process. Potent synthetic glycosidase inhibitors show 
promise as fungicides and insecticides in the agricultural industry. Successfully designed 
inhibitors have the potential to treat numerous metabolic and genetic disorders such as 
diabetes, obesity, and lysosomal storage diseases. They can also be used as therapeutic 
agents for cancer as well as viral, bacterial, and fungal  infection^.'^ 
~ l l o s a m i d i n ~ ~  18 and trehazolinZ6 19 (Figure 1 . l  1) are both heterocycle bearing 
carbohydrates with strong inhibitory activity toward chitinases. These compounds are 
capable of inhibiting the biosynthesis of the polysaccharide chitin and have been utilized 
as agricultural insecticides and fungicides. The inhibitory activity of these compounds 
has been correlated with their ability to mimic the glycoside hydrolysis transition state. 
In addition, the heterocycle portion of the molecule aids in the binding process through 
hydrogen bonding to amino acid residues within the active site of the enzyme pocket. 
Studies surrounding both allosamidin and trehazolin demonstrate that the disruption of 
chitin biosynthesis can have profound biological effects." 
Figure 1.1 1. Carbohydrate-based glycosidase inhibitors. 
Many potent glycosidase inhibitors are classified as azasugars (Figure 1.12), a 
group of carbohydrate derivatives in which the ring oxygen is replaced by nitrogen. This 
class of polybydroxypiperdines and polyhydroxypyrrolidines is represented by 
compounds derived from nojirimycinZ8 20 and its close analogue, the reduced form, 1- 
deo~ynoj i r im~cin~~ 21. Other related derivatives such as deoxyfuconojirimycin30 22 and 
a-homofuconojirimycin3' 23 are highly potent fucosidase inhibitors that are implicated in 
disruption of N-glycoprotein processing.32 These targets may be exploited for the 
treatment of HIV infection. Swainsonine 24 is an a-D-mannosidase inhibitor with 
antineoplastic activity.33 A similar compound, castanospermine 25, is an a- and P- 
glucosidase inhibitor with antiviral activity.34 This group of naturally occurring and 
synthetically modified azasugars shows further potential as an important category of 
carbohydrate-based therapeutics. 
Figure 1.12. Azasugar glycosidase inhibitors. 
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Virtually all living organisms have the need to break down complex sugars. In 
addition to polysaccharide digestion, glycoside hydrolases are involved in a plethora of 
biomolecule modification processes. Many potent natural product derivatives that 
contain a carbohydrate scaffold are known to inhibit these enzymes. As a result of their 
biological importance and potential to treat diseases, the study of carbohydrate-based 
glycosidase inhibitors has emerged as an important area of research. 
1.6. Industrial Importance of Carbohydrates 
The study of carbohydrates is required for many disciplines other than for the 
purpose of developing new therapeutics. One such area is human nutrition and its 
application to the agricultural industry. Carbohydrates are one of the most important 
energy providers among the macronutrients. Foods high in starch include breads, pastas, 
beans, potatoes, and cereals.' Carbohydrates therefore comprise an important dietary 
staple and are essential for the maintenance of human health through proper nutrition. 
Other industries with a substantial economic impact are also reliant upon 
chemical processes involving carbohydrates as the precursors to commercial products. 
The textile and paper industries, for instance, are two examples that are heavily based on 
the glucosederived polysaccharide, cellulose. Textiles, which are used to make clothing 
and other garments, utilize cotton as the essential natural product starting material. The 
cellulose of the cotton is chemically modified to form both rayon and acetate rayon. In 
addition, the papermaking process, which dates back to 2nd century China, also makes use 
of carbohydrate plant material. In the pulping process, the lignin is separated from the 
cellulose fibers. These fibers then undergo further chemical treatments to make paper.'0 
Clearly carbohydrate natural products play an important part in fulfilling many basic 
needs in everyday society, and continued research is necessary to ensure that the 
industrial processes are efficient and sustainable. 
Carbohydrates comprise the most common class of biomolecules found in nature. 
The word carbohydrate is derived from the observation that simple sugars are hydrates of 
the element carbon, and the term now encompasses monosaccharides, oligosaccharides, 
and polysaccharides as well as their derivatives. Multiple stereocenters and numerous 
functional groups make carbohydrates a diverse class of structurally unique compounds. 
The primary significance of carbohydrates lies in their major functional importance in 
biological entities. Glucose is a biologically prominent monosaccharide involved in 
energetic as well as metabolic pathways. One of the most influential discoveries 
surrounding carbohydrates is the relevance of glycoconjugates. All organisms, ranging 
from primitive unicellular microbes to complex mammals, depend on carbohydrates and 
glycoconjugates to maintain life. 
The previous underestimation of the biological significance of carbohydrates 
initially resulted in a lack of research attention. Progress in understanding the 
relationship between carbohydrate structure and function has been slow in comparison to 
other classes of biomolecules because the synthesis of carbohydrates for biochemical 
studies is problematic. In particular, synthetic carbohydrate chemistry is challenging due 
to issues involving stereochemistry as well as the selective protection and deprotection of 
saccharide building blocks. Despite these difficulties, carbohydrates are now known to 
be a diverse class of compounds with numerous functions that have far-reaching 
biological implications. The recent substantial interest in sugars has marked the start of 
increased exploration of carbohydrate drug candidates as therapeutics for a wide array of 
medical conditions. Both simple and complex carbohydrates have shown promise to treat 
human diseases such as cancer, diabetes, and infections. In addition to therapeutics, 
carbohydrates have a firm footing in the agricultural, clothing, and paper industries, and 
our modem society is heavily dependent upon carbohydrate-derived products. As a result 
of the prevalence and documented importance of carbohydrates, there is a significant 
future for basic research involving carbohydrates. 
Chapter 2 
Synthesis of Glycosylidene-Based Quinolines 
2.1. Introduction 
The significance of carbohydrates in the maintenance of homeostasis cannot be 
overstated, and the biological roles played by carbohydrates in living systems are too 
important to be neglected. Although numerous prescription medicines are available for 
the treatment of human diseases, medicinal chemists are continuously searching for 
compounds with improved efficacy. In addition, stable sugar derivatives have become 
attractive scaffolds for drug design due to their favorable pharmacokinetic properties. 
Natural product derivitization remains a viable drug discovery strategy, and a potentially 
promising target to exploit is the class of enzymes known as glycosidases. Several 
effective prescription medications are classified as sugar-based glycosidase inhibitors. 
For instance, the azasugar miglito135 26 is an inhibitor of a-glucosidase, and the carba- 
oligosaccharide, a c a r b o ~ e ~ ~  27, is an excellent inhibitor of a-amylase. Both of these 
carbohydrate-based glycosidase inhibitors (Figure 2.0) have successfully made it to 
market as approved therapies for the management of diabetes. Such examples illustrate 
the potential that sugar-derived compounds hold for the improvement of human health. 
Figure 2.0. Carbohydrate-based diabetes drugs. 
A survey of the structures of known glycosidase inhibitors indicates that many of 
these molecules possess both a carbohydrate moiety and an aromatic heterocycle. In 
numerous examples, the heterocycle is linked to the anomeric carbon in some manner 
(Figure 2.1). For instance, the spiro-compound, (+)-hydantocidin37 28, has generated 
substantial interest due to its activity as a herbicide. Modification of this structurally 
unusual spironucleoside has resulted in D-glucopyranosylidene-spiro-hydantocidin 
analogues.38 The glucose-based hydantocidin 29 possesses potent inhibitory activity 
towards muscle glycogen phosphorylase. The thio analogue 30 is also a potent inhibitor 
of glycogen phosphorylases a and b from both muscle and liver. These glycosylidene- 
spiro heterocycles have been the subject of research attention due to their biological 
activities and unique structures. 
Figure 2.1. Examples of carbohydrate-spiro heterocycles with glycosidase inhibitory 
activity. 
In addition to carbohydrates with spiro-heterocycles, numerous saccharides that 
contain a fused or C-linked heterocycle have also been characterized as glycosidase 
inhibitors (Figure 2.2). A common motif of monosaccharide derivatives 31'~, 3240, and 
3341 is an imidazole ring fused to the sugar. Imidazolyl C-glucopyranosides 34,35, and 
36 are also carbohydrate-linked heterocycles that inhibit glycoside hydrolases.42 These 
compounds illustrate the common theme that many glycosidase inhibitors are sugar-based 
heterocycles. In addition, this sampling of compounds, when evaluated in combination 
with the spiro examples, helps to indicate the observation that strategies within nature are 
conservative and structural patterns are often repeated. 
Figure 2.2. Examples of carbohydrate-fused or C-linked heterocycles with glycosidase 
inhibitory activity. 
Aside from imidazole rings, other heteroaromatics are widely distributed among 
natural products and their synthetic derivatives. For instance, one such example is the 
class of compounds derived from quinoline 37 (Figure 2.3). Structurally, quinoline 
consists of a benzene ring hsed to a pyridine ring. The synthesis of quinolines and their 
substituted derivatives has been a subject of great importance in the field of organic 
chemistry. Numerous preparative methods for the formation of quinolines have been 
determined since the late 1880s. Some of the most popular and widely used name 
reactions to synthesize quinolines include: (a) Camps synthesis; (b) Combes synthesis; 
(c) Doebner-Miller reaction; (d) Friedlander synthesis; (e) Knorr synthesis; (0 
Niementowski reaction; (g) Pfitzinger reaction; (h) Pomeranz-Fritsch reaction; (i) Pictet- 
Spengler synthesis; 6)  Riehm synthesis; and (k) Skraup rea~t ion.~ These well-known 
examples of quinoline preparations indicate that the synthesis of this hnctional group has 
been a critical objective for chemists. 
Figure 2.3. Structural representation of quinoline. 
Developments in the area of quinoline chemistry are also due, in part, to the 
biological activities of their  derivative^.^^ Accordingly, this group of compounds is of 
interest fiom a therapeutic point of view. This structural class includes fluoroquinolone 
antibiotics such as ~i~rofloxacin" 38 and antitumor alkaloids related to ~ t r e ~ t o n i g r i n ~ ~  39 
(Figure 2.4). In fact, many compounds containing a quinoline ring have the ability to 
bind to DNA. The planar aromatic system enables binding by insertion between the 
DNA base pairs. Such intercalating agents often possess anticancer properties.46 Other 
therapeutic areas in which quinoline derivatives have shown promising activity include 
asthma?' Alzheimers' disease>* and AIDS.~' 
Figure 2.4. Medicinally significant quinoline-based compounds. 
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A number of quinoline alkaloid natural products and their derivatives have 
displayed cytotoxic activity. Planar aromatic heterocycles function as intercalating 
antitumor agents by forming a ternary cleavable complex with DNA and various DNA 
polymerases such as t~~o i somerases .~~  Intercalators are among some of the most 
important compounds that reversibly interact with the double helix of DNA. Currently, 
intercalation is thought to be the binding model of choice for planar aromatics with a 
sufficiently large area and favorable steric properties.51 In particular, compounds such as 
the Stauranthus quinoline alkaloids stauranthine 40 and skimmianine 41 were shown to 
interactively dock consistently into DNA (Figure 2.5). Molecular modeling studies 
suggest that the docked orientations are electronically and energetically favorable. These 
theoretical experiments provide further validation for the potential of quinolines as DNA 
intercalat~rs.~~ 
Figure 2.5. Stauranthus quinoline alkaloids. 
A study has recently been published in which Li and colleagues synthesized and 
evaluated quinoline-glucose hybrids as potential DNA intercalators. Specifically, these 
compounds were designed to be bisintercalators because higher DNA binding capacity, 
slower dissociation rate, and improved sequence selectivity can be achieved when 
multiple intercalating functionalities are included in a ligand. Carbohydrate-derived 
quinolines 42 and 43 are examples of synthetic hydrids in which quinoline is linked to the 
sugar's C6 hydroxyl group (Figure 2.6). Preliminary binding assays suggest that these 
compounds could bind to calf-thymus DNA through intercalation. In addition, both 42 
and 43 exhibited moderate cytotoxicity against human breast cancer cell lines. While it is 
hypothesized that the quinoline groups are intercalating with the DNA, the researchers 
suggested that glucose groups may also help to regulate the interaction between the 
compound and the DNA duplex.s3 This study on quinoline-glucose hydrids fiuther 
reinforces the potential application of glucose-derived heterocycles as DNA intercalators. 
Figure 2.6. Quinoline-glucose hybrids evaluated as DNA intercalators. 
The observation that many small carbohydrate-based aromatics possess activity 
against a variety of targets sparked our synthetic interest in this area. We desired to make 
glucose derivatives with a quinoline heterocycle linked to the sugar's anomeric carbon. 
We felt that glucose was an ideal choice for the sugar scaffold due to its role as a 
monomer in complex polysaccharides as well as its documented importance in numerous 
biological pathways. Quinoline was selected as the heterocycle portion of the molecule 
because of the biological activity associated with this functionality. Heteroaromatics 
such as quinolines serve as bioisosteres for other substituents and can often improve upon 
biological activity and metabolic properties of the resulting compound.2 We theorized 
that combining these structural motifs and incorporating both a sugar and aromatic 
heterocycle would provide for a stable compound. Furthermore, if the quinoline and 
sugar were appended via carbon-carbon bonds (rather than carbon-oxygen bonds), this 
would impart an additional measure of stability to the molecule from endogenous 
glycosidases in the body. We also hypothesized that incorporation of a sugar would not 
only facilitate drug delivery, but may also aid in the DNA intercalation process as well. 
We surmised that the sugar moiety could help to stabilize DNA binding by interacting 
with the sugar-phosphate backbone once the quinoline has come in contact with the 
DNA. 
Carbohydrates and their derivatives are crucial for the survival of living entities 
because of their integral involvement in life sustaining processes. As a result of the 
biological prevalence and bioavailability of carbohydrates, stable sugar derivatives 
present themselves as potentially favorable platforms for drug design. In fact, 
monosaccharides have long been known as biologically relevant scaffolds.* Despite the 
volume of literature published on carbohydrate derivatives, it is surprising to note that no 
groups have cited examples of synthetic glycosylidene-spiro aromatic heterocycles. In 
addition, carbohydrate-derived quinolines represent a unique and potentially beneficial 
class of compounds. We feel that these novel types of glycosylidene-based heterocycles 
are particularly valuable targets. This project is worthy of study because it creates the 
opportunity for us to develop and apply some new synthetic methodology. We surmise 
that compounds with this novel structural motif can be accessed through a variation of the 
Povarov reaction with an exo-glycal. In addition, we predict that some of these 
compounds may possess pharmacological activity. The structural motifs of both a 
carbohydrate moiety and a heterocycle are prevalent throughout biological systems, and 
our proposed targets combine these common themes associated with some antitumor 
DNA intercalating agents as well as glycosidase inhibitors. Finally, we anticipate that 
our synthetic sugar derivatives also have the potential to act as antiviral, antifungal, or 
antibacterial agents. 
2.2. Background 
a. Glycals and Spiroanellation Chemistry 
Glycals are cyclic vinyl ether derivatives of sugars that contain a double bond 
between carbon atoms 1 and 2 of the ring (Figure 2.7). These 1,2 unsaturated sugars are 
either commercially available or easily prepared from 1-halogeno sugars. Manipulations 
of this double bond have been utilized in many syntheses, thereby making glycals useful 
starting materials. Addition reactions have been employed in the preparation of 
carbohydrate-based compounds, including fused heterocycles. A survey of the current 
scientific literature pertaining to the chemistry of glycals indicates that some of these 
synthetic strategies may prove useful when applied to sugars with double bonds at other 
positions of the molecule.54 
Figure 2.7. Structural representation of a generic glycal. 
glycal = 1,2 unsaturated sugar 
An example of glycal chemistry involving a heterocyclic fused sugar system is 
illustrated by the work carried out by Professor Knapp and colleagues. His group 
attempted the synthesis of carbohydrate-fused thiazoline derivatives through the use of a 
protected glycal (Scheme 2.0). Their work with galactal derivative 44 ultimately led to 
the synthesis of thiazoline 46 through azido intermediate 45.55 However, the cyclization 
step was problematic and subject to side reactions. In addition to these shortcomings, the 
reaction sequence was lengthy. Other approaches by Knapp have resulted in the 
preparation of heterocyclic products that were limited to substituted thiaz~l ines .~~ 
Scheme 2.0. Knapp's approach toward carbohydrate-fused thiazolines. 
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Upon careful review of the procedures utilized by Knapp and colleagues, the 
research group of Professor Marzabadi became interested in developing a general method 
which would not limit the type of heterocycle fused to the monosaccharide. Marzabadi 
and DeCastro predicted that carbohydrate-fused heterocycles could be accessed from 2- 
i ~ d o - ~ l ~ c o s ~ l a m i d e s . ~ ~  Th y revisited the haloglycosylation chemistry developed by 
~emieux" and   hi em:^ and ultimately applied the principle of alkoxyhalogenation to 
glycal47 in the synthesis of trans-diaxial iodo-glycosylamide 48 (Scheme 2.1). This 
intermediate was then cyclized under basic conditions to form fused heterocycle 49.60 
DeCastro and Marzabadi's efforts have resulted in the preparation of a series of 
heterocycles, and this approach also succeeded in the synthesis of selected urea 
oxazolines and thiazolines. A major advantage of this chemistry is that it is general 
enough to allow for the synthesis of both oxazolines and thiazolines." These 
heterocycles are accessible in two steps from protected glycals. In comparison, Knapp's 
chemistry permits substituted thiazolines only. DeCastro and Marzabadi's novel 
approach to carbohydrate-fused heterocycles is a general strategy that is more 
streamlined than Knapp's synthetic sequence. 
Scheme 2.1. DeCastro and Marzabadi's synthesis of oxazoline-fused carbohydrates. 
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In addition to carbohydrate-fused heterocycles, the Marzabadi group has also 
focused on cyclopropanated carbohydrate derivatives. Talisman and Marzabadi have 
synthesized a series of compounds based on glycal addition chemistry (Scheme 2.2). 
Specifically, carboethoxy cyclopropanated carbohydrate 51 was accessed through the 
reaction of 1,2 unsaturated glycal50 with a rhodium-derived carboxy carbene. 
Additional transformations further functionalized this carboethoxy derivative, and similar 
chemistry was applied to synthesize carbomethoxy cyclopropanated carbohydrates as 
we1L6' This route marks another application of the strategy of glycal addition in the 
synthesis of carbohydrate-based derivatives. 
Scheme 2.2. Talisman and Marzabadi's synthesis of carboethoxy cyclopropanated 
carbohydrates. 
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The synthetic studies surrounding glycosylidene-spiroanellated heterocycles were 
of particular interest to us because relatively few published examples targeting spiro- 
heterocycles exist. Somsak, Osz, and colleagues have described the synthesis of a 
pyranose ring version of 2-thiohydmtocidin 54 (Scheme 2.3). The 1,l-disubstituted 
glycosyl compound 52 was the key intermediate in the synthesis. Displacement of the 
bromo group with the thiocyanate ion followed by ring closure of 53 yielded the desired 
spiro compound 54.62 The group further elaborated upon this strategy of cyclizing 1,l- 
disubstituted glycosyl derivatives, and they successfully synthesized several 
glycosylidene-spiroanellated-thiazolidene and -thiazoline analogues.63 
Scheme 2.3. Somsak's synthesis of an analogue of 2-thiohydantocidin. 
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Gasch and colleagues have also verfied that isothiocyanato sugar derivatives have 
proven useful in the synthesis of both furanoid spiro-nucleosides of oxazolidine-2-thiones 
and oxazinane-2-thiones (Scheme 2.4). In the case of spirooxazolidine-2-thiones, the 
resulting isothiocyanate intermediate 56 spontaneously cyclizes to give isomeric products 
57 and 58. However, base-catalyzed intramolecular cycloaddition of the isothiocyanates 
59 and 60 is required to obtain spirooxazines 61 and 62, respectively. A similar reaction 
sequence has been utilized to access the pyranose analogues of these spiroanellated 
heterocycles." 
Scheme 2.4. Synthesis of furanoid spironucleosides of oxazolidine-2-thiones and 
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Although several research groups have synthesized glycosylidene-spiroanellated 
heterocycles, no published examples have been reported that include aromatic 
heterocycles. In addition, the sequences to access these spiro-heterocycles are rather 
lengthy and involve difficult chemistry. We desired to work in the area of glucose- 
derived spiro-aromatic heterocycles, with the goal of synthesizing novel compounds 
through the development of a facile synthetic sequence. Given the Marzabadi group's 
reliance on glycals as essential starting materials, we surmised that exo-glycals may 
prove useful for the project. exo-Glycals can be classified as C-glycosylidenes that are 
olefinic sugars with an exo-cyclic double bond at the anomeric center (Figure 2.8). 
Specifically, the exo-glycal double bond is a highly reactive functional group due to the 
presence of the ring oxygen substi t~ent.~~ We decided to exploit the reactivity of the 
olefinic system, and we therefore embarked upon the development of a general strategy 
to synthesize sugar-based quinolines. 
Figwe 2.8. Comparison of generic endo- and exo-glycals. 
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b. Synthesis of Quinolines Via the Povarov Reaction 
Despite the multitude of publications covering quinolines, we chose to focus our 
work on applications of the Povarov reaction. We hypothesized that a variation of the 
Povarov reaction could allow us access to glycosylidene-spiroanellated quinolines. In the 
1960s, Povarov and colleagues described an addition reaction between an aromatic Schiff 
base and activated alkene to give tetrahydroquinolines65 (Scheme 2.5). This type of 
cyclization reaction has also been referred to in the scientific literature as the aza-Diels- 
Alder reaction as well as the imino-Diels-Alder reaction. Electron-rich vinyl ethers or 
alkyl vinyl sulfides are the activated alkenes (dienophiles) that react with derivatives of 
benzaniline (dienes). The original Lewis acid catalyst for the transformation was 
BF3-Et20 while the solvent of choice was benzene. Povarov and colleagues also reported 
that these tetrahydroquinoline products could subsequently be oxidized to the 
corresponding fully aromatized dihydroquinolines with the elimination of the alkoxy or 
alkyl sulfide group. 
Scheme 2.5. Generalized Povarov reaction sequence. 
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Despite only modest yields at best, interest in the Povarov reaction was rekindled 
in the 1990s. A critical objective for the advancement of this reactions's utility was the 
determination of conditions leading to increased reaction yields. Recent publications 
have documented the usefulness of the Povarov and new catalysts have led to 
improved preparation  condition^.^" Specifically advantageous catalysts include the 
lanthanide triflates, Sc(OT03 and Yb(OTq3, while the new solvent of choice for the 
reaction is acetonitrile. This is likely due to the fact that both the substrates and catalysts 
are easily soluble in this solvent. Procedures involving three component syntheses as 
well as combinatorial methods on solid supports have also led to enhanced yields. The 
Povarov reaction has now grown into a popular and useful strategy for the preparation of 
substituted tetrahydroquinolines.66 
Previously Povarov and colleagues made the assumption that the reaction of 
activated alkenes and aromatic Schiff bases occurred via a conjugated [4+2] 
~ ~ c l o a d d i t i o n . ~ ~  Recently, however, the mechanism for this process has been debated. 
Experiments in which the ionic intermediates were captured by nucleophiles and 
subsequently characterized have been performed.68 These results call into question the 
prevailing thought of a concerted pathway and instead suggest that a stepwise reaction 
mechanism is more probable. Although there does not appear to be one generic 
mechanism to explain all reactions of this class, a majority of chemists now acknowledge 
that the Povarov reaction proceeds through a stepwise mechanism. In the currently 
postulated, non-concerted reaction mechanism66 (Scheme 2.6), the Lewis acid catalyst 
BF3-EtzO first complexes to the nitrogen of imine 63, resulting in formation of iminium 
ion intermediate 64 in which the nitrogen atom bears a positive charge. The electrons 
from the activated alkene 65 then react with compound 64 to create a bond which couples 
the two compounds together, resulting in the formation of intermediate 66. The second 
ring of compound 67 is created by electrophilic attack of the ortho carbon of the aniline, 
and a bond is formed between the phenyl ring directly attached to the nitrogen atom and 
the carbon atom bearing the positive charge. Next, hydrogen elimination re-aromatizes 
the aniline-derived phenyl ring. Trace quantities of water are required to break the 
complex between the nitrogen atom and the Lewis acid catalyst. The tetrahydroquinoline 
product mixture 68 results once this complex is broken. If desired, treatment of the 
reaction products with oxidizing agents (e.g. KMn04,p-toluenesulfonic acid, or 
atmospheric oxygen) may aid in the elimination of the alkoxy or alkyl sulfide group to 
give the fully aromatized dihydroquinoline 69. 
Scheme 2.6. Currently postulated, non-concerted mechanism for the Povarov reaction 
illustrated with BF3'Et20 as the Lewis acid catalyst. 
The tetrahydroquinolines formed under Povarov reaction conditions possess 
several asymmetric carbons. The ratio of diastereomers formed is often dependent upon 
a variety of factors, including the reaction conditions as well as the substrates, catalyst, 
and solvent.69 For instance, in situations when the activated alkene is a dihydrofuran or 
dihydropyran derivative, three chiral centers are formed during the reaction (Figure 2.9). 
In a majority of cases, the annulation proceeds in such a way that typically only four 
diastereomers can result. While the endo-trans 70 and endo,cis 71 isomers predominate, 
the exo,trans 72 and exo,cis 73 isomers are almost never formed in appreciable 
quantities.70 The preferential formation of diastereomers during the annulation of an 
alkene and benzaniline adds a unique stereochemical aspect to the Povarov reaction. 
Figure 2.9. Diastereomers resulting from Povarov condensations with dihydrofiuan and 
dihydropyran. 
\ 
endo, trans endo, cis exo, trans exo, cis 
Our interest in the Povarov reaction was sparked by a recent publication that 
reported cycloadditon chemistry involving a protected glycal as a scaffold. However, this 
report is the only known example of Povarov glycal cycloaddition chemistry published to 
date. Jiminez and colleagues performed multicomponent Povarov reactions utilizing tri- 
0-acetyl-D-glucal50 and tri-0-acetyl-D-galactal75, and the research group synthesized 
glycosylidene-fused compounds 74 and 76 from these starting reagents (Scheme 2.7). 
Reactions with these protected glycals displayed excellent facial selectivity. Although 
reaction times were quite long (two weeks) and yields were low (<40%) when the 
experiments were conducted at 40 OC, microwave irradiation increased the yields of the 
reaction, lowered the reaction time to two minutes, and enhanced stereoselectivities to 
99: 1. The researchers did not observe Ferrier-type rearrangements or ring-opening 
transformations that are common in acid-promoted reaction conditions with glycals. In 
addition, the research team also synthesized galactose-derived tetrahydroquinoline 77 
(Scheme 2.8)." This example is the first sugar-fused quinoline synthesized via the 
Povarov reaction to be reported in the scientific literature. Despite this group's success, it 
is surprising to note that they have yet to report additional work in this area. 
Scheme 2.7. Multicomponent reactions involving glycal addition reported by Jiminez 
and colleagues. 
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Scheme 2.8. First reported Povarov reaction utilizing a glycal derivative as the activated 
alkene. 
. 
AcO 
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Several other groups have made efforts focused on the synthesis of sugar-based 
quinolines via addition reactions. For instance, Schemer and colleagues have prepared 
sugar-anellated dihydroquinoline 80 through the condensation of 78 with benzaldehyde 
79a (Scheme 2.9J7' In addition, Yadav and coworkers reported the synthesis of glucose- 
fused tetrahydroquinline 82. This high yielding, stereoselective synthesis involved a 
Lewis acid catalyzed cycloaddition of aniline 81a with endo-glycal50 (Scheme 2.10).'~ 
These reports denote examples within the scientific literature that most closely resemble 
our proposed area of study focusing on the preparation of sugar-based quinolines. 
Scheme 2.9. Preparation of quinoline 80. 
Scheme 2.10. Preparation of glucose-fused quinoline 82. 
CeCI3.7H20, Nal HN PAC 
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The application of the Povarov reaction to glycals, as reported by Jiminez and 
colleagues, motivated us to focus on this reaction with exo-glycals. To the best of our 
knowledge, syntheses involving the Povarov reaction with exo-glycals have not yet been 
described. In an effort to overcome this limitation, we embarked upon studies to identify 
reaction conditions that would allow us access to our target compounds. This research 
project idea would also nicely complement the previous interests of the Marzabadi group, 
namely addition reactions and the synthesis of carbohydrate-derived heterocycles and 
carbocycles. A program of study focused on the Povarov reaction with exo-glycals is 
worthy of research attention because it will allow for the likely expansion of the scope of 
this reaction strategy. Finally, the resulting synthetic products have the potential to 
possess biological activity. 
2.3. Results 
a. Synthesis of Starting Materials 
Below we describe our synthetic efforts toward a series of novel, glycosylidene- 
based quinolines. In order to begin a survey of analogues, we needed to first prepare the 
common exo-glycal intermediate from we which would conduct our research (Scheme 
2.1 1). We began our synthesis with commercially available 2,3,4,6-tetra-O-benzyl-D- 
glucopyranose 83. Glucose was chosen as the sugar for the carbohydrate scaffold 
because of its known biological importance. We decided to utilize the benzyl group to 
protect the hydroxyl functionalities because of the observations that acetyl and silyl 
protected D-glucals reacted slowly under Povarov conditions and the corresponding 
products were not particularly stable.74 The anorneric hydroxyl group of compound 83 
was oxidized with DewMartin periodinane,75 and lactone 84 was produced in 93% yield. 
Next we needed to obtain the terminal alkene, and a Tebbe olefination reaction76 resulted 
in a 75% yield of the desired exo-glycal85. With this crucial intermediate in hand, we 
then turned our attention to studies involving the Povarov reaction with different imines. 
We were able to purchase several benzanilines through commercial sources while others 
were synthesized according to published literature procedures (Scheme 2.12)'' A 
representative experimental procedure involved a room temperature reaction between 
derivatives of benzaldehyde 79 and aniline 81 to give imine 86. Once the required 
intermediate compounds were synthesized, we began to perform experiments aimed at 
studying Povarov reaction conditions. 
Scheme 2.11. Synthesis of the essential exo-glycal intermediate. 
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Scheme 2.12. Synthesis of benzanilines. 
6. Catalyst Screening 
In order to investigate conditions for the Povarov reaction between exo-glycal85 
and benzaniline 86a, we screened several rare earth metal triflates as Lewis acid catalysts 
(Table 2.0). Based on our literature survey, we chose to study Sc(OT93, Yb(OTg3, and 
Tb(OTf)3. With all three catalysts (Entries 1 -3), we observed the complete conversion of 
85 to a mixture of products. In each reaction, we noticed that the molecular weight of the 
products differed by two amu. We surmised that this difference may correspond to the 
presence of an oxidizedlreduced pair. Of the screened catalysts, Sc(0Tf)j gave the 
highest ratio of 88a:87 (oxidized to reduced products) as well as the cleanest reaction 
(Entry 1). Catalysis of the reaction with Yb(OTQ3 and Tb(OTf)3 resulted in almost 
identical ratios of 88a:87 (Entries 2 & 3). These preliminary results were encouraging, 
and we next proceeded to isolate the reaction products and perform structural 
characterization studies. 
Table 2.0. Catalyst and reaction condition screening. 
OBn 
BnO+ BnO 86a + 
BnO CH2 
85 
Reduced Product Oxidized Product 
MW=717 + MW= 715 
87 88a 
I I I 
1 1 Sc(OTf)3 I room temperature, overnight 1 2.67:1 
Entry 
2 I Yb(OT& I room temperature, overnight I 0.92:l 
Catalyst 
L 1 I I I 
a 85 (1.0 equiv), 86a (1 .O equiv), and catalyst (0.2 equiv) were dissolved in MeCN and 
allowed to react under the specified conditions. Determined by HPLCMS analysis. 
I 
Reaction Conditionsa 
3 
Ratio of 88aWb 
Tb(OTf)3 room temperature, overnight 0.96:1 
c. Shwctural Determination 
A series of 1D and 2D NMR experiments were conducted in order to determine 
the structural identity of the reaction products. The proton spectra of 87 in CDC13 
indicated that this reduced product was isolated as a 4: 1 mixture of diastereomers. In 
addition, assignment of both 'H and I3c spectra of the isomeric mixture indicates that the 
reduced products are two of the four possible glycosylidene-spiroanellated stereoisomers 
that we predicted to synthesize from the reaction. High resolution mass spectrometry 
(HRMS) also validated the molecular weight of the products. The signals for the 'H and 
"C spectra have been assigned, and Nuclear Overhauser Effect (NOE) experiments have 
confirmed the stereochemistry of both isomers of 87. Tables 2.1 and 2.2 summarize the 
I H and l3c NMR data and illustrate the assigned structures. For 87Major (Table 2. l), 
NOES were observed between the hydrogens attached to the following carbon atoms: 2 
with both j and a, b with both 3  and 5, and 4  with a. These interactions indicate that the 
stereochemistry is (R) at both carbons 1 and j. For 87Minor (Table 2.2), NOES were 
observed between the hydrogens attached to the following carbon atoms: b with both 2 
and 4 , 3  with a, and 5 with j. The stereochemistry of this isomer is (3 at carbon 1 and 
(R) at carbon j. These interactions observed from the advanced NMR experiments 
definitively confirm the stereochemistry of the glucose-spiro tetrahydroquinolines 
87Major and 87Minor. 
Table 2.1. Spectral analysis for the spiroanellated tetrahydroquinoline 87~ajor ."  
OBn 
Atom Label I 'H Chemical Shift (ppm) I '>c Chemical Shift (ppm) 
1 1 ..... I 76 7 
c 
d 
e 
f 
g 
h 
1 
6.78 
7.16 
6.58 
7.19 
buried under Bn aromatics 
buried under Bn aromatics 
----- 
- 
116.9 
128.9 
113.7 
buried under Bn aromatics 
buried under Bn aromatics 
buried under Bn aromatics 
145.1 
Table 2.2. Spectral analysis for the spiroanellated tetrahydroquinoline 8 7 ~ i n o r . ~ ~  
A similar analysis was conducted on the oxidized product 88a from the Povarov 
reaction with exo-glycal85. A variety of advanced NMR experiments were performed in 
order to assign the structure of the oxidized product as the open-ring glycosylidene-based 
quinoline 88a. Table 2.3 summarizes the 'H and I3c NMR data and illustrates the 
assigned structure. Both 1D and 2D NMR experiments, conducted in CD3CN, were 
required to confirm the open-ring structure of 88a. Evidence includes the I3c shift of Cl  
(145.9 ppm) and the coupling constant for the hydrogen attached to C2 (3.1 Hz). The 
broad I3c resonance of C2 (78.5 ppm) sharpened upon increased temperature, indicating 
restricted rotation about the C1-C2 bond. NOES were observed between the hydrogens 
attached to the following carbon atoms: 2 with both a and b. COSY and NOESY signals 
were also observed between the hydrogen and hydroxyl group attached to C5. This 
evidence, when taken in conjunction with KRMS data, provides strong support for the 
structural assignment of 88a as the open-ring, fully aromatized quinoline. 
Table 2.3. Spectral analysis for the open-ring glycosylidene-derived quinoline 88a.'* 
Atom Label 1 '11 Chemical Shift (ppm) I "C Chemical Shift (ppm) I 
Isolation and structural characterization of the resulting compounds from the 
Povarov reaction indicated the formation of spiroanellated tetrahydroquinoline 87 as a 
mixture of diastereomers in addition to the open-ring glycosylidene-based quinoline 88a. 
Although the spiro-compound mixture 87 is stable while refrigerated, we observed the 
slow, partial oxidation to 88a at room temperature. The aromatization of the 
tetrahydroquinoline portion of 87 likely drives the opening of the glucopyranose ring. 
This observation is consistent with the traditional Povarov additionloxidation sequence 
(Scheme 2.5) in which elimination of the alkoxy group ultimately leads to ring 
aromatization to form the dihydroquinoline. 
d Reaction Optimization 
In consideration of these initial results, it was therefore our desire to exclusively 
obtain the oxidized product 88a, preferably from a one-pot reaction. Of the screened 
catalysts, Sc(OTf), (Table 2.0, Entry 1 )  gave the highest ratio of 88a:87 as well as the 
cleanest reaction. We therefore chose to focus solely on this Lewis acid catalyst. We 
decided to monitor the reaction on an hourly basis, and noted that the exo-glycal starting 
material 85 was entirely consumed within one hour when the mixture was stirred at room 
temperature. In addition, the spiro mixture 87 steadily converted to the open-ring 
quinoline 88a until the ratio of -2.7: 1 was reached. Extension of the reaction time to four 
days (96 hours) did not appreciably change the ratio (Table 2.4, Entry 1). We next 
altered the experimental conditions by conducting the reaction under the reflux 
temperature of acetonitrile ovemight, and observed the ratio of 88a:87 to be -2.5:l 
(Entry 2). In order to complete our studies of the influence of the reaction's temperature 
on the ratio of 8 8 ~ 8 7 ,  we conducted the reaction at 0 OC. After three hours of stimng, 
we observed a mixture of starting material as well as oxidized and reduced products 
(Entry 3). Allowing the reaction to stir ovemight while warming to room temperature 
resulted in the consumption of the exo-glycal starting material 85. Surprisingly, a 
majority of the reaction's products was in the reduced form (Entry 4). These reaction 
temperature optimization studies led to the observation that overnight stimng at room 
temperature resulted in the highest ratio of 8 8 ~ 8 7 .  However, we were still unable to 
completely convert the spiroanellated tetrahydroquinoline mixture 87 to the open-ring 
glycosylidene-based quinoline 88a. 
Table 2.4. Screening of Povarov reaction conditions involving catalysis by Sc(OTf)3 at 
various temperatures. 
Entry 
I I 
Conditions a 
1 
I I 
4 1 0 OC for 3 hours, then room temperature overnight I 1:1.62 
Ratio of 
88a:(87Major + 8 7 ~ i n o r ) ~  
2.51:1 2 
I I 
I I I 
a 85 (1 0 equiv), 86. (1 0 equiv), and Sc(OTQ3 (0.2 equiv) were dissolved in MeCN and I 
allowed to react under the specified conditions. Determined by HPLCMS analysis. 
room temperature, 4 days 
reflux, overnight 
Throughout our early optimization studies, we were concerned primarily with the 
2.67: 1 
still mostly exo-glycal85 3 
ratio of 88a:87. However, we also observed several by-products that resulted from the 
reaction. In an effort to overcome this limitation. we next turned our attention to 
0 "C, up to 3 hours 
minimizing these by-products. We set out to scale up the reaction so that we could obtain 
compound quantities sufficient for the characterization and identification of the side- 
products. We allowed 1 .O equiv of exo-glycal85 to react with 1 .O equiv of benzaniline 
86a and 0.2 equiv of Sc(OTf)3 overnight. Upon chromatographic workup, we isolated 
three reaction by-products. We assigned tentative structures based on NMR and 
HPLCMS data (Figure 2.10). By-product 89 is likely a hydrated version of the starting 
material, exo-glycal85. We also isolated addition product 90, and we tentatively 
assigned its structure to be a hydrated version of the "pre-cyclization intermediate". The 
formation of this compound helps to validate the currently accepted reaction mechanism 
as a stepwise process rather than a concerted one. Finally, we also observed a minor 
amount of a third by-product, compound 91. Although we were unable to obtain a 
sufficient amount of pure material for an NMR, HPLCIMS data led us to hypothesize that 
its identity could be a phenyl amino derivative of 85. In total, these three by-products 
accounted for less than one-third of the mass balance. Having identified the by-products, 
we surmised that we could minimize these side reactions in order to improve upon 
conversion of exo-glycal85 to desired product 88a. 
Figure 2.10. Tentative structural assignment of Povarov reaction side-products. 
OBn / , OBn OBn / 
89 90 91 
observed ion: 577 observed ion: 735 Observed ion: 629 
MW = 5.54 MW = 735 MW = 629 
Na (t23) adduct 
Since the side-products that we primarily observed were hydrated exo-glycal89 
and hydrated, pre-cyclization intermediate 90, we decided to focus on ways in which we 
could eliminate excess water fiom the reaction and still promote cyclization. We 
hypothesized that 4A molecular sieves may absorb the excess water and help to minimize 
the formation of these side products. In addition, we theorized that a bulky, non- 
nucleophilic organic base may help to break the complex between the Lewis acid and the 
nitrogen of the tetrahydroquinoline system. Therefore, we thought that the addition of 
2,6di-tert-butylll-methylpyridine 92 (Figure 2. 11) could promote cyclization and 
tetrahydroquinoline formation. 
Figure 2.11. Structure of the organic base, 2,6-di-rert-butyl-4-methylpyridine. 
We designed a series of optimization experiments in order to evaluate the effect 
of molecular sieves and the organic base 92 on the Povarov reaction with exo-glycal 85 
(Table 2.5). In general, molecular sieves alone drastically slowed the reaction and 
limited the conversion to the open-ring sugar based quinoline 88a. No reaction was 
observed after stirring for 90 minutes at room temperature, and only one-third of the 
product mixture consisted of 88a when the reaction was stirred overnight at room 
temperature (Entry I). Even after four days of refluxing, an approximate 1 : 1 ratio of 
88a:(87Major + 87Minor) resulted from the reaction (Entry 2). This compared to a 
2.5: 1 ratio when the reaction mixture was refluxed without sieves (Table 2.4, Entry 2). 
These observations helped to confirm that trace amounts of water are necessary to drive 
the cyclization, as indicated by the proposed reaction mechanism depicted in Scheme 2.6. 
The presence of organic base 92 did not alter the ratio of oxidized to reduced 
product. No difference was observed between refluxing reactions with and without base 
(Table 2.5, Entry 3, and Table 2.4, Entry 2). Next we decided to incorporate both 
molecular sieves and the pyridine base in one experiment. When run at room 
temperature for one hour, a 1:2.67 ratio of 88a:(87Major + 87Minor) was observed 
(Entry 4). In comparison to the room temperature reaction lacking organic base 92 in 
which no reaction was observed after 90 minutes, this result marked a substantial 
improvement in terms of exo-glycal consumption. However, refluxing the mixture for 
three hours did not alter the product ratio (Entry 5) .  Continuing to reflux the mixture did 
not result in any additional conversion to the oxidized product 88a. As a direct result of 
these experiments, we concluded that molecular sieves slowed the rate of consumption of 
exo-glycal85 and also resulted in a diminished ratio of 88a:(87Major + 87Minor). In 
addition, the pyridine base 92 did not help push the conversion to the oxidized open-ring 
glycosylidene based quinoline 88a. The reaction conducted at room temperature in the 
absence of sieves and organic base 92 (Table 2.0, Entry 1) resulted in the most favorable 
ratio of 88a:87. Ultimately, these base addition reaction modifications did not entirely 
eliminate the problem of incomplete cyclization, and side-products 89,90, and 91 were 
detected by HPLCMS analysis. After performing this series of experiments, we were 
still unable to attain 100% conversion to 88a. 
Table 2.5. Reaction optimization experiments involving addition of molecular sieves 
and/or 2,6-di-tert-butyl-4-methylpyridine 92. 
Ratio of 
88a:(87Major + 8 7 ~ i n o r ) ~  
Entry 
I I 
Conditionsa 
1 
I I 
2 
I I 
5 92, sieves, reflux, 3 hours 1 :2.43 1 
sievesc, room temperature, overnight 
3 
I I 
I J 
a 85 (1.0 equiv), 86a (1.0 equiv), and Sc(OTQ3 (0.2 equiv) were dissolved in MeCN and 
allowed to react under the specified conditions. Determined by HPLCMS analysis. 
C 1.3 mg of activated 4A molecular sieves per 1 mg of em-glycal85. 1.0 equiv added 
1:2.34 
sieves, reflux, up to 4 days 
4 
Next we chose to study the effects of conducting the Povarov reaction in a 
microwave reactor. We decided to perform these experiments because Jimenez and 
colleagues reported success with multicomponent Povarov additions that were subjected 
to microwave irradiation." One of the main advantages of the use of a microwave 
reactor is the attainment of reaction temperatures which exceed the solvent reflux 
temperature. These "pressure-cooking" conditions have the potential to enhance 
reactivity while shortening reaction times." In our first microwave experiment, we 
heated the reaction mixture for two minutes at 120 OC (Table 2.6, Entry 1) and observed 
about a 1 : 1 ratio of oxidized to reduced products. In a separate experiment, 4A molecular 
sieves were added to the reaction mixture. After 20 minutes of heating, however, no 
product was formed (Entry 2). This observation again confirms the fact that trace 
quantities of water are required for the cyclization step of the reaction to occur. Finally, 
1.03:l 
92" reflux, overnight 2.53:l 
92, sieves, room temperature, 1 hour 1:2.67 
addition of organic base 92 did not enhance the conversion to the open-ring form. After 
70 minutes of heating, the ratio of 88a:(87Major + 87Minor) was still nearly 1 : 1 (Entry 
3). Clearly microwave reaction conditions did not result in enhanced conversion of the 
spiro mixture 87Major + 87Minor to the open-ring sugar based quinoline 88a. 
Table 2.6. Reaction optimization experiments involving a microwave reactor. 
Entry 
I 
Conditionsa 
1 
2 
I I I I 
" 85 (1.0 equiv), 86a (1.0 equiv., and Sc(0Tf)j (0.2 equiv) were dissolved in MeCN and 
allowed to react under the specified conditions. Determined by HPLCMS analysis. 
1.3 mg of activated 4A molecular sieves per 1 mg of em-glycal85. * 1.0 equiv added 
Ratio of 
88a:(87Major + 8 7 ~ i n o r ) ~  
I I 
In order to address the issues that we were facing, we next decided to turn our 
2 minutes at 120 OC 
sievesc, 20 minutes at 120 OC 
3 
attention to the reaction solvent, acetonitrile. As a result of the scale-up studies, we 
1:1.12 
still mostly exo-glycal85 
observed hydrated products, suggesting to us that water was attacking the intermediate 
that resulted during this stepwise reaction. In the experiments involving molecular 
92d, 70 minutes at 120 OC 
sieves, we noted that the reaction's progress was very slow. When we conducted 
experiments with unopened, sure/sealTM anhydrous bottles of acetonitrile, we no longer 
1 : 1.07, still exo-glycal 85 
encountered substantial amounts of hydrated side-products. In addition, since the 
reactions went to completion, enough water must be present in the system to allow for 
cyclization of the intermediate to the tetrahydroquinoline. Going forward, all reaction 
experiments were conducted with unopened sure/sealW bottles of acetonitrile. 
Now that the problem with the solvent and excess water was behind us, we 
decided to explore the synthesis of the spiro compounds in more depth. Interestingly, we 
observed that predominately spiroanellated tetrahydroquinolines were present when the 
Sc(OT& catalyzed reaction was stopped after a period of one hour. We were able to 
successfully isolate 87Major + 87Minor (-4:l ratio) in 65% yield with only a trace 
amount (<4%) of 88a. However, as previously noted, this mixture of isomers is not 
stable at room temperature and partially converts to the fully aromatized, open-ring 
compound 88% Therefore we set out to study the effect of oxidizing agents on the 
reaction as another strategy to exclusively obtain the open-ring product. We 
hypothesized that an inorganic oxidizing agent added to the reaction may help drive the 
tetrahydroquinoline aromatization and subsequent ring opening of the glucose 
spiroanellated tetrahydroquinoline 87 to yield the fully aromatized glycosylidene-derived 
quinoline 88a. To our delight, we quicMy discovered that the addition of 2.0 equiv of 
manganese (IV) oxide (Mn02) resulted in the complete conversion of exo-glycal starting 
material 85 to the open-ring glycosylidene-derived quinoline 88a in high yield. A 
representative procedure for the synthesis of 88a is as follows: To a solution of exo- 
glycal85 (100 mg; 0.186 mmol) in acetonitrile (1 mL, unopened ~urel~eal"  bottle) was 
added benzaniline 86a (33.8 mg; 0.186 rnrnol) followed by SC(OT~)~ (18.3 mg; 0.0372 
mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen. 
After two hours, Mn02 (32.4 mg; 0.372 mmol) was added and the mixture was stirred 
overnight. The reaction was diluted with ethyl acetate (1.5 mL), filtered through Celite, 
and concentrated in vacuo. The crude material was purified over silica gel, eluting with a 
gradient of 0% - 40% ethyl acetate in hexane to give 88a as a colorless oil (87 mg; 65% 
yield. 
e. Evaluation of Substituent Effects 
We next applied this one-pot Povarov cycloaddition/oxidation procedure to a 
series ofpara-substituted benzanilines in order to evaluate the electronic effect of 
substituents on this reaction (Table 2.7). First we chose to examinepara-substituted 
benzanilines in which the R-group is derived from the benzaldehyde precursor. In 
general, the halogen substituted benzanilines (Entries 2 & 3) reacted efficiently to 
produce the corresponding open-ring glycosylidene-based quinolines. The yields, which 
exceeded 60%, were very similar when compared to the non-substituted phenyl ring 
(Entry 1). The electron-withdrawing inductive effect of the halogens is due to their 
electronegativity values, and it acts in a manner opposite to their electron-donating 
resonance effects. These properties are counter to each other and result in no net impact 
on the reaction yields. However, reactions that involved an imine with an electron- 
withdrawing group, such as a cyano or trifluoromethyl substituent, resulted in moderate 
yields of the desired product (Entries 4 & 5). The reaction yield also suffered when 
benzaniline was substituted with an electron-donating methoxy group (Entry 6). These 
observations suggest that benzanilines containing strongly electrondonating or 
withdrawing moieties in thepara position result in diminished reaction yield in 
comparison to halogen substituents. Nonetheless, this procedure represents an effective 
way to access unique carbohydrate-based quinolines. 
Table 2.7. Examination of the electronic effect ofpara-substituted, benzaldehyde- 
derived imines on the one-pot synthesis of glycosylidene-based quinolines. 
OBn ,.,OBn 
Sc(OTO3, MeCN 
BnO 
Mn02 
We then decided to employ this methodology to synthesize compounds in which 
the aniline-derived phenyl ring is para-substituted. In order to accomplish this, we made 
several imines which are derived from benzaldehyde and apara-substituted aniline. We 
chose to evaluate the same substituents as we studied previously (Table 2.7). In this 
series of experiments, reactions of all substituted imines resulted in diminished yields 
when compared to the non-substituted phenyl ring (Table 2.8, Entries 1-6). Of the 
substituents evaluated in this series, the imine substituted with the electron-donating 
methoxy group gave the best cycloaddition/oxidation reaction yield at 55% (Entry 6). 
This compound marks the only instance in which the yield in this series is higher than its 
counterpart in the series involving the benzaldehyde-derived phenyl substitutions. The 
halogen substituted imines gave modest yields in the Povarov cycloaddition/oxidation 
sequence (Entries 2 & 3). For these benzanilines (86g & 86h), the electron-withdrawing 
inductive effect of the halogens must have been more influential than the electron- 
releasing resonance effect. In addition, the experiment involving the benzaniline with the 
electron-withdrawing trifluoromethyl group gave the lowest yield at 18% (Entry 5). In 
the case of cyano-substituted imine 86i, the expected product was not isolated (Entry 4). 
Instead, the non-cyclized, hydrated adduct was formed in 45% yield. One potential 
reason for this result is that the electron-withdrawing nature of the cyano group prevented 
cyclization of the aromatic carbon with the anomeric carbon. Another possible 
explanation for this result could be that the imine reactant was impure. The condensation 
reaction between the aldehyde and aniline did not go to completion, and successfiil 
recrystallization conditions were not determined. In general, the success of the Povarov 
cycloaddition/oxidation reaction sequence with this particular series of compounds 
appears to be negatively affected by the presence ofpara substituents on the aniline ring. 
This effect was most pronounced with imines containing an electron-withdrawing group 
in thepara position. We theorize that removal of electron density from the aniline- 
derived phenyl group renders the pi-bond electrons of the aromatic ring less available for 
attack of the positively charged anomeric carbon (see Scheme 2.6 for generic 
mechanism). In contrast, release of electron density into the ring by the methoxy group 
favorably impacts ring closure. 
Table 2.8. Examination of the electronic effect ofpara-substituted, aniline-derived 
imines on the one-pot synthesis of glycosylidene-based quinolines. 
1 Entry I Benzaniline I Benzaniline Product I Isolated Yield 1 
I I I I I I 
a Required 8 equiv of MnOz for complete conversion. "N analogue of 90 isolated. 
2 
3 
4 
86g 
86h 
86i 
F 
Bra 
CN 
88g 
88h 
88i 
39% 
38% 
Not isolatedb 
The one-pot Povarov cycloaddition/oxidation methodology allows for the 
preparation of novel glycosylidene-based quinolines. Our studies indicate that the 
procedure worked best for benzaniline itself. We have determined that para substitutions 
on either phenyl ring of the imine result in diminished yields. However, yields for 
reactions involving imines with halogen substituents on the benzaldehyde phenyl ring 
were essentially equal to that benzaniline. Halogen substituted imines in the 
benzaldehyde-derived series also gave higher yields than the corresponding reaction in 
the aniline substituted series. The halogen group's electron-donating and withdrawing 
properties acted in a counteractive manner for the benzaldehydederived series. Based 
upon yields in the aniline-derived benzaniline series, however, the electron-withdrawing 
inductive effect of the halogen substituent was stronger than the electron-releasing 
resonance effects. Interestingly, moderate yields were obtained with imines that possess 
both electron-donating and electron-withdrawing groups on the benzaldehyde-derived 
phenyl ring. The most dramatic electronic effects were observed with imines substituted 
in the para position of the aniline-derived phenyl ring. Electron-withdrawing groups 
substantially reduced reaction yields, while the yield with the example involving the 
electron-releasing methoxy group was rather close to that of benzaniline. These results 
can be explained by considering the postulated reaction mechanism depicted in Scheme 
2.6. Removal of pi-bond electron density makes ring closure more difficult while 
electron donation into this ring enhances the likelihood of cyclizaiton. Overall, the facile 
reaction sequence that we developed works well for a variety of benzaniline derivatives, 
and very respectable product recoveries were obtained from this one-pot procedure. 
f: Deprotection Attempts 
We next turned our attention to the the final step in our synthetic sequence, the 
debenzylation reaction (Scheme 2.13). In order to demonstrate the synthetic utility of the 
one-pot Povarov additiodoxidation chemistry, we needed to determine conditions to 
successfully remove the benzyl protecting groups. Traditionally, benzyl ethers are 
among the most common hydroxyl protective groups used in organic synthesis. In 
addition, a variety of reliable conditions exist for benzyl ether cleavage.g Our general 
plan was to first screen the most straightforward conditions with the highest probability 
of success. If required, we would then progress to the less commonly used procedures. 
Specifically, our strategy was to start out with room temperature, palladium (Pd)- 
catalyzed hydrogenolysis conditions before attempting high pressure, high temperature 
reactions. If those conditions were not successful in removing the benzyl groups, we 
would move to transfer hydrogenation conditions followed by more specialized chemical 
methods. Theoretically, the final product produced by the Pd-catalyzed reactions should 
not require purification other than catalyst filtration and solvent concentration. We 
predicted that chromatographic purification of the crude material would be difficult due 
to the polar nature of the final product. The issue of purification provided additional 
motivation for our rationale of beginning the debenzylation experiments with standard 
hydrogenolysis conditions. 
Scheme 2.13. Benzyl ether deprotection of glucose-based quinoline 88a. 
Our first attempted debenzylation experiment involved a room temperature 
reaction under a hydrogen gas balloon catalyzed by PdK (5% wet, 1:OS wt,.b:w&) 
(Table 2.9, Entry 1). Pd-promoted hydrogenolysis is the most common reaction 
procedure used to remove benzyl ether groups, and Pd is the preferred catalyst because 
the use of platinum (Pt) often results in ring hydrogenation.80 Unfortunately, after 
ovemight stimng, no reaction was observed. We next added Pd(OH)z/C (Pearlman's 
catalyst (20% wet)) to give a total catalyst loading of 1 :1 Nub:%. Again, no reaction 
was observed after overnight stirring at room temperature (Entry 2). The reaction 
mixture was then heated to 50 OC in an attempt to drive the deprotection (Entry 3). 
However, only a trace amount of product with one benzyl group removed was observed. 
As a result of this first pass study, we quickly learned that deprotection of the four benzyl 
groups would require harsher reaction conditions. Clearly, the standard room 
temperature and balloon pressure hydrogenolysis procedure followed by catalyst 
filtration did not apply to our complex glycosylidene-derived quinoline. 
Table 2.9. Hydrogen balloon debenzylation experiments. 
I Entry I Conditions a Results 
I I 
I I (1 : 1 w&,:%), room temperature I I 
2 
no reaction 1 
I I I I 
a Stirred overnight in ethanol. Determined by HPLCIMS analysis. 
PdIC (5% wet, 1:O.S w&:mat), 
H2 balloon, room temperature 
Entry 1 reaction vessel + Pd(OH)2/C (20% wet)) 
I I 
We next turned our focus to a variety of Pd-based catalysts at conditions 
no reaction 
3 
involving higher pressure and temperature. In general, for all catalysts attempted at 50 
"C and below (Table 2.10, Entries 1 - 9 ,  we observed no debenzylation by HPLCIMS 
analysis. Instead we noticed a reduction of two double bonds of the quinoline system to 
yield isomers of 9423 with a MW of 719 (Figure 2.12a). This result was rather 
unexpected, as Pd-based catalysts usually do not affect double bonds within an aromatic 
ring.9 We then decided to increase the temperature of the reactions to see if the enhanced 
temperature would result in deprotection (Entries 6-9). After overnight heating at 60 OC, 
we did in fact observe complete debenzylation in all screens that we performed. 
However, by NPLCMS, we also observed product 94b with a MW of 365, and this mass 
likely corresponds to the complete reduction of the quinoline system (Figure 2.12b). 
Entry 2 reaction vessel, 50 "C 
While this result is rather interesting, it still did not give us the final compound that we 
desired. As a result of this series of screens, we learned that high pressure, high 
trace of loss of 1 Bn group 
temperature conditions would not remove the benzyl groups while leaving the quinoline 
system intact. Therefore, we decided to try transfer hydrogenation conditions for the 
benzyl ether deprotection. 
Table 2.10. High pressure, high temperature debenzylation experiments." 
I I 
1 pd/C (lo%, wet) (1 :1 ~tmb:~t ta) ,  40 OC, 40 psi H2 I 94a isomers 
Results Entry Conditions a 
I 
I I 
I I 40 psi Hz, acetic acid charge I I 
94a isomers 2 
I I 
I I 
5 1 Pd/C eggshell (lo%, wet) (1:0.5 ~&,~ :wt ,~ ) ,  50 O C ,  50 psi HZ I 948 isomers 
P&C (5%, dry) (1 :1 \ " r t sub :~a ) ,  40 OC, 40 psi Hz 
94a isomers 3 Pd(OH)2/C (20%, wet) (1 :l ~&:wt ,~ ) ,  40 OC, 40 psi H2 
94a isomers 4 Pd(OH)2/C (20%, wet) (1:l %,b:wk,), 40 OC, 
I I 
I I 
94b isomers 6 
I 
I I I I 
a Stirred overnight in methanol. Determined by HPLCIMS analysis. 
Entry 1 reaction vessel, 60 OC, 40 psi H2 overnight 
94b isomers 7 
I I 
Entry 2 reaction vessel, 60 OC, 40 psi H2 overnight 
94b isomers 8 Entry 3 reaction vessel, 60 "C, 40 psi Hz overnight 
94b isomers 9 Entry 4 reaction vessel, 60 OC, 40 psi HZ, overnight 
Figure 2.12. Tentative structural assignments of the products formed from reaction 
conditions in (a) entries 1-5 and (b) entries 6-9 of Table 2.1 0. 
Transfer hydrogenation is a reaction strategy in which hydrogen gas is formed in 
situ. It requires a PdK catalyst as well as either cyclohexene or ammonium formate to 
generate the hydrogen gas necessary for the reaction to take place. For our debenzylation 
attempts using transfer hydrogenation conditions, we decided to utilize Pearlman's 
catalyst.82 Our initial experiment (Table 2.1 1, Entry 1) involved cyclohexene, and these 
conditions successfully cleaved off all of the benzyl protective groups after refluxing the 
reaction for two days. However, the reaction vessel continually dried out and the 
solvents needed to be replenished periodically. In order to work around this problem, we 
tried the same reaction in the microwave reactor. We had also hoped that microwave 
irradiation could shorten the reaction time. Unfortunately, heating in the microwave for 
over five hours did not result in complete conversion to the desired product (Entry 2). 
The experiment was discontinued because the reaction tube broke due to extended 
heating times. We then modified our transfer hydrogenation conditions by increasing the 
catalyst loading to 1 :I (\KtsUb:wt&. We conducted the reaction in a sealed tube as 
opposed to a nitrogen-linked condenser. We hypothesized that this modification would 
prevent the solvents from evaporating. We also thought that the sealed tube approach 
would keep the generated hydrogen gas within the reaction vessel. These conditions 
successfully debenzylated compound 88a (Entry 3). However, we also observed two by- 
products (MW-16, MW-18) that comprised approximately 25% of the crude reaction 
mixture. One of these compounds (MW-18) likely corresponds to a dehydration of one 
of the hydroxyl groups. Purification of the mixture by silica gel chromatography 
(gradient of 0% to 15% methanol in dichloromethane) did not successfully separate the 
impurities from the desired product due to the polar nature of the compounds. We also 
tried similar transfer hydrogenation conditions with ammonium formate 83 (Entry 4). 
However, we only observed a trace amount of compound in which one benzyl group was 
removed. It is likely that the ammonium formate conditions did not generate enough 
hydrogen gas required for the reaction to occur. Even portion-wise addition of a large 
excess of this reagent did not have a favorable effect on the reaction. This series of 
experiments led us to the conclusion that successful debenzylation is possible without 
reduction of the quinoline system. However, we turned our attention to chemical 
methods because of the difficulty of separating the desired compound from the side 
products that formed. 
Table 2.1 1. Transfer hydrogenation debenzylation experiments. 
I (reflux), cyclohexene, 2 days I dries out 
Entry 
1 
I (microwave), cyclohexene, 5 hours tube breaks in microwave 
Conditions a 
Pd(OH)z/C (20%, wet) (1:0.25 w&,,b:%t), 90 OC 
I I 
Results 
938 but reaction continually 
2 
/ (sealed tube), cyclohexene, overnight / (MW-18, MW-16) 
I 
Pd(OH)z/C (20%, wet) (1 :0.25 \~ts,,~:*~), 120 OC 
3 
(sealed tube), ammonium formate, overnight 
a Stirred for the time indicated in ethanol. Determined by HPLCIMS analysis. 
partial conversion to 93a; 
I I 
Numerous chemical conditions are known to remove benzyl ether protecting 
groups.9 However, due to potential purification difficulties, we made this strategy our 
last resort. For our first debenzylation attempt using chemical methods (Table 2.12, 
Entries 1 & 2), we tried conditions involving excess methanesulfonic acid. Since no 
reaction was observed at room temperature, the mixture was heated overnight. 
Unfortunately, no desired product resulted from the reaction and the compound was 
instead destroyed. Another deprotection experiment involved the use of excess ferric 
chloriden4 (Entry 3). This reagent successhlly removed the benzyl protecting groups 
when stirred at room temperature overnight. However, the reaction was very messy. 
Given the promising results with ferric chloride, we decided to try another Lewis acid, 
Pd(OH)z/C (20%, wet) (I:] w&:&,), 90 'C 
4 
93a but -25% by-products 
Pd(OH)z/C (20%, wet) (1 :I w&"b:%,), 90 OC trace of loss of 1 Bn group 
boron trichloridess (Entry 4). To our delight, this reagent successfully cleaved the 
protective groups after one hour of stirring at -78 OC. 
Table 2.12. Debenzylation experiments utilizing chemical methods. 
I Enby I Conditions Results a 
I I 
1 
2 
I I 
I I I I 
a Determined by HPLCIMS analysis. 
methanesulfonic acid, DMF, DCM, room 
temperature, overnight 
Entry 1 reaction vessel, 75 OC, overnight 
3 
I I 
-- 
The crude material generated by the boron trichloride conditions required 
purification by reverse phase high performance liquid chromatography (HPLC) in order 
to remove the borane-ligated by-products. Method development resulted in conditions 
that utilized acetonitrile and water (ammonium hydroxide, pH The ammonium 
hydroxide mobile phase modifier does not result in a product counterion, and 
lyophilization of the solvents yielded the free base in high yield. A representative 
procedure for the synthesis of 93a is as follows: To a solution of 88a (70 mg; 0.098 
mmol) in dichoromethane (2.0 mL) at -78 OC was added BC13 (1 M in hexane; 0.39 mL; 
0.39 mmol). The reaction was stirred at -78 "C under an atmosphere of nitrogen. After 
one hour, additional BC13 (1 M in hexane; 0.195 mL; 0.195 mmol) was introduced, and 
no reaction 
compound destroyed 
4 
FeC13, DCM, room temperature, overnight 93a, messy reaction 
BCI3, DCM, -78 "C, 1 hour 93a, clean reaction 
the reaction was maintained at -78 OC for one hour. The reaction was quenched with the 
addition of methanol (2.0 mL). The crude material was concentrated in vacuo. The 
residue was coevaporated twice with methanol, and then purified with a Waters mass 
directed reverse phase prep HPLC system. The following chromatographic conditions 
were used: (a) column: Waters Xbridge C-18,30 x 75 mm, 5 micron; (b) flowrate: 50 
mllmin; (c) mobile phase: A = water + ammonium hydroxide (pH lo), B = acetonitrile; 
(d) mobile phase gradient method: time = 0 min, A = 98, B = 2; time = 11 min, A = 65, 
B = 35; time = 11.2 min, A = 0, B = 100; time = 14.2 min, A = 98, B = 2; time = 15 min, 
A = 98, B = 2. Lyophilization of the resulting fractions yielded 93a as a fluffy white 
solid (24 mg; 69% yield). These deprotection conditions were also attempted with other 
perbenzylated compounds. Application of this debenzylation procedure to fluoro 
analogue 88b resulted in its deprotected counterpart, 93b, in 63% yield. 
2.4. Summary 
We have successfully developed a one-pot synthetic methodology that leads to the 
preparation of novel glucose-derived quinolines. This Povarov additionloxidation 
chemistry takes place between an exo-glycal dienophile and a benzaniline diene. We 
have also shown that this reaction proceeds through the glucose-spiroanellated 
tetmhydroquinoline intermediates, which subsequently oxidize to the open-ring, fully 
aromatized forms. Extensive catalyst screening and reaction optimization experiments 
were performed, and they have led us to the conclusion that Sc(OTf)3 is the optimal 
catalyst for the synthesis of the open-ring compound. Careful ID and 2D NMR 
experiments have confirmed the structure of both the spiro and open-ring glucose-linked 
quinolines. This one-pot methodology has been successfully employed with a series of 
para-substitued benzanilines to access several novel open-ring, glycosylidenederived 
quinolines in moderate to good yields. A lengthy set of deprotection experiments was 
carried out in order to develop conditions to remove the benzyl protective groups. The 
success of the debenzylation chemistry verifies that this one-pot synthetic methodology is 
a useful way to obtain carbon-linked glucose-derived quinolines. 
Chapter 3 
Reaction Scope Expansion 
3.1. Introduction 
The field of organic synthesis has the impressive ability to construct complex and 
diverse molecular structures from relatively simple compounds. The tools of total 
synthesis are the chemical reactions which drive structural transformations. Discovery 
and development of new reactions is crucial for the invention of strategies that ultimately 
lead to the synthesis of increasingly complex defined target molecules. Research into the 
development and expansion of new and improved synthetic methodologies will help to 
propel studies involving target synthesis. Further reaction scope expansion research 
provides a strong sense of utility for organic name reactions. 
The one-pot Povarov cycloaddition/oxidation reaction sequence that we have 
developed is a facile and convenient way to synthesize novel glucose-derived quinolines. 
Successful removal of the benzyl ether protective groups validates this approach as a 
viable strategy toward sugar-derived quinolines. It was our desire, however, to build 
upon and expand the scope of the reaction methodology. Practically all of the classical 
organic name reactions have been extensively studied in an attempt to broaden the 
general applicability of the chemistry. We wanted to test the effect of other sugar exo- 
glycals on the reaction. In addition to varying the sugar-based dienophiles, we 
hypothesized that other dienes, such as aliphatic imines and azobenzenes, may be 
applicable to our newly developed reaction methodology. We also theorized that the 
quinoline system could be further transformed through alkylation chemistry. Finally, we 
desired to study the facial and diastereoselectivity of the addition reaction through both 
chemical reactions as well as molecular modeling calculations and simulations. In total, 
this set of experiments is required to more thoroughly understand the extent of the 
broadness and overall applicability of the reaction. We therefore embarked upon further 
studies to address the breadth and capacity of this one-pot reaction. 
3 .2  Background 
a. Biological Relevance ofArabinose and Galactose 
Aside from glucose, several other biologically significant monosaccharides are 
present throughout nature. Many of these monosaccharides serve as crucial structural 
components of more complex natural products. For instance, one such example is 
arabinose 95 (Figure 3.0), a biologically important sugar that is a key monosaccharide of 
biopolymers such as hemicellulose and pectin.6 In addition, this monosaccharide is also a 
component of the antiviral agent, vidarabine 96 (Figure 3 .0 ) .*~  We therefore surmised 
that incorporation of an arabinose-based sugar may lead to potentially bioactive 
compounds. 
Figure 3.0. Arabinose and an antiviral derivative. 
In addition to arabinose, galactose 97 is also a monosaccharide with biological 
relevance (Figure 3.1). Aside from D-glucose and 2-deoxy-D-ribose, galactose is one of 
the few sugars found to any great extent in the animal kingdom3 Galactose, like 
arabinose, is a component of the polysaccharide, hemicellulose. Galactose is 
incorporated into various glycolipids and glycoproteins, and it is also a key component of 
the determinant saccharides (blood group antigens) that comprise the classical ABO 
blood group system. More importantly, galactose, along with glucose, are 
monosaccharides that make up lactose 98 (Figure 3.1). This crucial disaccharide is 
present in mammalian milk as well as other dairy products.6 Given the biological 
relevance of galactose, we concluded that incorporation of this monosaccharide into our 
sugar-based quinolines would be worthy of our efforts. 
Figure 3.1. Structures of galactose and the disaccharide, lactose. 
b. Scope Expansion Rationale 
The cycloaddition reaction of N-aryl imines with nucleophilic olefins is a 
convenient method of quinoline preparation. This aza-Diels-Alder reaction, also known 
as the Povarov reaction, involves the reaction between an azadiene and dienophile. 
Traditionally, the dienophile is an activated vinyl ether or vinyl sulfide. In addition, the 
Povarov reaction's diene is most frequently a derivative of benzaniline. Although the 
imine is capable of acting as either a dienophile or azadiene, it is almost always the diene 
in the Povarov reaction.66 
There are numerous reports in the literature documenting Povarov reactions 
conducted with an N-aryl imine in which the diene is derived from an aliphatic aldehyde 
and an aniline analogue.66 Reactions with these imines are thought to proceed through 
the same pathway as their benzaniline counterparts. We envisioned utilizing 
propionaldehyde-derived imine 99 in ow reaction (Figure 3.2). In addition, to the best of 
our knowledge, there are no reports of Povarov reactions in which an azobenzene 
derivative acts as a diene in the cycloaddition. Azobenzene 100 is an analogue of 
benzaniline in which the nitrogen replaces the imine carbon (Figure 3.2). It also seemed 
reasonable to attempt to apply this type of diene to our synthetic methodology. 
Figure 3.2. Alternate azadienes. 
Scope expansion studies are vital to the development of broadly applicable 
chemical reactions. In fact, the most widely used reaction methods are those which are 
highly general in nature. Such comprehensive reactions are preferred, especially if the 
products can serve as synthetically advantageous intermediates. Further derivatization of 
usehl intermediates is both effective and efficient, especially in SAR studies performed 
by medicinal chemists. 
c. Reaction Stereochemistry 
Both the Diels-Alder reaction and the Povarov reaction are synthetically useful 
reactions that have the potential to be conducted in a stereo- and regio- specific manner. 
Stereoselective catalysis is frequently promoted by chiral ligands such as BINAP 101'~ 
and BINOL 102'~ (Figure 3.3). In fact, there is literature precedent for catalytic 
asymmetric aza-Diels-Alder reactions involving chiral ligands. Ishanti and Kobayashi 
prepared a chiral lanthanide Lewis acid complex from Yb(OT&, (R)-(+)-BINOL 102 
DBU, and 2,6-di-[err-butyl-4-methylpyridine 92. The researchers used this chiral 
ytterbium catalyst to successfully synthesize tetrahydroquinoline derivatives with high 
diastereo- and enantioselectivities. The group applied this strategy to the Povarov 
reaction between vinyl ether 103 and benzaniline derivative 104, and they obtained 
quinoline derivative 105 (Scheme 3.0)~' These favorable results indicate that control 
over the stereochemistry of Povarov reactions is attainable. 
Figure 3.3. Structures of the chiral ligands, BINAP and BINOL. 
101 (BINAP) R = PPh2 
102 (BINOL) R = OH 
Scheme 3.0. Ishanti and Kobayashi's stereoselective Povarov reaction. 
Yb(OTf)3, 92, 102, DBU 
H ~ C ~ O E ~  + 
OH 
103 104 105 
3.3. Results 
a. exo-Glycal Dienophiles 
In order to probe the generality of the reaction and further expand our one-pot 
Povarov cycloaddition/oxidation methodology to other sugars, we chose to target a series 
of arabinose-based quinolines. We decided to use arabinose 95 as the sugar portion of 
the compound because we wanted to test the effect of using an exo-glycal dienophile that 
is derived from a five-membered ring sugar. Our synthesis in the arabinose series began 
with commercially available 2,3,5-tri-0-benzyl-PD-arabinofuranose 106 (Scheme 3.1). 
We conducted our preparative route in an analogous manner to the synthesis of glucose- 
derived exo-glycal85. First the anomeric hydroxyl group was oxidized with Dess-Martin 
periodinane to give lactone 107 in nearly quantitative yield?' Next, the lactone was 
subjected to Tebbe olefination reaction conditions to give the C1 exo-glycal108 in 43% 
yield.92 With this required terminal alkene in hand, we set out to apply the Povarov 
additiodoxidation chemistry to synthesize arabinose-derived compounds. 
Scheme 3.1. Synthesis of the arabinose-derived exo-glycal. 
BnO BnO BnO 
Dess-Martin yyO Tebbe Reagent ' y y 2  
OBn OBn OBn 
106 107 108 
For this series of compounds, we chose to sample several benzanilines (86a, 86b, 
86f, & 86g) that we utilized in the previous series. Our initial efforts focused on the 
reaction of exo-glycal 108 and benzaniline 86a. We observed that this reaction also 
proceeded through the spiroanellated intermediate, just like the reaction with exo-glycal 
85. We discovered that exo-glycal 108 was consumed within one hour, and we isolated 
109Isomers as a complex mixture of spiro products in 60% yield (Scheme 3.2). 
However, we were unable to characterize the stereochemistry of the individual 
components of the mixture and were also unsuccessful in the determination of separation 
conditions for these compounds. 
Scheme 3.2. Synthesis of the arabinose-spiroanellated tetrahydroquinoline. 
Following our one-pot Povarov cycloaddition/oxidation methodology involving 
MnOz, we synthesized arabinose-derived quinoline llOa in 57% yield (Table 3.0, Entry 
1). We also attempted this reaction with several para-substituted benzanilines and 
isolated open-ring arabinose-derived quinolines in moderate yields (Entries 2-4). In 
general, the yields for the open-ring products in the arabinose series are similar (within 
10%) of the glucose series. However, with exception of the reaction with benzaniline 
86a, none of the reaction yields exceeded 50%. Interestingly all of the oxidations with 
arabinose-derived exo-glycal 108 ultimately required 8.0 equiv of MnO2 for complete 
conversionto the open-ring form. This leads us to surmise that the arabinose- 
spiroanellated tetrahydroquinoline diastereomers are less susceptible to ring opening than 
the spiroanellated products in the glucose series. Perhaps this is due to entropic factors, 
as only three rotatable bonds result from a ring-opening event as compared to four for the 
glucose series. Nonetheless, our one-pot procedure can still be utilized to effectively 
synthesize novel carbohydrate-based quinolines. This set of experiments demonstrates 
that the Povarov cycloaddition/oxidation chemistry successfUy works with a pentose 
exo-glycal dienophile. In addition, application of our BClj-based debenzylation 
procedure with llOa and llOb produced perhydroxylated compounds llla and lllb in 
63% and 48% yield respectively (Scheme 3.3). 
Table 3.0. Synthesis of arabinose-based quinolines. 
BnO nR' Sc(0Tfl3, MeCN y%y2 +pN\ Mn02 - R 2 4  \ \ 
OBn 
/ 
108 86a,b,f,g IlOa,b,f,g R ' 
Scheme 3.3. Debenzylation of arabinose-based quinolines llOa and 110b. 
l l l a  R1 = H 
I l l b  R' = F 
We also decided to target a small series of galactose-derived quinolines in order 
to expand upon the breadth of our one-pot Povarov cycloaddition/oxidation methodology 
that we developed with glucose and successfilly applied to arabinose. We selected 
galactose 97 as the monosaccharide portion of our quinoline derivative because this 
hexose is a close analogue of glucose, differing only by the configuration of the C4 chiral 
center. In galactose, the hydroxyl group is in the axial position as opposed to the 
equatorial position that it occupies in glucose. 
exo-Glycal synthesis in the galactose series required the use of commercially 
available 2,3,5,6-tetra-0-benzyl-D-galactopyranose 112 (Scheme 3.4). We conducted 
our synthetic route in an analogous manner to the synthesis of glucose-derived exo-glycal 
85. Dess-Martin periodinane oxidation of the anomeric hydroxyl group formed lactone 
113 in nearly quantitative yield.93 Next, this intermediate was treated with Tebbe reagent 
to give the C1 exo-glycal 114 in 51% yield?4 With the necessary galactose-derived 
dienophile in hand, we set out to apply the additionfoxidation sequence with several 
benzaniline dienes in order to synthesize galactose-derived quinolines. 
Scheme 3.4. Synthesis of the galactose-derived exo-glycal. 
Dess-Martin Tebbe Reagent 
P
BnO BnO BnO 
BnO OH BnO 0 
For this series of galactose-based compounds, we performed reactions with 
several benzanilines (86a, 86b, & 86g) utilized previously with the glucose and 
arabinose-based exo-glycals. Our initial efforts focused on the additiodoxidation 
reaction between exo-glycal 114 and benzaniline 86a. We observed the spiroanellated 
intermediate by HPLCNS, but did not isolate the isomeric mixture because of a limited 
supply of 114. We instead decided to proceed directly to the open-ring quinoline and 
synthesized 115a in 51% yield (Table 3.1, Entry 1). We also attempted this reaction with 
the para-fluoro-substituted benzanilines and isolated moderate yields of open-ring 
galactose-derived quinolines (Entries 2 & 3). As with the arabinose series, the yields for 
the open-ring products in the galactose series are lower than the glucose series. Although 
not enough compounds were synthesized in this series to formulate conclusions regarding 
electronic effects, we did in fact successfully demonstrate that our method works for 
hexoses other than glucose. In addition, perbenzylated galactose-based quinoline 115a 
was subjected to BC13, and the deprotected analogue 116a resulted in 60% yield. The 
success of the debenzylation chemistry once again validates the merit of our strategy 
directed at the synthesis of sugar-based quinolines. 
Table 3.1. Synthesis of galactose-derived quinolines. 
,,OBn 
BnO OBn n R 1 S c ( O T t ) 3 ,  MeC\ 
BnO & BnO CHZ ' ,MN\ MnOz R2& / 
114 86a,b,g R1 115a,b,g 
Scheme 3.5. Debenzylation of galactose-based quinoline 115a. 
Product 
1 15a 
115b 
115g 
~ ' - ~ r o u p  
H 
H 
F 
Isolated 
Yield 
51% 
48% 
45% 
~ ' - ~ r o u p  
H 
F 
H 
Entry 
1 
2 
3 
Benzaniline 
86a 
86b 
8% 
Another scope expansion idea that we pursued was to use an ethenyl-exo-glycal a s  
the Povarov reaction dienophile. This experiment was performed in an attempt to insert a 
methylene linker in between the quinoline heterocycle and the anomeric carbon of the 
glucose portion of the molecule. We also thought that this type of system would be less 
likely to undergo complete aromatization of the tetrahydroquinoline and may therefore 
avoid ring opening of the sugar. In order to conduct these experiments, we first needed to 
synthesize the required olefin (Scheme 3.6). Following direct literature procedures 
developed by ~ o s o r n i ~ ~  and a n i s h e f s k ~ y ~  we obtained olefin 118 in 63% yield. We 
next applied our SC(OT~)~  catalyzed Povarov cycloaddition reaction conditions with 
benzaniline 86a. We did not detect desired product 119a and instead observed that no 
reaction occurred when the mixture was stirred overnight at room temperature (no 
Mn02). Literature precedent for Povarov reactions involves only vinyl ethers and vinyl 
sulfides. We concluded that this reaction did not occur because the olefin starting 
material does not contain a vinylic ether system and is therefore too electron deficient. 
Scheme 3.6. Povarov reaction attempts with ethenyl exo-glycal 118. 
OBn H2CA/TMS 
BnO TfOSiMe3, MeCN 
OBn 
86a 119a 
b. Azadienes 
We also decided to try the Povarov cycloaddition/oxidation sequence with an 
imine derived fiom an aliphatic aldehyde and aniline. Our initial experiments involved 
the synthesis of imine 99. We were unable to obtain complete conversion of the reaction 
between propionaldehyde and aniline, despite carefully following the literature 
procedure.97 Our crude imine 99 was approximately 70% pure by weight, and we used it 
directly in the one-pot reaction sequence (Scheme 3.7). When subjected to the Povarov 
additiontoxidation reaction, we observed only a trace quantity of desired product 120 by 
HPLCIMS. Instead, the major product, identified by mass spectrometry, was a hydrated 
exo-glycal, likely compound 89. This outcome indicates that the reaction contained too 
much water content. Further attempts at this reaction, including the use of molecular 
sieves and starting reagents azeotroped with toluene, failed to give desired product. 
These inconclusive results do not allow for an adequate determination regarding the 
reactivity of N-aryl aliphatic aldimines. On the basis of this data, we reasoned that it is 
unlikely that aliphatic imines can be readily utilized in our additiodoxidation reaction 
sequence. We therefore did not further pursue experiments in this area of study. 
Scheme 3.7. Povarov reaction attempts with imine 99. 
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We envisioned substituting azobenzenes for benzanilines in an attempt to expand 
the scope of the Povarov reaction with exo-glycal85. We surmised that our previously 
developed chemistry may be applicable to the addition of azobenzenes. We could easily 
access a variety of azobenzenes through the reaction of a nitrosobenzene and an aniline 
derivative as previously documented by ~ n s ~ o n . ~ '  Unfortunately, attempts to apply our 
Povarov cycloadditon conditions to this reaction expansion idea with azobenzene 100 
were unsuccessful. We screened the same rare earth metal triflate catalysts (Sc(OTQ3, 
Yb(OTQ3, & Tb(OTQ3; Table 3.2) as we did for the Povarov reaction between exo-glycal 
85 and benzaniline 86a. In each case, the starting material was consumed, but desired 
product, 121Isomers, was not formed. According to HPLCMS data, all three catalysts 
produced the same major by-product. Unfortunately, we were unable to structurally 
identify the major by-product that resulted from these scope expansion experiments. The 
electronics of this particular reaction are substantially different from that of the Povarov 
reaction with benzaniline 86a. In benzaniline, a net electronegativity difference exists 
between the carbon and nitrogen atoms of the imine, leading to an electron cloud that is 
distorted toward the nitrogen side of the bond. Since azobenzene is a symmetrical 
molecule, no such difference exists. This theoretical explanation is a potential reason to 
account for the failure of the attempted reaction. In addition, to the best of our 
knowledge, there is no literature precedent for this particular type of transformation. 
Based upon our observations with this series of experiments, we decided not pursue 
alternate conditions. 
Table 3.2. Catalyst and reaction condition screening with azobenzene 100. 
Reaction Conditionsa 
room temperature, overnight 
room temperature, overnight 
room temperature, overnight 
w 
121 Isomers 
unidentified by-product 
MW=659/682(+23) 
unidentified by-product 
MW=659/682(+23) 
unidentified by-product 
MW=659/682(+23) 
I I I 
a 85 (1.0 equiv), 100 (1.0 equiv), and catalyst (0.2 equiv) were dissolved in MeCN and 
allowed to react under the specified conditions. Determined by HPLCIMS analysis. 
c. Further Transformations of Sugar-Derived Quinolines 
We hypothesized that we could utilize our sugar-derived quinoline as an 
intermediate for the synthesis of additional novel compounds. For instance, we desired to 
synthesize the N-methyl analogue of 88a (structure 122a in Table 3.3). The rationale 
behind this design was to create a positively charged nitrogen within the quinoline 
system. We thought that this charge may be a way to help increase the likelihood of the 
affinity of the sugar-derived quinoline for DNA. More specifically, we theorized that the 
positively charged nitrogen may interact electrostatically with the negatively charged 
phosphate groups on the DNA backbone. Examples of N-methylated quinolines as DNA 
intercalators have been reported in the literature and help to provide further validation for 
this strategy.99 
We followed modified literature procedures in order to carry out this synthetic 
transformation (Table 3.3). Several of our attempts involved iodomethanetoO as the 
methylating reagent (Entries 1 & 2). Both room temperature and reflw conditions did 
not give any reaction with the quinoline. This could be due to the volatility of 
iodomethane as a result of its low boiling point. Our next attempts utilized another 
common alkylating agent, dimethyl sulfate.lO' When allowed to stir at room temperature, 
no reaction occurred (Entry 3). Refluxing overnight, however, destroyed the glucose- 
based quinoline starting material (Entry 4). Our final attempts employed methyl triflate 
as the methylating reagentIo2 (Entries 5-8). This reagent initially showed promising 
results, as we observed nearly 50% conversion to 122a at room temperature. The 
reaction, however, was not able to be pushed any further. Increasing the quantity of 
reagent and heating the mixture to reflux temperature did not enhance the conversion. In 
addition, an experiment in which a large excess of methyl triflate was added initially did 
not result in improved conversion. We were unsuccessful in our attempts to consume all 
of the starting material as well as our efforts to separate the starting material from the 
methylated product. The associated triflate counterion rendered the separation 
problematic. Due to the fact that these strategies did not drive the reaction to completion, 
we decided not to devote any additional resources to the synthesis of the N-methylated 
quinoline target 122a. 
Table 3.3. Quinoline N-methylation attempts. 
BnO - 
~ e s u l t ~  Entry 
I I 
Conditionsa 
I 
no reaction 1 
3 
I 
5 MeOTf (1.2 equiv), room temperature, 1 hour 1 -50% conversion 
Iodomethane (5.0 equiv), room temperature, overnight 
no reaction 2 
I I 
Entry 1 reaction vessel, reflux, overnight 
Dimethyl Sulfate, (10.0 equiv), room temperature, 
overnight 
no reaction 
compound destroyed 4 
6 
Entry 3 reaction vessel, reflux, overnight 
7 
I I I I 
a Reagents were dissolved in MeCN and allowed to react under the specified conditions. 
Determined by HPLCIMS analysis. 
Entry 5 reaction vessel (2.4 equiv total), 
room temperature, overnight 
8 
-50% conversion 
Entry 5 reaction vessel (10.0 equiv total), 
reflux, overnight 
compound destroyed 
MeOTf (30 equiv), room temperature, 1 hour trace product, 
unknown by-product 
We decided to make a hydrochloride salt of 93a as a way to install a positive 
charge on the nitrogen within the quinoline system. The monohydrochloride was easily 
formed in quantitative yield by treatment of 93a with excess hydrogen chloride in diethyl 
ether (1 M solution). The salt stoichiometry was determined by potentiometric titration 
to be 1 : 1 .Io3 While the charge may be transient depending upon the pH of the 
surrounding environment, this compound may also prove beneficial because 
hydrochloride salts are often more soluble in aqueous environments than their free base 
counterparts. 
Scheme 3.8. Formation of the hydrochloride salt of 93a. 
HCI in diethyl ether & .& 
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We also thought that the hydroxyl group of sugar-based quinoline 88a could serve 
as a glycosyl acceptor and lead to the preparation of a compound with two sugar-derived 
moities linked together by a glycoside bond. Specifically, we hypothesized that we 
would be able to perform a Koenigs-Knorr glycosidation reaction between sugar-based 
quinoline 88a and glycosyl halide 123. We made two separate unsuccessful attempts at 
target compound 125. Experiments utilizing the heavy metal salts ~ ~ 2 ~ 0 3 ' "  and 
Ag(O~f)'OS resulted in no observed reaction (Table 3.4, Entries 1 & 2). Potential reasons 
for the failure of these Koenigs-Knon glycosidation reactions include glycosyl halide 
hydrolysis as well as 1,2-elimination.lo6 We then decided to proceed to thioglycoside 
 condition^'^' in an attempt to form the glycoside bond and access compound 126. This 
glycosylation method also did not succeed, as the starting materials failed to react (Entry 
3). The lack of success of our first pass condition screening approach toward glycoside 
bond formation indicates that the hydroxyl group of 8821 is unreactive. This lack of 
reactivity is likely due to steric hindrance surrounding the hydroxyl functionality. 
Although a shortage of material prevented us from continuing to pursue these targets, 
Kahne sulfoxide glycosylation conditions are more likely to yield the desired glycoside 
product because this type of reaction typically succeeds with unreactive as well as 
sterically hindered substrates.lo6 
Table 3.4. Glycosylation attempts. 
1 
I I 
3 1 124, NIS, TfOH, DCM, -40 "C, 30 minutes I no reaction 
I I 
a Reactions were run with 4A molecular sieves under the specified conditions. 
Determined by HPLCJMS analysis. 
123, Ag2C03, MeCN, diethyl ether, room temperature, overnight 
2 
d. Stereochemistry of the Povarov Addition Reaction 
no reaction 
An interesting aspect of the Povarov addition between glucose-based exo-glycal 
85 and benzaniline 8623 that warranted M e r  theoretical investigation was the observed 
facial selectivity and stereocontrol of the reaction. The regiochemistry of addition to the 
glycal to produce the spiroanellated products is as what would be anticipated based upon 
mechanistic predictions (Scheme 2.6). According to the non-concerted reaction process, 
123,92, Ag(OTf), MeCN, room temperature, overnight no reaction 
attack of the imine carbon by the more nucleophilic C2 carbon of the vinyl ether occurs 
first. This is followed by electrophilic attack of the resulting oxonium ion by the ortho 
carbon of the aniline ring. The two step process has been described by other 
 researcher^'^^ and was further supported by our isolation of an intermediate addition 
product. Compound 90 forms when the imine carbon of the benzaniline is added to the 
C2 carbon of the vinyl ether, and water is added to the C1 carbon of the vinyl ether. The 
observed axial facial preference for addition to exo-glycal85 leading to the P-substituted 
methylene group at the anomeric carbon most likely arises because of steric effects 
experienced by the bicyclic component in the equatorial plane.'09 The steric effects may 
account for the observation that only 20% of the spiro mixture consists of product 
(87Minor) in which the axial substituent from the anomeric carbon is derived from the 
C2 carbon of the vinyl ether. 
As previously discussed, we observed only two of the four possible 
tetrahydroquinoline stereoisomers, 87Major and 87Minor, from the Povarov cyclization 
reaction with the glucose-derived exo-glycal85. Interestingly, neither isomer with the 
(5')-configuration at benzylic carbon j (see Tables 2.1 & 2.2 for the atom labeling system) 
was formed. This observation led us to utilize molecular modeling calculations to search 
for an energy trend concerning the product distribution of the spiroanellated compounds. 
Spartan06 software was used to determine the energy for both molecular mechanics force 
field (Merck Molecular Force Fields or MMFF) and semi-empirical quantum calculations 
(Recife Model 1 or RMI) . "~  MMFF is a family of force fields that is used for the 
modeling of molecular systems. It involves minimization of a compound's potential in an 
artificial force field.'" RMl, a recently reparameterized version of Austin Model 1 or 
AM], is a semi-empirical method for the quantum calculation of molecular orbital 
electronic structure that calculates enthalpy of formation.'12 Both computational models 
are highly theoretical in nature and offer a crude approximation for the total energy of the 
compounds."3 When comparing calculation results within a simulation model, the 
compound with the lowest energy value is favored. Although the absolute energy values 
are not necessarily indicative of actual heat of formation values, a trend may or may not 
be apparent through comparison of the calculated data for the stereoisomers studied. 
The MMFF and RMI calculations for the four possible spiroanellated 
stereoisomers do not correlate with the experimentally observed product distribution 
(Table 3.5). All four spiro stereoisomers have similar MMFF calculated values as well as 
nearly identical results for the RMl simulations. These molecular modeling calculations 
lead us to conclude that the observed distribution of the spiro compounds is not entirely 
explained by the thermodynamics of all of the possible products. In addition, these 
models do not account for the absence of the isomers with the (5')-configuration at the 
benzylic carbon. Therefore thermodynamic factors must not be the sole reason that only 
two of the four possible spiroanellated stereoisomers were produced by the reaction. 
Table 3.5. Molecular modeling calculations for both the observed and potential Povarov 
- 
reaction products. 
Compound r------ Stereochemistry 
(R), (9 
Not Observed 
(9, (9 
Not Observed 
MMFF 
potential 
(kJ/mol) 
RMl 
enthalpy 
(kJ/mol) 
We next applied the Boltzmann Distribution Law to analyze the simulated energy 
values for the two observed spiro products that resulted from the reaction in order to look 
for a correlation between the observed and calculated stereoisomer ratio. This 
distribution function provides a probability measure for the distribution of the states of a 
system based on energy differences. The Boltzmann Distribution for a fractional number 
of particles, NI/N2, occupying a set of states possessing energies El and E2 is: N1/N2 = 
eA"AmT) where R (gas constant) is 8.314510 ~ m o l - l ~ - I  and T is the temperature in 
Kelvin.'14 This distribution equation was used only with the RMl data set because the 
potential calculations of the MMFF model did not favor the major observed product. 
Application to the RMI simulation data yielded the 87Major:87Minor ratio of 
0.896:0.104. This calculated ratio compares to the 4:l product ratio that was observed 
for the reaction and conforms with the trend. However, this correlation is not substantial 
because the energy difference between 87Major and 87Minor (5.6 Wlmol) is less than 
the standard error inherent to the model (-25 k~lmol)."~ In addition, the Spartan 
software simulations cannot be used to explain the absence of the other two potential 
stereoisomers. 
The lack of correlation on the part of these modeling calculations suggests that it 
is likely that kinetic andlor thermodynamic factors involving a transition state may 
instead impact the observed product distribution. The energy calculations of the spiro 
compounds cannot be directly compared to the results for the open-ring products because 
the molecular formulas of the compounds under consideration are not identical (differ by 
two hydrogen atoms). Finally, as a general trend, errors in the determination of 
conformational energy barriers can be rather large and oftentimes unpredictable, leading 
to deviations between calculated and experimental results.'" 
Despite the inconsistencies with the output of the modeling methods, we 
confidently contend that 88a is more favorable from the perspective of Gibb's free 
energy (AG = AH- TAS) than its spiro precursors. We hypothesize that the observed 
transformation is driven enthalpically by the aromatization of the tetrahydroquinoline to 
the dihydroquinoline. It is widely accepted that aromatization is an enthalpically favored 
process, and it confers additional stability to the resulting compound due to the 
delocalization of the pi electrons within the ring system. In addition to the enthalpic 
contributions to Gibb's free energy, the oxidized, open-ring form has five additional 
rotatable bonds which make an entropic contribution to the overall favorability of the 
process. Clearly the freely rotatable bonds create a more disordered compound. The 
capacity for bond rotation of the open-ring form contrasts with the conformationally 
ordered pyranose sugar and spiroanellated ring system. We theorize that the rotational 
capabilities of the open-ring compound provide for an entropic enhancement to the 
overall favorability of the process. In consideration of both enthalpy and entropy, the 
open-ring quinoline product is thermodynamically favored over the spiro forms. The 
observed lack of stability of the spiro conformers also correlates well with the Povarov 
additionloxidation pathway (Scheme 2.5) in which alkoxy group elimination results in an 
aromatized compound. 
While the molecular modeling calculations did not reveal an energy trend 
concerning the product distribution of the glucose-spiroanellated tetrahydroquinoline 
stereoisomers, we nonetheless decided to conduct a series of experiments in an attempt to 
control the stereochemistry of the spiro products. Ligands such as BINAP 101'' and 
BINOL 102'~ are often utilized as part of a general strategy for stereoselective catalysis. 
We surmised that these chiral auxiliaries may prove useful to us, and we therefore 
decided to attempt a modified version of the procedure developed by Ishanti and 
Kobayashi on our system with exo-glycal85 and benzaniline 86a. 
When we applied this strategy to our Povarov reaction involving exo-glycal85 
and benzaniline 86a, no reaction was observed (Table 3.6, Entries 1-3). Unreacted 
starting material remained after 24 hours of stimng at room temperature. We concluded 
that either the presence of base (DBU) or the chiral ligand (BINAP or BINOL) prevented 
the Povarov reaction from taking place by interfering with the action of the lanthanide 
triflate catalyst. The organic base and chiral ligand were the only reaction condition 
differences compared to the original cyclization experiments (Table 2.0). Based on these 
results, we decided not to m e r  pursue stereoselective catalysis conditions. 
Table 3.6. Stereoselective reaction condition screening. 
OBn 
BnO? BnO 
86a BnO BnO 
or BnO NH 
85 I 
\ 
or other possible isomers 
Entry 1 Ln(OTQ3 Catalyst 1 Ligand Result" 
I 
1 
I I I 
I 
a Ln(OTo3 (0.2 equiv), ligand (0.225 equiv) and DBU (2 uL in 100 uL MeCN) were 
stirred for 30 minutes at room temperature. 86a (1.0 equiv), 92 (1.0 equiv), and 85 (1.0 
equiv) were then added. The reaction was stirred at room temperature and monitored by 
HPLCIMS after 1 hour and 24 hours. 
2 
I I I 
While our efforts to control the reaction's stereochemistry through the use of 
Sc(OTf)3 I (R)-(+)-BINAP 101 1 no reaction 
3 
chiral ligands failed, we were committed to the determination of conditions for the 
separation of 87Major and 87Minor. Although diastereomers can theoretically be 
no reaction Sc(OTfl3 
separated via silica gel chromatography, we were unable to identify suitable normal 
phase silica gel chromatographic conditions. In an effort to overcome this limitation, we 
(R)-(+)-BINOL 102 
next turned our attention to chiral columns. Frequently chemists utilize specialized 
no reaction Yb(OTf)3 (R)-(+)-BINOL 102 
columns because the chiral stationary phase environment can create non-bonding 
interactions which may lead to differences in retention and ultimately the separation of 
the stereoisomers. After a screen involving several chiral columns, we determined that 
the following analytical conditions successfully separated 87Major and 87Minor: 
ChiralPak IB 4.6 x 250 mm column, 5 micron particle size, 10% ethanol in heptane 
(isocratic), 0.5 mllmin flowrate, 254 nm wavelength, retention time 87Minor (8.48 min), 
87Major (13.89 min). We then proceeded to separate the spiro mixture on a prep scale. 
The fractions containing the compound needed to be concentrated promptly because we 
observed partial decomposition to the open-ring, fully aromatized form if the fractions sat 
out on the bench overnight. We successfully separated, concentrated, and characterized 
each spiro isomer before decomposition occurred. This chromatography work allowed us 
to isolate individual isomers despite the fact that our attempts to synthesize the spiro 
isomers stereoselectively failed. 
We also attempted to deprotect the perbenzylated spiroanellated 
tetrahydroquinoline intermediate (Scheme 3.9). When 87Major was subjected to BCI3 
conditions, we were unable to isolate any debenzylated spiro product. Although the 
benzyl protective groups were removed, we also observed that the tetrahydroquinoline 
aromatized to the open-ring, fully aromatized quinoline 93a, despite the absence of 
oxidizing agent MnOz. Under these reaction conditions, we are led to conclude that the 
BCI, is accelerating the rate of tetrahydroquinoline oxidation. The perhydroxylated spiro 
tetrahydroquinoline is not stable and its counterpart, the open-ring, dihydroquinoline is 
clearly favored. 
Scheme 3.9. Deprotection of spiroanellated tetrahydroquinoline, 87Major. 
OBn OH 
BnO 
87Major 127Major 
3.4. Summary 
We have made progress in our efforts to broaden the scope of the substrates that 
can be applied to the one-pot methodology that we have developed. Initially our model 
system was limited to glucose-derived exo-glycal85 and benzaniline 86 analogues. We 
have succeeded in expanding the capacity of the Povarov chemistry by altering the sugar- 
derived dienophile involved in the reaction. The additionloxidation reaction proceeded 
smoothly with both arabinose and galactose-derived exo-glycals, indicating that the 
chemistry is not limited by the size of the glycal ring or the configuration at the C4 
position. However, attempts to apply an ethenyl-exo-glycal dienophile were 
unsuccessful, likely because the Povarov reaction only proceeds with activated alkenes. 
We also conducted diene modification experiments, but we were unable to substitute 
azobenzene and an aliphatic aldehyde-derived imine for benzaniline 86 analogues. In 
addition, we attempted to utilize compound 88a as an intermediate substrate for further 
transformations. We explored several conditions for N-methylation of the quinoline ring, 
but were not successful in our efforts to develop a procedure that resulted in complete 
substrate conversion. On the other hand, we were able to form the monohydrochloride 
salt of 93a. We also unsuccessfully tried to form a glycoside bond by using the hydroxyl 
group of 88a as a glycosyl acceptor. Finally, we examined the stereochemistry of the 
Povarov reaction by studying computer simulations as well as stereoselective reaction 
conditions. Despite the fact that modified literature procedures involving chiral ligands 
failed to produce spiro products, we did succeed in separating 87Major and 87Minor 
through chiral chromatography. 
Chapter 4 
Biological Evaluation of Selected Compounds 
4.1. Introduction 
The molecular architecture of compounds derived from nature has been, and 
continues to be, an excellent source of inspiration for the design of drug-like precursors. 
For instance, nearly 40% of the drugs approved between 1983 and 1994 were natural 
products or their derivatives. Even a larger percentage of anticancer or antiinfective 
compounds researched during this period of time fit into the broad category of modified 
natural products."5 A common strategy for the rapid evaluation of drug candidates that 
has been employed by drug discovery scientists is to first screen a library of synthetic 
molecules for potency against a specific target and then follow up by determining the 
pharmacokinetic properties of several of the most potent compounds. This multifaceted 
approach to medicinal chemistry allows for a balance to be attained between potency and 
bioavailability by simultaneously assessing both in vitro and in vivo properties. 
4.2. Background 
a. Physiochemical Properties 
Yet another important consideration for the development of bioactive compounds 
as therapeutic agents is the evaluation of pharmacokinetic properties, especially 
bioavailability. One of the significant goals of drug research and development is to 
understand the molecular properties that impact a compound's bioavailability. Lipinski's 
rule of five provides a series of guidelines that can be utilized to predict the oral 
bioavailability of a drug candidate. This set of principles takes into account such factors 
as molecular weight (MW), lipophilicity (log P), and the number of hydrogen bond 
donors and acceptors. In general, Lipinski's rule of five suggests that poor oral 
absorption is likely when at least two of the following criteria are met: ( 1 )  the molecular 
weight of the compound exceeds 500, (2) the logP is five or greater, (3) the molecule 
possesses more than five hydrogen bond donors, and (4) the compound has more than ten 
hydrogen bond acceptors. Since its proposal in the late 1990s, Lipinski's rule of five has 
helped medicinal chemists to make general estimations regarding the absorption 
properties of lead structures.'16 
Although implementation of this analysis has proven useful, there are limitations 
as it relates to oral bioavailability predictions. For instance, the data that Lipinski 
analyzed lacked quantitative bioavailability assessment. In addition, numerous scientists, 
including Veber, noted that poor oral bioavailability can often result in variable dosing. 
Therefore, in an attempt to further refine Lipinski's guidelines, Veber and colleagues also 
examined the relationship between the structure of a compound and oral 
bioavailabi~it~.'" Veber determined that acceptable bioavailability (>20%) was observed 
for compounds that possessed increased rigidity as measured by the total number of 
rotatable bonds (single, non-ring bonds that are bound to a non-hydrogen atom). In 
addition, Veber's analysis also led to the conclusion that total polar surface area (tPSA) is 
an important consideration in the prediction of oral bioavailability. Veber suggests that a 
prediction of high oral bioavailability can be made if a compound meets the following 
two criteria: (1) ten or fewer rotatable bonds are present in the molecule, and (2) the 
tPSA does not exceed 140 square angstroms. In general, the guidelines developed by 
both Lipinski and Veber provide a useful set of principles which can be applied by 
chemists to aid in the process of converting a compound with initially unpromising 
pharmacokinetic properties into a drug-like lead candidate. 
In addition to the molecular properties examined by Lipinski and Veber, there are 
a plethora of other factors that can have an impact on the overall bioavailability of a 
compound. Several considerations include protein-assisted active transport, cellular 
efflux, cellular membrane permeation, and metabo~ism.'~ Carbohydrates are also known 
to be assisted across a range of cellular membranes as well as through the blood-brain 
barrier by glucose transporters, enabling the sugar compounds to act within the cell. 
These properties are frequently evaluated in the latter stages of the drug discovery 
process. However, it was our desire to make theoretical predictions regarding absorption 
and bioavailability parameters while obtaining experimental in vitro activity data. 
b. Anticancer Screening 
The in vitro screening approach is a viable strategy to rapidly evaluate the 
potency values of a large quantity of compounds. In many cases, this data is considered 
to determine if a compound is worthy of study in live animals. Due to the high 
throughput nature of rational drug design, resource allocation dictates that it is impossible 
to conduct in vivo analysis of all compounds synthesized for a program. Therefore it is 
essential to to utilize a robust and reliable in vitro assay in order to generate preliminary 
data. 
In the late 1980s the US National Cancer Institute (NCI) developed a 60 human 
tumor cell line anticancer drug screen (NCI60). This in vitro screening assay was 
originally designed as a replacement for transplantable animal tumors. Over the years, 
this model has become a drug discovery tool and has enabled the screening of compounds 
submitted by academic scientists who work in the area of cancer research. The aim of the 
screen is to identify and prioritize the further evaluation of compounds that show 
selective growth inhibition of particular tumor cell lines. In addition, the program and its 
associated database have generated experimental data for numerous types of tumors 
including leukemia, lung, colon, central nervous system, melanoma, ovarian, renal, 
prostate, and breast cancers. The productivity of the screen is illustrated by the fact that 
several outcomes have contributed to advances in cancer therapy.'" 
4.3 Results 
a. Physiochernical Property Assessment 
In order to maintain control over bioavailability parameters, we utilized the 
guidelines of both Lipinski and Veber to help us roughly predict absorption and oral 
bioavailability. Specifically, we calculated the following physiochemical parameters via 
Advanced Chemistry Development's (ACD) software: molecular weight (MW), number 
of hydrogen bond acceptors and donors, logP, logD, acidic pKa, the number of rotatable 
bonds, and the total polar surface area (tPSA). The parameter lo@ is a measure of the 
octanol-water partition coefficient that takes into account all ionized forms of the 
substrate, while logP only considers the neutral species. Although there is no preferred 
value for pKa, it is widely accepted that charged species are less likely to readily 
permeate the lipid bilayers of cell membranes.14 In consideration of this trend, an 
acceptable logD value for permeation, as predicted by Lipinski, should be under 5.0. A 
thorough examination of the parameters included in Lipinski's rule of five in conjunction 
with the properties noted by Veber's analysis will help us to make predictions regarding 
the oral bioavailability of the novel compounds that we had evaluated for biological 
activity. 
Table 4.0. Calculated physiochemical properties of novel glycosylidene-derived 
quinolines. 
Hydrogcn 
bond 
acceptors 
- donors 
6 - 2  
6 - 5 
6 - 5 
5 - 4  
6 - 5  
clogP clogD Acidic Rot. tPS A 
(7.4) pKa Bonds 
10.29 10.29 4.29 19 70.04 
Of the compounds analyzed by ACD software, only 88a would be predicted to 
have poor oral bioavailability. According to Lipinski's rule of five, this perbenzylated 
intermediate exceeds the threshold limit requirements for the parameters of molecular 
weight and lipophilicity. This compound also fails Veber's guidelines due to the large 
number of rotatable bonds. All of the deprotected sugar-based quinolines pass Lipinski's 
rule of five and would be predicted to possess acceptable oral bioavailability. 
Compounds 93a, 93b, l l l a ,  and 127Major are structurally similar in that they all 
possess numerous hydroxyl groups as well as a quinoline ring derivative. Glucose-based 
quinoline 93a and its fluoro analogue, 93b, have practically identical values for all fields 
calculated. Each of these compounds exceeds Veber's requirements for the number of 
rotatable bonds. However, since both molecules surpass the cutoff by only one rotatable 
bond, it is reasonable to conclude that acceptable bioavailability may still be anticipated. 
In addition, based upon the pKa values, these compounds are also likely to readily 
permeate cell membranes because they are predicted to be neutral (no net charge) at 
physiological p ~ . " g  Despite the fact that the spiro compound, 127Major, was unable to 
be synthesized, we decided to analyze its calculated properties nonetheless. 127Major is 
the only glucose-based compound that passes all of the guidelines as set forth by both 
Lipinski and Veber. However, this compound has the lowest logD of the series, and a 
lipophilic modification may be required to boost the values of logD and logP over 1 .O. 
The arabinose-based quinoline, 11 la, displays the most favorable calculated 
physiochemical properties when compared to the glucose derivatives. This result is due 
to the fact that it is derived from a five-membered furanose ring as opposed to a six- 
membered pyranose ring. This seemingly minor difference improves the calculated 
molecular properties by reducing the molecular weight, polar surface area, and number of 
rotatable bonds as well as the number of hydrogen bond acceptors and donors. In 
addition, the higher logD and logP values of nearly 1.5 are in the range of optimum 
favorability for permeation (1.5 to 3.0).14 The arabinose-derived quinoline l l l a  passess 
the bioavailability guidelines as set forth by both Lipinski and Veber, and we therefore 
surmise that this compound will have the most favorable pharmacokinetic profile. 
Despite these predicted properties, l l l a  did not pass the NCI's screening filters and was 
not assayed for anticancer activity. Overall, the deprotected sugar-derived quinolines 
represent leads that are predicted to possess potentially favorable oral bioavailability and 
can therefore be readily modified into drug-like compounds. 
b. in vitro Anticancer Activig 
The anticancer activity of several novel, open-ring glucose based quinolines was 
evaluated in NCI's 60 cell line screening model.'20 Specifically compounds 88a, 93a, 
93a HCI Salt and 93b were tested at a 10 micromolar concentration. NCI reports the 
data as growth percent of the cell lines, and this number allows for the determination of 
growth inhibition. For instance, a growth percent value of 100 corresponds to no growth 
inhibition while a growth percent value of 40 corresponds to a 60% growth inhibition 
(growth inhibition = 100 -growth percent). Growth percent values greater than 100 
indicate cell proliferation and values less than 0 can be interpreted as lethality. Based 
upon literature precedent of the unique structural attributes of our compounds, we 
hypothesized that compounds 93a, 93a HCI Salt and 93b are likely to possess anticancer 
activity. 
Perbenzylated compound 88a displayed the best anticancer profile of the four 
open-ring, glucose-based quinolines from this project evaluated by the NCI 60 cell line 
screen (Table 4.1). This compound exhibited more than 40% growth inhibition for eight 
separate cell lines (values of growth percent are shown in bold). In addition, leukemia 
cell lines were most susceptible to this compound. Deprotected compounds 93a, 93a 
HCI Salt, and 93b, on the other hand, displayed an overall similar profile and resulted in 
little to no growth inhibitory effect for most cell lines. The most favorable results were 
20.5% growth inhibition (RXF 393, Renal) for 93a and 18.8% growth inhibition (SR, 
Leukemia) for 93b. The presence of 93b resulted in substantial proliferation of the 
following cell lines: NCI-H322M (Non-Small Cell Lung), MALME-3M (Melanoma), 
and IGROVl(0varian). Interestingly, 93a HCI Salt was highly effective against the 
CCRF-CEM leukemia cell line and led to 68.7% cell growth inhibition. Although there 
is no data for the parent compound 93a in this cell line, this result seems to deviate from 
the trend observed for 88a and 93b. Perhaps this cell line may be particularly sensitive to 
the residual hydrochloric acid from this compound. In general, the tested compounds 
were most effective against leukemia cells and least effective for melanoma cell lines. 
Despite the modest anticancer properties of 88a, this compound was not selected 
by NCI for dose titration experiments. We anticipated that the deprotected products 
would possess more favorable anticancer activity than the perbenzylated compounds. 
Perhaps the highly lipophilic nature of the benzyl groups of 88a contributes to the activity 
of this compound. Alternately, the benzyl ether groups of 88a may be aiding in the 
intercalation process. Based upon the data, we conclude that the lack of tumor cell 
growth suppression involving 93a, 93a HCI Salt, and 93b is attributed to insufficient 
DNA intercalation. Future follow-up studies to determine the DNA binding capacity of 
compounds 88a, 93a, 93a HCI Salt, and 93b are planned. 
Table 4.1. Results from the NCI60 human tumor cell line anticancer drug screen assay. 
(Non-Small Cell Lung) 
Lung) 
HOP-62 (Non-Small Cell 
Lung) 
HOP-92 (Non-Small Cell 
L u g )  
NCI-H226 
(Non-Small Cell Lung) 
NCI-H23 (Non-Small Cell 
EKVX (Non-Small Cell 1 88.7 
Lung) 
NCI-H322M 
(Non-Small Cell L u g )  
NCI-H460 
(Non-Small Cell Lung) 
NCI-H522 
120.4 123.0 
76.7 
54.3 
87.9 
59.9 
93.3 
104.7 
91.6 
101.2 
103.6 
---- 
98.3 
99.5 
122.8 
101.2 
---- 
107.5 
84.8 
106.5 
105.2 
106.3 
---- 
107.4 
98.6 
130.1 
108.8 
103.8 
151.0 
106.1 
86.8 
(Breast) 
HS 578T (Breast) 
BT-549 (Breast) 
T-47D (Breast) 
MDA-MB-468 (Breast) 
89.0 
104.1 
56.6 
58.1 
105.8 
---- 
94.8 
97.3 
108.6 
1 17.0 
101.0 
97.1 
101.7 
98.7 
100.7 
109.2 
4.4. Summary 
The simultaneous assessment of both pharrnacokinetic properties and in vitro 
activity is a proven strategy for the evaluation of the drug-like properties of compounds. 
In order to adhere to this approach, we utilized the data output fiom ACD Labs software 
in conjunction with Lipinski and Veber's rules to help us make predictions regarding the 
bioavailability of the glycosylidene-based quinolines. Based upon our interpretation of 
the software's physiochemical property calculations, we anticipate that the 
perhydroxylated compounds should possess favorable bioavailability. In addition, we 
also submitted several compounds to the NCI (compounds 88a, 93a, 93a HCI Salt, & 
93b) for anticancer screening. We thought that the protected compound 88a would be 
less active than the deprotected analogues 93a, 93a HCI Salt, and 93b. Although the 
perbenzylated precursor displayed moderate anticancer activity against several cell lines, 
the deprotected compounds that were assayed did not promote growth inhibition of most 
cell lines. We were particularly surprised by this outcome because we hypothesized that 
the sugar-based quinolines may behave as DNA intercalators. The only exception to this 
trend was the 68.7% growth inhibition of CCRF-CEM leukemia cells resulting fiom 
treatment with 93a HCI salt. Overall the tested compounds were most effective agains 
leukemia cell lines. None of the compounds tested possessed sufficient anticancer 
activity against the cell lines to proceed to the dose titration stage of NCI's evaluation 
process. 
Chapter 5 
Conclusions 
5.1. Summary 
The objective of this research project was to develop a synthetic method for the 
preparation of novel glycosylidene-based quinolines. Through a survey of the scientific 
literature, we have noticed that the structural motif of a carbohydrate moiety in 
combination with an aromatic heterocycle is common among biologically active natural 
products. As a result of the widespread prevalence and favorable pharmacokinetics of 
carbohydrates, stable sugar derivatives have attracted attention as scaffolds for drug 
design. In addition, quinoline-based compounds are also a beneficial class of compounds 
with therapeutic applications. Our proposed targets integrated the common structural 
themes associated with some DNA intercalating agents as well as glycosidase inhibitors. 
These target compounds were chosen, in part, because we anticipated that they may 
possess favorable biological activities and pharmacokinetic properties. The unique 
structures would also allow for the investigation of new synthetic methodology strategies. 
We have successfidly developed a facile one-pot approach toward the synthesis of 
novel glycosylidene-based quinolines. We hypothesized that carbon-linked glucose- 
quinoline hybrids could be accessed through a Povarov reaction between benzaniline and 
a glucose-based exo-glycal. We performed extensive screening experiments with several 
Lewis acids and discovered that scandium triflate is the optimal catalyst for this reaction. 
We have also determined through comprehensive NMR studies that the reaction produces 
an open-ring glucose-based quinoline in addition to diastereomers in which the 
tetrahydroquinoline portion of the compound is spiroanellated to glucose at the anomeric 
carbon. These spiro products are not stable at room temperature, and they slowly 
undergo oxidative ring opening. We presume that the aromatization of the 
tehahydroquinoline likely drives the opening of the glucopyranose ring. In addition to 
the aromatization, the resulting increase in the number of rotatable bonds renders this 
process favorable from an entropic standpoint. We desired to exclusively obtain the 
open-ring compound, and soon discovered that addition of 2.0 equiv of manganese 
dioxide to the reaction mixture drives the complete conversion of the exo-glycal into the 
oxidized product to form a novel C-linked, glycosylidene-based quinoline. In the one-pot 
reaction, the open-ring compound is accessed through the glucose-spiroanellated 
tetrahydroquinoline intermediates. 
We next applied this one-pot additiodoxidation reaction to a series ofpara- 
substituted benzanilines in order to evaluate the electronic effect of substituents on the 
reaction. The highest yield for reactions in this series was 65%, and this result occurred 
with benzaniline itself. In addition, similar yields (>60%) were obtained when 
benzaldehyde-derived imines substituted with para-halogen groups were reacted with the 
glucose-based exo-glycal. The methoxy-substituted, aniline-derived imine also reacted 
efficiently to give the desired product. However, yields were dimished when imines with 
electron-donating and electron-withdrawing groups on the phenyl ring originating from 
the benzaldehyde were allowed to react with the exo-glycal. Perhaps the most dramatic 
effects were observed with imines in which the aniline-derived phenyl ring waspara- 
substituted with electron-withdrawing groups. The poor reactivity with these 
benzanilines is likely due to removal of electron density from the aniline-derived phenyl 
ring. As a consequence, the pi-bond electrons are less available for the ring closure event 
which takes place upon attack of the positively charged anomeric carbon. Nonetheless, 
this procedure represents an effective way to access a variety of glucose-derived 
quinolines with para-substituted benzanilines. 
The one-pot Povarov cycloaddition/oxidation reaction sequence that we have 
developed is a convenient route to access C-glycosylated quinolines. Upon consideration 
of the favorable results of the reaction with the glucose-based exo-glycal, we desired to 
extend this methodology to exo-glycals derived from other sugars. When further studies 
were conducted to address the breadth of this stategy, we were able to successfUlly apply 
our reaction to both arabinose and galactose-based exo-glycal dienophiles. Overall, the 
yields were slightly lower with these different sugar exo-glycals in comparison to the 
correspondingpara-substituted benzanilines in the glucose series. Interestingly, all of the 
reactions in the arabinose series required 8.0 equiv of manganese dioxide for complete 
conversion to the open-ring form. We hypothesize that opening of this furanose sugar is 
not as entropically favorable due to the fact that fewer rotatable bonds result from 
arabinose, a pentose, than from a hexose such as glucose. Regardless, we have 
demonstrated that moderate to good yields (40-50%) can be obtained when our one-pot 
reaction conditions are applied to other sugar exo-glycals. This synthetic method is broad 
enough to permit changes to both the ring size and stereochemistry of the sugar-based 
dienophile. 
A thorough set of debenzylation experiments was conducted in order to determine 
conditions for removal of the protective groups. Attempts using standard hydrogenolysis 
strategies and high temperature, high pressure palladium-based deprotection procedures 
were not successful in obtaining the anticipated perhydroxylated product. Transfer 
hydrogenation conditions involving palladium hydroxide and cyclohexene gave the 
desired product. However, this procedure was prone to unwanted side reactions which 
are likely attributed to high catalyst loading and sealed tube beating conditions. Facile 
deprotection conditions were later identified utilizing the Lewis acid, boron trichloride, 
and prep scale HPLC conditions were also determined that successfully purified the 
resulting perhydroxylated material. 
Computer software was utilized to calculate the physiochemical properties of 
several novel, sugar-based quinolines, and this data was interpreted in accordance with 
Lipinski's and Veber's rules to make predictions regarding bioavailability. In general, the 
perhydroxylated sugar-derived quinolines are anticipated to possess favorable absorption 
and distribution properties while the perbenzylated precursor is not. Although several 
compounds do display modest anticancer efficacy, particularly in leukemia cell lines, the 
in vitro data generated by NCI's 60 cell line screen indicate that the tested compounds do 
not possess sufficient activity at ten micromolar drug concentrations to proceed to the 
dose titration stage of the screen. 
In conclusion, we have demonstrated that carbon-linked, glycosylidene-derived 
quinolines can be obtained in moderate to good yields from a one-pot, scandium triflate 
catalyzed Povarov reaction followed by oxidative tetrahydroquinoline aromatization and 
sugar ring opening with manganese dioxide. We have also isolated and characterized the 
reaction intermediates in which the tetrahydroquinoline is spiroanellated to the sugar's 
anomeric carbon. The utility of this facile procedure has been effectively employed with 
a series ofpara-substituted benzanilines as well as several different sugar-derived exo- 
glycal dienophiles to access novel open-ring glycosylidene quinolines. A straightforward 
deprotection reaction involving boron trichloride was identified to remove the benzyl 
protective groups. Several of the C-glycosylated quinolines have been evaluated for 
biological activity in the NCI60 human tumor cell line anticancer drug screen, but the 
compounds lacked sufficient growth inhibition properties to facilitate dose titration 
experiments. 
5.2. Experimentals 
General Remarks 
All reactions were performed under a nitrogen atmosphere unless otherwise noted. 
Anhydrous solvents were purchased from Sigma Aldrich Chemical Company and were 
used as received. Unless otherwise specified, commercially available reagents were used 
without further purification. Nuclear magnetic resonance spectra were taken on a Varian 
Inova (500 or 600 MHz) spectrometer in CDC13, CD3CN, or CD30D as solvent using 
tetrarnethylsilane as an internal standard. Chemical shifts (6) are expressed in ppm, 
coupling constants are expressed in Hz, and splitting patterns are described as follows: s 
= singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet. 
High resolving power accurate mass measurement electrospray (ES) mass spectral data 
were acquired by use of a Bruker Daltonics apex-Qe Fourier transform ion cyclotron 
resonance mass spectrometer (FT-ICR MS). External calibration was accomplished with 
oligomers of polypropylene glycol. IR spectra were obtained as thin films on NaCl plates 
with use of a Nicolet 380 FT-IR from Thermo Electron Cop. Melting points values 
(uncorrected) were measured with an Electrothermal MEL-TEMP30 melting point 
apparatus. Rotation values were obtained through use of a Perkin Elmer 241 Polarimeter. 
Silica gel column chromatography was carried out using a Combi Flash Companion 
system and silica gel columns from Teledyne Isco. Thin layer chromatography was 
carried out with Whatman MK6F silica gel TLC plates. Microwave experiments were 
conducted with a Biotage Initiator microwave reactor. Prep scale HPLC was conducted 
with a Waters mass directed reverse phase HPLC system. The following chromatographic 
conditions were used: (a) column: Waters Xbridge C-18,30 x 75 mrn, 5 micron; (b) 
flowrate: 50 mL/min; (c) mobile phase: A = water + ammonium hydroxide (pH lo), B = 
acetonitrile; (d) mobile phase gradient method: time = 0 min, A = 98, B = 2; time = 11 
min, A = 65, B = 35; time = 11.2 min, A = 0, B = 100; time = 14.2 min, A = 98, B = 2; 
time = 15 min, A = 98, B = 2. Analytical HPLCMS was conducted on an Agilent 1 100 
Series HPLC system equipped with a 3.0 x 50 mm XTerra C-18 column utilizing solvents 
buffered with 0.05% TFA. The following method was used: a gradient of 10% to 98% 
MeCN in H20 for 3.75 min, then 98% MeCN in Hz0 for 1 .O min. Low resolution mass 
spectrometry electrospray (ES) analysis was performed with a Micromass ZQ by Waters. 
Prep scale HPLC of chiral samples was carried out with a Gilson Unipoint semi-prep 
HPLC equipped with a 20 x 250 mm ChiralPak IB column, 5 micron, 9 mL/min flow 
rate. Screening conditions of chiral samples were performed with a Shimadzu Discovery 
analytical HPLC. 
Lactones 
General procedure for the preparation of compounds 84, 107, & 113." 
To a solution of anomeric alcohol (500 mg; 0.925 rnrnol) in dichloromethane (4 mL) was 
added tert-butanol(0.l mL; 0.999 mmol) followed by Dess-Martin periodinane (408 mg; 
0.962 rnmol). The reaction was stirred at room temperature under an atomosphere of 
nitrogen for four hours. The reaction mixture was diluted with diethyl ether (50 mL) and 
saturated aqueous sodium carbonate solution (50 rnL). The layers were separated and the 
aqueous layer was extracted four times with diethyl ether. The combined organics were 
washed with brine, dried (Na~S04), and concentrated in vacuo. The crude material was 
filtered through a pad of silica gel, eluting with 40% ethyl acetate in hexane. 
(3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-[(beno)methyl] tetrahydro-2H-pyran-2- 
one (84) 
Isolated in 93% yield as an off-white solid. 'H and I3c NMR data were consistent with 
literature values.'' 
(3R,4R,5S)-5-[(Benzyloxy)methyl]-3,4bis(pheno~methyl)dihydrofuran-Z(3~-one 
(107) 
Isolated in 98% yield as an off-white solid. 'H and I3c NMR data were consistent with 
literature va~ues.~'  
(3R,4S,5S,6R)-3,4,5-Tris(benzyloxy)-6-[(loxy)methy] tetrahydro-ZH-pyran-2- 
one (113) 
Isolated in 98% yield as a colorless oil. 'H and "C NMR data were consistent with 
literature values.93 
exo-alycals 
General procedure for the preparation of compounds 85,108, & 114.'~ 
To a solution of lactone (I95 mg; 0.362 mmol) in toluene (1 mL), THF (0.3 mL), and 
pyridine (5 pL) was added Tebbe reagent (0.5 M in toluene, 0.8 mL, 0.398 mmol) at 
-45 OC. The reaction was stirred at -45 "C under an atomosphere of nitrogen for one 
hour, and then at 0 "C for one-half hour. The flask was then cooled to -10 to -15 O C ,  and 
15% sodium hydroxide solution (0.15 mL) was slowly added to quench the reaction. The 
cold bath was removed, and the mixture was diluted with diethyl ether (20 mL), dried 
(Na2S04), filtered through a pad of Celite, and concentrated in vacuo. The crude material 
was purified over silica gel, eluting with a gradient of 0% to 80% ethyl acetate in hexane. 
2,6-Anhydro-3,4,5,7-tetra-O-benzyl-l-deoxy-D-gluco-hept-l-enitol(85) 
Isolated in 75% yield as an off-white solid. 'H and 13c NMR data were consistent with 
literature va~ues.'~ 
1,4-Anhydro-5-O-benzyl-2~-dideoxy-1-methylidene-2,3-bis(phenoxymethyl)-D- 
arabinitol(108) 
Isolated in 43% yield as an off-white solid. 'H and I3c NMR data were consistent with 
literature values.92 
2,6-Anhydro-3,4,5,7-tetra-O-benzyl-l-deoxy-D-galacto-hept-l-enitol(ll4) 
Isolated in 5 1% yield as a colorless oil. 'H and I3c NMR data were consistent with 
literature values.94 
Benzanilines 
General procedure for the preparation of compounds 86c, 86d, 86e, 86g, 86h, 86i, 86j, & 
86k." (Compounds 86a, 86b, & 86f were obtained from commercial sources). 
A mixture of a substituted benzaldehyde derivative (1.105 g; 5.5 mmol) and substituted 
aniline derivative (51 1 mg; 5.5 mmol) was vigorously stirred at room temperature under 
an atomosphere of nitrogen. After a few minutes, solidification of the mixture took place 
and the resulting product was recrystallized from ethanol. 
N-[(a-(4-Bromophenyl)methylidene]aniline (86c) 
Isolated in 83% yield as a white solid. 'H and "C NMR data were consistent with 
literature values. 121, 122 
4-[(a-(Phenylimino)methyl]benzonitrile (86d) 
Isolated in 68% yield as a yellow solid. 'H and I3c NMR data were consistent with 
literature values. 123, 122 
N-{(~-[(4-Trifluoromethyl)phenyl]methylidene)aniline (86e) 
Isolated in 12% yield as an off-white solid. 'H and I3c NMR data were consistent 
with literature values.124 
4-Fluoro-N-[(a-phenylmethylidenejaniline (86g) 
Isolated in 70% yield as an off-white solid. 'H and I3c NMR data were consistent 
with literature values.125 
4-Bromo-N-[(Q-phenylmethylidenejaniline (86h) 
Isolated in 42% yield as an off-white solid. I H  and I3c NMR data were consistent 
with literature values. 126, 127 
4-([Q-Phenylmethylidene]amino}benzonitrile (86i) 
Recrystallization attempts were unsuccessful. Crude material (90% by wt) was used in 
the next reaction. I H  and I 3 c N ~ R  data were consistent with literature values.'28 
N-[(Q-Phenylmethylidene]-4-(trifluoromethyl)aniine (86j) 
Isolated in 51% yield as a white solid. I H  and I 3 c N ~ R  data were consistent with 
literature values.129 
4-Methoxy-N-[(Q-phenylmethylidenejaniline (86k) 
Isolated in 69% yield as a light brown solid. I H  and I3c NMR data were consistent 
with literature values. 130, 127 
Spiroanellated sugar-derived tetrahvdroauinolines 
Procedure for the preparation and separation of 87Major + 87Minor 
To a solution of exo-glycal85 (1 00 mg; 0.186 mmol) in acetonitrile (1 mL, unopened 
sure/sealTM bottle) was added benzaniline 86a (33.7 mg; 0.186 mmol) followed by 
Sc(OTf), (18.3 mg; 0.0372 rnmol). The reaction was stirred at room temperature under 
an atmosphere of nitrogen for one hour. The reaction was concentrated in vacuo, and the 
crude material was purified over silica gel, eluting with a gradient of 0% - 40% ethyl 
acetate in hexane to give 87Major + 87Minor as a colorless oil (4:l mixture of 
diastereomers) in 65% yield. The isomers were separated by applying the prep scale 
version (20 x 250 mm ChiralPak IB column, 5 micron, 9 mL/min flow rate) of the 
following analytical chromatography conditions: ChiralPak IB 4.6 x 250 mm column, 5 
micron particle size, 10% ethanol in heptane (isocratic), 0.5 mL/min flow rate, 254 nm 
wavelength, retention time: 87Minor (8.48 min), 87Major (13.89 min). 
(ZRJ'R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-[(benzyloxy)methyl]-Z'-phenyl- 
2'J,3',4,5,6-hexahydro-lIT-spiro[pyran-2,4-quinoline] (87Major) 
IH NMR (500 MHz, CDC13): 6 7.62 (d, J = 7.5 Hz, 1 H), 7.42-7.37 (m, 2 H), 7.36-7.25 
(m,19H),7.20-7.11(m,5H),6.78(t,J=7.25Hz,1H),6.58(d,J=6.5Hz,1H),4.73 
(d, J =  ll.OHz, 1 H),4.67-4.54(m,4H),4.54-4.43 (m,2H),4.41-4.31 (m, 2 H),4.31- 
4.24 (m, 1 H), 4.15-4.12 (m, 1 H), 4.06-4.03 (m, 1 H), 4.02-3.97 (m, 1 H), 3.84-3.75 (m, 
2 H), 2.64 (dd, J =  13.25,4.75 Hz, 1 H), 2.22-2.16 (m, 1 H); I3C NMR (126 MHz, 
CDCL): 6 145.1, 144.4, 139.0, 138.8, 138.4, 138.2, 129.9, 128.9, 128.7, 128.6, 128.5, 
128.4, 128.1, 128.0, 127.9, 127.9, 127.9, 127.5, 126.9, 123.2, 116.9, 113.7, 84.9, 79.9, 
78.9, 76.3, 73.8, 73.6, 73.3, 72.4, 70.2, 55.2,42.8; IR (NaCI): 3405, 3038, 291 1,2795, 
1778, 1607, 1491, 1362, 1094,698 cm-'; HRMS calcd for [M+H+]: 
718.3527, found 718.3529; [a]22D -13.5' (c 1.0, CHCI,). 
(ZSJ'R,4S,5R,6S)-3,4,5-Tris(benzyloxy)-6-[(benloxy)methy1]-2'-phenyl- 
2',3J',4,5,6-hexahydro-lIT-spiro[pyran-2,4'-quinoline] (87Minor) 
IH NMR (500 MHz, CDC13): 6 7.55 (d, J = 7.5 Hz, 1 H), 7.46-7.12 (m, 26 H), 6.68 (t, J 
= 7.25 Hz, 1 H), 6.60 (d, J = 8.0 Hz, 1 H), 5.07-5.00 (m, 2 H), 4.98-4.88 (m, 3 H), 4.80- 
4.67 (m, 2 H), 4.68-4.56 (m, 3 H), 3.89-3.85 (m, 1 H), 3.83-3.75 (m, 2 H), 3.68-3.62 (m, 
2 H), 2.22(t, J =  12.75 Hz, 1 H), 1.91 (dd, J =  12.75,3.75 Hz, 1 H); "CNMR(126MHz, 
CDC13): 6 145.9, 144.4, 138.9, 138.8, 138.6, 130.8, 129.3, 128.9, 128.7, 128.6, 128.4, 
128.3, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8, 127.5, 127.4, 127.2, 117.7, 115.4, 114.9, 
87.1,86.6,79.9,76.3,76.1,75.8,75.2,73.4,71.3,69.3,52.5,44.4;IR(NaCl): 3405,
3038,291 1,2795,1778,1607, 1491, 1362,1094,698 cm-'; HRMS calcd for C48H48NO5+ 
[M+H+]: 718.3527, found 718.3529; [al2'D +40.2' (c 1.0, CHC13). 
109Isomers was prepared in an analogous manner to 87Major + 87Minor and was 
isolated as a colorless oil in 60% yield by stopping the room temperature, Sc(OTQ3 
catalyzed reaction after one hour. However, separation conditions for the complex 
mixture of isomers were not found. 
( 3 S , 4 R , S R ) - 3 , 4 - B i s ( b e n z y l o x y ) - 5 - [ ( b e n z y l d r o -  
l'H,3H-spiro[furan-2,4'-quinoline] (109Isomers) 
'H NMR (500 MHz, CDC13): 6 7.58 (t, J = 8.0 Hz), 7.51 (d, J = 8.0 Hz), 7.48-7.12 (m), 
7.10-7.05(m),6.84(t,J=7.0Hz),6.80(t,J=7.0Hz),6.75-6.70(m),6.68(d,J=7.5 
Hz), 6.58 (d, J = 7.5 Hz), 4.85-4.82 (m), 4.76-4.63 (m), 4.61-4.55 (m), 4.49-4.40 (m), 
4.38-4.30 (m), 4.28-4.24 (m), 4.21-4.17 (m), 4.10-3.99 (m), 3.85-3.72 (m), 3.64-3.60 (m), 
2.63 (dd,J= 13.0,3.0Hz),2.52(dd,J=13.0,3.0Hz),2.42(s),2.35-2.30(m),2.25-2.10 
(m); "CNMR(126MHz,CDC13):6 146.2, 145.2, 144.5, 144.4, 144.0, 143.7, 138.7, 
138.7, 138.6, 138.5, 138.5, 138.3, 138.2, 138.2, 138.2, 138.1, 132.5, 130.2, 129.4, 129.0, 
128.9, 128.9, 128.8, 128.7, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 
127.9, 127.9, 127.8, 127.8, 127.7, 127.5, 127.2, 127.0, 126.9, 125.0, 123.0, 120.0, 118.5, 
118.4, 118.1, 117.6, 116.0, 115.4, 115.3, 115.2,, 114.6, 113.8,92.5,91.2, 90.4, 88.3, 
87.9,85.1,83.8,83.5,82.4,81.0,80.7,80.4,79.5,79.4,79.2,79.2,73.7,73.6,73.5,73.1, 
72.8, 72.6,72.4, 72.1, 71.5, 71.0, 70.4, 70.2, 55.5, 55.4, 54.3, 53.1,45.9,42.1,40.8,40.3; 
IR (NaC1): 3376,3029,2925, 1724, 1608,1485,1096,747,699 cm-'; HRMS calcd for 
C ~ O H ~ ~ N O ~ '  [M+H+]: 598.2957, found 598.2963; [a]22D +0.5' (c 1.0, CHCI3). 
Open-ring glycosvlidene-based auinolines (benzvlated) 
General procedure for the preparation of compounds 88a, 88b, 88c, 88d, 88e, 88g, 88h, 
88j, 88k, 110a, 110b, 110f, 110g, 115a, 115b, & 115g. 
To a solution of exo-glycal(100 mg; 0.186 mmol) in acetonitrile (1 mL, unopened 
surelsealTM bottle) was added substituted benzaniline derivative (33.7 mg; 0.186 mmol) 
followed by Sc(OTf)3 (18.3 mg; 0.0372 mmol). The reaction was stirred at room 
temperature under an atmosphere of nitrogen. After two hours, Mn02 (32.4 mg; 0.372 
mmol) was added and the mixture was stirred overnight. If required, additional Mn02 
(up to 6.0 equiv) was added to drive the ring opening to completion. The reaction was 
diluted with ethyl acetate (15 mL), filtered through Celite, and concentrated. The crude 
material was purified over silica gel, eluting with a gradient of 0% - 40% ethyl acetate in 
hexane. 
(1R)-1,2,3,5-Tetra-0-benzyl-l-C-(2-phenylquinolin-4-yl)-D-arabinitol(88a) 
Isolated in 65% yield as a colorless oil: 'H NMR (500 MHz, CDC13): 6 8.27 (d, J = 8.5 
Hz,1H),8.19(s,1H),8.16(d,J=7.0Hz,2H),8.03(d,J=6.5Hz,1H),7.74(t,J= 
7.75 Hz, 1 H), 7.56-7.49 (m, 3 H), 7.42-7.31 (m, 14 H), 7.30-7.25 (m, 2 H), 7.08 (t, J =  
7.5Hz,1H),7.00(t,J=7.5Hz,2H),6.89(d,J=7.5Hz,2H),5.65(d,J=1.5Hz,lH), 
4.67-4.56(m,6H),4.39(d,J=11.5Hz,lH),4.16(m,1H),4.11-4.03(m,2H),3.92 
(m, 1 H), 3.76 (dd, J = 10.0,3.75 Hz, 1 H), 3.68 (dd, J = 10.0,5.0 Hz, 1 H), 3.05 (br s, 1 
H); "C NMR (126 MHz, CDCI,): 6 157.0, 148.7, 145.7, 139.5, 138.4, 138.3, 137.5, 
137.3, 130.8, 129.7, 129.6, 129.1, 128.8, 128.8, 128.7, 128.7, 128.7, 128.3, 128.2, 128.2, 
128.1, 128.0, 128.0, 127.9, 126.6, 125.6, 123.1, 118.7,81.7, 78.0, 77.0, 75.1,74.0, 73.8, 
72.1, 71.9, 71.4; IR (NaCI): 3676,2836,2364,2016, 1724, 1598, 1075, 697 cm-'; 
HRMS calcd for c ~ ~ H ~ ~ N o ~ +  [M+H+]: 716.3371, found 716.3377; [alZ2D +67.3' (c 1.0, 
CHCl3). 
(1R)-1,2,3,5-Tetra-0-benzyl-l-C-(2-(4-fluorophenyl)quinoIin-4-yl]-D-arabinitol 
(gab) 
Isolated in 60% yield as a colorless oil: IH NMR (500 MHz, CDC13): 6 8.24 (d, J = 8.0 
Hz, 1 H), 8.12(t, J=6.7Hz,3H),8.03 (d, J=7.5  Hz, 1 H),7.74(t, J=7.75Hz, 1 H), 
7.42-7.31 (m, 14H),7.30-7.26(m,2H),7.20(t,J=8.75Hz,2H),7.09(t,J=7.5Hz, 1 
H),7.00(t,J=7.5Hz,2H),6.88(d,J=7.0Hz,2H),5.64(d,J=2.0Hz,1H),4.68-4.55 
(m,6H) ,4 .44(d , J= l lSHz,  1 H),4.14-4.10(m, 1H),4.10-4.03(m, lH),4.04(brs, 1 
H), 3.92(m,1 H),3.76(dd,J=9.75,3.75Hz, lH),3.68(dd,J=9.75,4.75Hz, 1 H), 
3.05 (brs, 1 H); 13CNMR(126MHz,CDC13): 6 165.1, 163.2, 155.9, 148.6, 145.9, 138.4, 
138.3, 137.5, 137.3, 130.6, 129.9, 129.8, 129.7, 128.8, 128.8, 128.7, 128.6, 128.4, 128.3, 
128.2, 128.1, 128.1, 128.0, 127.9, 126.7, 125.5, 123.1, 118.3, 116.1, 115.9, 81.9, 78.0, 
77.0,75.1,74.0, 73.8, 72.1, 71.9, 71.3; IR (NaCI): 3649,291 1,2537, 2356,2051, 1502, 
1090,697 cm"; HRMS calcd for C4~H4~FbJ05f [M+H+]: 734.3276, found 734.3276; 
[alZ2D +74.2' (c 1.0, CHC1,). 
(1R)-l,2~,5-Tetra-O-benzyl-l-C-[2-(4-bromophenyl)quinolin-4-yl]-D-arabinitol 
(W 
Isolated in 64% yield as a colorless oil: IH NMR (500 MHz, CDC13): 6 8.24 (br s, 1 H), 
8.11 (s, 1 H),8.05-7.97(m,3H),7.74(t,J=7.3Hz, 1 H),7.64(d,J=8.5Hz,2H),7.44- 
7.32 (m, 14 H), 7.29-7.26 (m, 2 H), 7.09 (t, J = 7.5 Hz, 1 H), 7.01-6.96 (m, 2 H), 6.86 (d, 
J=7.0Hz,2H),5.64(d,J=2.0Hz,lH),4.67-4.56(m,6H),4.43(d, J = l l S H z , l H ) ,  
4.14-4.04 (m,2H),4.03 (s, 1 H), 3.93 (m, 1 H), 3.76(dd, J=9.75, 3.75 Hz, 1 H), 3.67 
(dd, J=9.75, 5.0Hz, 1 H), 3.03 (brs,l H); 13CNMR(126MHz, CDCl3): 6 155.7, 138.4, 
138.3, 137.4, 137.3, 132.2, 130.8, 129.8, 129.5, 128.9, 128.8, 128.7, 128.6, 128.4, 128.3, 
128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 126.8, 125.6, 123.1, 118.2, 81.8, 78.0, 77.5, 
75.1, 74.0, 73.8, 72.1, 71.9, 71.3; IR (NaC1): 3567, 3030,2868, 1958, 1596, 1073, 698 
cm-'; HRMS calcd for C ~ ~ H ~ ~ B ~ N O ~ '  [M+H']: 794.2476, found 794.2504; [ a l Z 2 ~  +39.0° 
(c 1 .O, CHC13). 
( l R ) - 1 , 2 , 3 , 5 - T e t r a - O - b e n z y l - l - C - [ 2 - ( 4 - ~ y l ] - D - a r a b i n i t o 1 ( 8 8 d )  
Isolated in 43% yield as a colorless oil: 'H NMR (500 MHz, CDC13): 6 8.25 (d, J = 8.5 
Hz,1H),8.20(d,J=8.0Hz,2H),8.14(s,1H),8.05(d,J=8.0Hz,1H),7.82-7.74(m, 
3 H), 7.44 (t, J = 7.5 Hz, 1 H), 7.40-7.32 (m, 13 H), 7.28 (m, 2 H), 7.07 (t, J = 7.25 Hz, 1 
H),6.97(t,J=7.5Hz,2H),6.84(d,J=7.5Hz,2H),5.66(d,J=l.SHz, 1H),4.70-4.54 
(m,6H),4.44(d, J =  11.50Hz, 1 H),4.10-4.05(m,2H),4.02(brs, 1 H),3.94(m, 1 H), 
3.77 (dd, J = 10.0, 3.5 Hz, 1 H), 3.67 (dd, J = 10.0, 5.0 Hz, 1 H), 3.01 (br s, 1 H); 13C 
NMR(126MH2, CDCI,): 6 154.6, 148.7, 146.4, 143.7, 138.4, 138.3, 137.4, 137.3, 132.8, 
131.0, 130.0, 129.0, 128.8, 128.7, 128.5, 128.4, 128.2, 128.2, 128.1, 127.9, 127.4, 125.9, 
123.2, 119.2, 118.4, 113.0, 82.0, 77.9, 76.9, 75.1, 74.1, 73.8, 72.2, 72.0, 71.3; IR(NaC1): 
3556,3030,2829,2227, 1779, 1597, 1073,699 cm-'; HRMS calcd for C49H4s~205+ 
[M+H']: 741.3323, found 741.3322; [a12'D +56.3' (c 1.0, CHC13). 
(lR)-l,2,3,5-Tetra-O-benzy1-1-C-{2-[4-(trifluorometbyl)phenyl]quinolin-4-yl)-D- 
arabinitol(88e) 
Isolated in 46% yield as a colorless oil: 'H NMR (500 MHz, CDCb) 6 8.26 (d, J = 8.5 
Hz, 1 H), 8.21 (d, J=8.0Hz,2H),  8.15 (s, 1 H), 8.04(d, J =  8.0Hz, 1 H), 7.79-7.73 (m, 
3H),7.45-7.31(m, 14H),7.29-7.26(m,2H),7.07(t,J=7.5Hz,lH),6.97(t,J=7.5 
Hz, 2 H), 6.84 (d, J = 7.5 Hz, 2 H), 5.65 (d, J = 2.0 Hz, 1 H), 4.68-4.55 (m, 6 H), 4.44 (d, 
J=11.5Hz, IH),4.14-4.05(m,2H),4.03(~, lH),3.93(m, lH),3.76(dd,J=9.75, 
3.75Hz, 1 H),3.67(dd, J =  10.0,5.0Hz, 1 H),3.01 (brs, 1 H); "CNMR(126MH2, 
CDC13): 6 155.3, 148.5, 146.4, 142.8, 138.4, 138.3, 137.4, 137.2, 130.8, 129.9, 128.8, 
128.8, 128.7, 128.5, 128.4, 128.2, 128.2, 128.1, 128.0, 127.9, 127.2, 125.9, 125.9, 125.8, 
123.2, 118.5,81.8, 77.9, 77.3, 75.1, 74.1, 73.8, 72.2, 72.0, 71.3; IR(NaC1): 3549, 3030, 
2865,1598,1324, 1107,698 cm-'; HRMS calcd for C49&5~3N05+ [M+H+]: 784.3244, 
found 784.3242; [a]22D +53.7O (c 1.0, CHCI3). 
(lR)-1,2,3,5-Tetra-0-benzyl-l-C-[2-(4-methoxyphenyl)quinolh-4-yl]-D-arabinitol 
(880 
Isolated in 45% yield as a colorless oil: 'H NMR (500 MHz, CDCb): 6 8.23 (d, J = 8.5 
Hz,lH),8.13(d,J=9.0Hz,3H),8.02(brs,lH),7.72(t,J=8.5Hz,2H),7.58(m,1 
H),7.52-7.47(t, J=8.5Hz, 1 H),7.40-7.31 (m, 12H),7.30-7.26(m,2H),7.12-6.97(m, 
4 H), 6.91 (d, J = 7.0 Hz, 2 H), 5.63 (br s, 1 H), 4.68-4.53 (m, 6 H), 4.44 (d, J =  11.5 Hz, 
I H), 4.20-4.12 (m, 1 H), 4.07 (m, 3 H), 3.94 (s, 3 H), 3.76 (dd, J = 10.0, 3.75 Hz, 1 H), 
3.68 (dd, J = 9.85, 5.0 Hz, 1 H), 3.09 (br s, 1 H); I3C NMR (1 26 MHz, CDC13): 6 138.4, 
138.3, 137.4, 137.1, 133.2, 132.4, 132.3, 132.2, 128.9, 128.8, 128.7, 128.7, 128.4, 128.2, 
128.2, 128.1, 128.1, 128.0, 125.2, 123.1, 118.5, 114.6,81.6,77.9,77.0,75.0,74.1,73.8, 
72.2, 72.0, 71.3, 55.7; IR (NaCI): 3555,2912,2008, 1601, 1503, 1118,697 cm-I; HRMS 
calcd for c ~ ~ & ~ N o ~ ~  [M+H+]: 746.3476, found 746.3478; [a12'o f40.2" (c 1 .O, CHC13). 
(1R)-1,2,3,5-Tetra-0-benzyl-l-C-(6-fluoro-2-phenyl)quinolin-4-yl)-D-arabinitol(88g) 
Isolated in 39% yield as a colorless oil: IH NMR (500 MHz, CDC13): 6 8.26-8.20 (m, 1 
H),8.18-8.09(m,3H),7.77(d,J=9.25Hz, lH),7.56-7.48(m,4H),7.41-7.28(m, 15 
H), 7.06(t, J=7.25 Hz, 1 H),6.97 (t, J =  7.5 Hz,2 H), 6.84(d, J= 7.5 Hz, 2 H), 5.48 (d, 
J=2.5Hz,l H),4.69-4.56(m,6H),4.42(d,J=ll.5Hz,lH),4.20-4.11 (m,1 H),4.09- 
4.04 (m, 1 H), 4.02-3.97 (m, 1 H), 3.95-3.90 (m, 1 H), 3.75 (dd, J= 9.75,3.75 Hz, 1 H), 
3.63 (dd, J = 9.75, 5.25 Hz, 1 H), 3.00 (br s, 1 H); I3C NMR (126 MHz, CDCl3): 6 161.5, 
159.6, 156.4, 146.1, 145.0, 144.9, 139.5, 138.3, 138.2, 137.4, 137.1, 133.3, 133.3, 129.7, 
129.1, 128.8, 128.8, 128.7, 128.4, 128.3, 128.3, 128.2, 128.1, 127.9, 127.8, 126.2, 126.1, 
119.7, 119.5, 119.3, 107.2, 107.0, 81.3, 77.8, 77.6, 75.0, 74.1, 73.7, 72.1, 71.9, 71.2; IR 
(NaC1): 3419,2927,2360, 1724, 1625, 1073,697 cm"; HRMS calcd for c&&No~+ 
[M+H+]: 734.3276, found 734.3300; [al2'D +48.9' (c 1.0, CHCl3). 
Isolated in 38% yield as a colorless oil: IH NMR (500 MHz, CDC13): 6 8.30 (s, 1 H), 
8.17-8.06 (m, 4 H), 7.80 (dd, J = 9.0,2.0 Hz, 1 H), 7.57-7.49 (m, 3 H), 7.40-7.28 (m, 15 
J=2.5Hz,1H),4.70-4.62(m,3H),4.61-4.55(m,3H),4.43(d,J=11.5Hz,1H),4.16- 
4.08 (m, 2 H), 3.99-3.96 (m, 1 H), 3.93-3.89 (m, 1 H), 3.74 (dd, J = 9.75,3.75 Hz, 1 H), 
3.63 (dd, J = 9.75, 5.25 Hz, 1 H), 3.04 (s, 1 H); I3C NMR (126 MHz, CDC13): 6 157.3, 
147.6, 144.7, 139.3, 138.3, 137.4, 137.1, 132.9, 132.6, 129.9, 129.1, 128.8, 128.8, 128.7, 
128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 126.8, 125.7, 120.6, 119.5, 81.4, 77.5, 77.3, 
74.9, 73.9, 73.8, 72.2, 71.9, 71.3; IR (NaC1): 3442,2927,2091, 1643, 1072,697 cm-'; 
HRMS calcd for C ~ ~ H ~ ~ B ~ N O ~ '  [M+H+]: 794.2476, found 794.2513; [a]22D +59.8' (c 
1 .O, CHC13). 
(1R)-l~J,5-Tetra-O-benzyl-1-C-[2phenyl-6-(trifluoromethyl)quinolin-4-yl]-D- 
arabinitol(88j) 
Isolated in 18% yield as a colorless oil: 'H NMR (500 MHz, CDC13): 6 8.49 (s, 1 H), 
8.31 (d, J=8.5Hz, 1 H), 8.20(s, 1 H),8.17-8.14(m,2H),7.91-7.87(m, 1 H),7.57-7.52 
(m, 3 H), 7.40-7.29 (m, 13 H), 7.27-7.24 (m, 2 H), 7.02 (t, J = 7.25 Hz, 1 H), 6.93 (t, J = 
7.5Hz,2H),6.81(d,J=7.5Hz,2H),5.58(d,J=2.5Hz,lH),4.73-4.49(m,6H),4.43 
(d, J =  11.5 Hz, 1 H),4.20-4.14(m, 1 H),4.10-4.05 (m, 1 H),4.01-3.97(m, 1 H), 3.89- 
3.84(m, 1 H),3.70(dd,J=9.75,3.5Hz, 1 H),3.58(dd,J=9.75,5.5Hz, 1 H),2.99(d,J 
=4.5 Hz, 1 H); I3CNMR(126 MHz, CDCI3): 6 159.0, 150.0, 146.6, 139.1, 138.3, 138.2, 
137.3, 137.0, 132.0, 130.2, 129.2, 128.8, 128.7, 128.6, 128.4, 128.2, 128.1, 128.0, 128.0, 
127.9, 125.1, 124.7, 121.6, 119.8, 81.2, 77.5, 77.3, 77.0, 74.9,73.9, 73.7, 72.3, 71.5; IR 
(NaC1): 3555,2927, 1727, 1274, 1073,698 cm-'; HRMS calcd for ~ 4 9 ~ 4 5 ~ , ~ 0 5 +  
[M+H+]: 784.3244, found 784.3267; [a]22D +47.0° (c 0.5, CHCI,). 
Isolated in 56% yield as a colorless oil: 'H NMR (500 MHz, CDC13): 6 8.21-8.13 (m, 4 
H), 7.54 (t, J = 7.5 Hz, 2 H), 7.53-7.47 (m, 1 H), 7.45-7.33 (m, 15 H), 7.28-7.24 (m, 2 H), 
7.14 (t, J = 7.25 Hz, 1 H), 7.07 (t, J = 7.25 Hz, 2 H), 6.99 (d, J = 7.0 Hz, 2 H), 5.58 (d, J = 
3.0Hz, 1 H), 4.70-4.54 (m, 6 H), 4.43 (d, J =  11.5 Hz, 1 H), 4.31-4.23 (m, 1 H), 4.14- 
4.07 (rn, 2 H), 3.90-3.84 (m, 1 H), 3.74 (dd, J = 9.5, 3.5 Hz, 1 H), 3.69-3.64 (m, 4 H), 
3.00 (d, J = 4.0 Hz, 1 H); I3C NMR (126 MHz, CDC13): 6 158.0, 154.8, 145.1, 143.8, 
139.9, 138.6, 138.3, 137.7, 137.6, 132.3, 129.2, 129.0, 129.0, 128.8, 128.7, 128.6, 128.3, 
128.3, 128.2, 128.1, 128.0, 127.9, 127.7, 126.7, 122.0, 119.0, 101.9, 81.9, 77.7, 77.6, 
77.1, 75.4, 73.7, 72.2, 71.7, 71.5, 55.6; IR(NaC1): 3418,2930,2015, 1622, 1497, 1073, 
697 crn-I; HRMS calcd for C ~ & ~ N O ~ +  [M+&]: 746.3476, found 746.3508; [a]'*,, 
+56.0° (c 1.0, CHC13). 
(2R,3R,4S)-1,3,4-tris(benzyloxy)-4-(2-phenylquinolin-4-yl)butan-2-ol(110a) 
Isolated in 57% yield as a colorless oil: 'H NMR (500 MHz, CDC13): 6 8.31-8.27 (m, 2 
H),8.21(d,J=7.5Hz,2H),7.98(d,J=8.0Hz,2H),7.78(t,J=7.Hz,lH),7.59-7.47 
(rn, 4 H), 7.61-7.14 (m, 10 H), 7.07 (t, J = 7.5 Hz, 1 H), 6.98 (t, J = 7.5 Hz, 2 H), 6.76 (d, 
J=7.0Hz,2H),5 .69(~,  1 H),4.75(d, J =  12.0Hz, 1 H),4.56(~,2H),4.41 (d, J =  12.0 
Hz,1H),4.31-4.27(m,1H),4.11(d,J=ll.OHz,1H),3.86(d,J=7.5Hz,1H,),3.77- 
3.65 (m, 3 H), 2.70 (s, 1 H); I3C NMR(126 MHz, CDCl3): 6 157.2, 148.8, 145.3, 139.8, 
138.0, 137.6, 137.0, 131.0, 129.7, 129.5, 129.3, 129.1, 129.0, 129.0, 128.8, 128.8, 128.8, 
128.7, 128.5, 128.3, 128.2, 128.0, 127.9, 126.7, 125.6, 122.8, 118.5, 80.7, 75.5, 74.8, 
73.8,72.2,71.3,70.2; IR (NaCI): 3449,3027,2983, 1723, 1597, 1484, 1075,745,696 
cm-I; HRMS calcd for ~ 4 0 ~ 3 8 ~ 0 4 '  [M+H+]: 596.2801, found 596.2812; [alZ2D -44.9O (c 
1 .O, CHCI,). 
(2R,3R,4S)-1,3,4-tris(benzyloxy)-4-[2-(4-fluorophenyl)quinolin-4-yl]butan-2-ol 
(110b) 
Isolated in 47% yield as a colorless oil: IH NMR (500 MHz, CDCI3): 6 8.26 (d, J = 8.5 
Hz,1H),8.21(s,1H),8.19-8.16(m,2H),7.97(d,J=8.5Hz,1H),7.80(t,J=7.5Hz,1 
H), 7.50 (t, J=7 .5  Hz, 1 H), 7.40-7.33 (m, 9H), 7.21 (t, J=8.5  Hz,2H),7.08 (t, J = 7 . 5  
Hz, 2 H), 6.98 (t, J = 7.5 Hz, 2 H), 6.74 (d, J = 7.5 Hz, 2H), 5.69 (s, 1 H), 4.74 (d, J = 
11.5Hz, lH),4.56(~,2H),4.41 (d, J =  12.0Hz, 1H),4.31-4.27(m, 1 H),4.12(d, J =  
ll.OHz, 1 H),3.84(dd,J=7.75, 1.75Hz, 1 H),3.7-3.68(m,3H),2.68(~, 1H);13C 
NMR(126 MHz, CDCl3): 6 165.1, 163.1, 156.1, 148.7, 145.5, 137.9, 137.6, 137.0, 136.0, 
130.9, 129.8, 129.8, 129.7, 129.0, 128.8, 128.8, 128.6, 128.5, 128.3, 128.2, 128.0, 126.8, 
125.4, 122.7, 118.1, 116.1, 115.9, 80.7, 75.4, 74.8, 73.8, 72.2, 71.3, 70.1; IR(NaC1): 
3448,3030,2962,2360,1724,1598, 1450,1073,737,698 cm-I; HRMS calcd for 
C 4 0 H 3 7 ~ ~ 0 4 +  [M H+]: 614.2706, found 614.2707; [alZZD -43.0' (c 1.0, CHCI3). 
(2R,3R,4S)-1,3,4-tris(benzyloxy)-4-[2-(4-methoxyphenyl)quinolin-4-yl] butan-2-01 
(110f) 
Isolated in 44% yield as a colorless oil: 'H NMR (500 MHz, CDC13): 6 8.25-8.23 (m, 2 
H), 8.18 (d, J=9.0Hz, 2 H), 7.95 (d, J =  8.5 Hz, 1 H), 7.75 (t, J=7 .5  Hz, 1 H),7.46 (t, J 
=7.25 Hz, 1 H),7.39-7.33 (m, 10H),7.08-7.06(m,3 H),6.98(t, J=7 .5  Hz,2H),6.76 
(d ,J=7.5Hz,2H),5 .67(~,  1 H),4.74(d,J=12.0Hz, I H),4.55(~,2H),4.40(d,J= 
12.0Hz, 1 H),4.16(s, 1 H),4.08(d, J =  10.5Hz, 1 H),3.94(~,3 H),3.85 (m, 1 H),3.74- 
3.68(m,3 H),2.68(brs, 1 H);"CNMR(126MHz,CDC13):6 161.1, 156.7, 148.8, 
145.0, 138.0, 137.6, 137.0, 132.4, 130.8, 129.4, 129.3, 129.0, 128.8, 128.8, 128.7, 128.4, 
128.3, 128.2, 128.2, 127.9, 126.3, 125.3, 122.7, 118.0, 114.4, 80.7, 75.4, 74.8, 73.8, 72.1, 
71.3,70.2,55.7; IR (NaCI): 3450,3033,2927, 1723, 1599, 1453, 1072,737,698 cm-'; 
HRMS calcd for C ~ I H ~ ~ N O ~ '  [M+H+]: 626.2906, found 626.291 8; [ a ] 2 2 ~  -3 1.9' (c 1 .O, 
CHC13). 
(2R,3R,4S)-1,3,4-tris(benzylolry)-4-(6-fluoro-2-phenyqinolin-4-yl]butan-2-ol(110g) 
Isolated in 49% yield as a colorless oil: IH NMR (500 MHz, CDCl3): 6 8.28-8.21 (m, 2 
H), 8.16 (d, J=7.0Hz,2H),  7.63 (d, J=9.0Hz, 1 H), 7.58-7.48 (m, 5 H), 7.40-7.31 (m, 
9H), 7.05 (t, J=7 .5  Hz, 1 H),6.96(t, J=7.5  Hz,2 H),6.74(d, J=7.5  Hz,2H), 5.51 (s, 
1 H), 4.70 (d, J = 12.0 Hz, 1 H), 4.62-4.51 (m, 2 H), 4.39 (d, J = 12.0 Hz, 1 H), 4.28-4.23 
(m, 1 H), 4.18-4.12 (m, 1 H), 3.82-3.65 (m, 4 H); I3C NMR (126 MHz, CDCl3): 6 161.6, 
159.6, 156.5, 145.9, 145.1, 145.0, 139.4, 137.8, 137.4, 136.8, 133.3, 133.2, 129.7, 129.1, 
128.9, 128.8, 128.7, 128.5, 128.3, 128.2, 128.2, 127.9, 127.8, 126.2, 126.1, 119.8, 119.6, 
119.2, 106.9, 106.7, 80.5, 76.0,74.7,73.9,72.3,71.1,70.l;IR(NaCl): 3461,3031, 
2925,2363, 1723, 1623, 1496, 1072,738,697 cm-'; HRMS calcd for ~ 4 0 ~ 3 7 ~ ~ 0 4 '  
[M+H+]: 614.2706, found 614.2731; [a ]22~  -21.3' (c 1.0, CHCI3). 
(5R)-1,2,3,5-Tetra-0-benzyl-5-C-(2-phenyquinolin-4-y)-D-arabinito (1 15a) 
Isolated in 51% yield as a colorless oil: 'H NMR (500 MHz, CDCl3): 6 8.34 (s, 1 H), 
8.22 (s, 1 H), 8.16 (d, J = 6.5 Hz, 2 H), 8.03 (s, 1 H), 7.79 (t, J = 7.5 Hz, 1 H), 7.58-7.48 
(m,4H),7.40-7.27(m, 13 H),7.20(d, J=6.5Hz,2H),7.08(t,  J=7.5Hz, 1 H),6.99(t, 
J=7.5Hz,2H),6.9O(d,J=7.0Hz,2H),5.56(~,  1 H),4.70(d,J= 12.0Hz, 1 H),4.58 
(d, J = 12.0 Hz, 1 H), 4.51 (d, J = 12.0 Hz, 1 H), 4.46-4.42 (m, 2 H), 4.34-4.22 (m, 3 H), 
4.09-4.07 (m, 2 H), 3.83-3.76 (m, 1 H), 3.68-3.63 (m, 1 H), 3.58-3.53 (m, 1 H), 2.56 (br 
s, 1H); I3C NMR (126 MHz, CDC13): 6 156.9, 138.2, 138.1, 137.6, 137.0, 130.6, 129.9, 
129.1, 128.8, 128.8, 128.7, 128.7, 128.3, 128.2, 128.2, 128.1, 128.0, 127.9, 127.0, 125.6, 
122.9, 118.6, 80.4, 78.0, 77.3, 75.4, 74.3, 73.5, 71.7, 71.6,69.5; IR(NaC1): 3674,2835, 
2364,2015, 1724, 1598, 1073, 697 cm-'; HRMS calcd for C48H46N05+ [M+H+]: 
716.3371, found 716.3405; [alUo -6.9" (c 1.0, CHC13). 
(5R)-1~,4,5-Tetra-0-benzyl-5-C-[2-(4-fluorophenyl)quinolin-4-yl]-D-arabinitol 
(115b) 
Isolated in 48% yield as a colorless oil: 'H NMR (500 MHz, CDC13): 6 8.27 (d, J = 8.5 
Hz, 1 H), 8.15-8.06 (m, 3 H), 8.02 (s, 1 H), 7.78 (t, J = 7.75 Hz, 1 H), 7.53 (t, J = 7.75 
Hz, 1 H), 7.40-7.27(m, 13 H), 7.23-7.16(m,4H), 7.08 (t, J=7.0Hz, 1 H), 7.00(t, J =  
7.5Hz,2H),6.89(d, J=7.5Hz,2H),5.56(~,  1 H),4.67(d, J =  12.0Hz, 1 H),4.58(d, J 
= 12.0 Hz, 1 H), 4.55-4.39 (m, 3 H), 4.33-4.27 (m, 2 H), 4.27-4.21 (m, 1 H), 4.13-4.03 
(m, 2 H), 3.75-3.71 (m, 1 H), 3.67-3.64 (m, 1 H), 3.58-3.55 (m, 1 H), 2.55 (br s, 1 H); 13C 
NMR(126MHz, CDC13): 6 165.2, 163.2, 155.8, 138.2, 137.6, 137.1, 130.7, 129.9, 128.8, 
128.7, 128.7, 128.6, 128.3, 128.2, 128.2, 128.1, 128.0, 127.9, 127.0, 125.5, 123.6, 118.2, 
116.1, 115.9, 80.5, 78.0, 77.3, 75.4, 74.4, 73.6, 71.8, 71.6, 69.5; IR(NaC1): 3549, 2915, 
2360, 1725, 1503, 1080,697 cm-'; HRMS calcd for c ~ & I ~ ~ F N o ~ +  [M+H+]: 734.3276, 
found 734.3306; [a]220 -6.6' (c 1.0, CHCl,). 
Isolated in 45% yield as a colorless oil: lH NMR (500 MHz, CDC13): 6 8.25-8.21 (m, 1 
H),8.18(s, 1 H),8.14-8.10(m,2H),7.67(brs, 1 H),7.55-7.49(m,4H),7.40-7.27(m, 
13 H), 7.19(d, J=7 .0  Hz, 2 H), 7.07(t, J=6.75 Hz, 1 H), 7.00(t, J=7 .5  Hz,2H), 6.91 
(d, J=7.0 Hz,2H), 5.36(s, 1 H),4.65 (d, J =  12.0Hz, 1 H),4.56(d, J =  12.0Hz, 1 H), 
4.51(d,J=12.0Hz,lH),4.47-4.42(m,2H),4.28-4.21(m,3H),4.07(d,J=7.5Hz,l 
H), 4.00 (d, J = 9.0 Hz, 1 H), 3.81 (d, J = 10.5 Hz, 1 H), 3.66-3.62 (m, 1 H), 3.57-3.53 
(m, 1 H), 2.58-2.54 (m, 1 H); "C NMR (126 MHz, CDC13): 6 156.4, 146.1, 144.7, 139.4, 
138.2, 138.1, 137.5, 137.0, 133.4, 133.4, 129.7, 129.1, 128.8, 128.8, 128.7, 128.4, 128.2, 
128.1, 128.0, 128.0, 127.7, 119.9, 119.6, 119.1, 82.2, 80.3, 77.9, 75.4, 74.3, 73.5, 71.7, 
71.6, 69.4; IR (NaCI): 3543, 2913,2360, 1724, 1524, 1073,697 cm-'; HRMS calcd for 
c ~ ~ H ~ ~ F N ~ ~ +  [M+H+]: 734.3276, found 734.3307; [a]220 -5.4" (c 1.0, CHCl3). 
Open-ring glvcosvlidene-based quinolines (debenzvlated) 
General procedure for the preparation of compounds 93a, 93b, l l l a ,  l l l b ,  & 116a. 
To a solution of perbenzylated intermediate (70 mg; 0.098 mmol) in dichoromethane (2.0 
mL) at -78 "C was added BC13 (1 M in hexane; 0.39 mL; 0.39 mmol). The reaction was 
stirred at -78 OC under an atmosphere of nitrogen. After one hour, additional BC13 (1 M 
in hexane; 0.195 mL; 0.195 mmol) was introduced, and the reaction was maintained at 
-78 "C for one hour. The reaction was quenched with the addition of methanol (2.0 mL). 
The crude material was concentrated in vacuo. The residue was coevaporated twice with 
methanol, and then purified with a Waters mass directed reverse phase prep HPLC 
system. The following chromatographic conditions were used: (a) column: Waters 
Xbridge C-18,30 x 75 mm, 5 micron; (b) flowrate: 50 mllmin; (c) mobile phase: A = 
water + ammonium hydroxide @H lo), B = acetonitrile; (d) mobile phase method: time 
= 0 min, A = 98, B = 2; time = 1 l min, A = 65, B = 35; time = 11.2 min, A = 0, B = 100; 
time = 14.2 min, A = 98, B = 2; time = 15 min, A = 98, B = 2. The resulting fractions 
that contained the desired compound were lyophilized. 
(lR)-lC-(2-Phenylquinolin-4-yl)-D-arabinitoI (93a) 
Isolated in 69% yield as a white solid: 'H NMR (500 MHz, CD3OD): 6 8.34 (d, J = 8.0 
Hz, 1 H), 8.21 (s, 1 H), 8.17-8.13 (m,3 H),7.77(t, J=7.75 Hz, 1 H), 7.61 (t, J=7.75 
Hz, 1 H), 7.56 (t, J = 7.5 Hz, 2 H), 7.53-7.48 (m, 1 H), 5.73 (d, J = 5.0 Hz, 1 H),4.24 (dd, 
J = 5.0, 2.0 Hz, 1 H), 3.78-3.72 (m, 2 H), 3.60-3.55 (m, 1 H), 3.52 (dd, J = 8.0, 1.5 Hz, 1 
H);"CNMR(126MHz,CD30D): 6 157.6, 150.0, 148.1, 139.7, 129.6, 129.5, 129.1, 
128.7, 127.7, 126.4, 125.3, 123.8, 118.2, 72.9, 72.5, 71.9, 71.7, 63.6; IR(NaC1): 3631, 
2822, 1794, 1599, 1554, 1415, 1027,697 cm-'; HRMS calcd for c ~ o H ~ N O ~ '  [M+H+]: 
356.1492, found 356.1496; [a]220 +22.3' (c 1.0, CH30H); mp 178-180 OC. 
(1R)-lC-[2-(4-Fluorophenyl)quinolin-4-yl]-D-arabinitol(93b) 
Isolated in 63% yield as a white solid: 'H NMR (CD30D): 6 8.32 (d, J = 8.5 Hz, 1 H), 
8.23-8.17(m,3H),8.13(d,J=8.5Hz,l H),7.76(t,J=7.25Hz, 1 H),7.60(t,J=7.5 
Hz, 1 H), 7.29(t, J=8.75 Hz,2 H), 5.72 (d, J=5.0Hz, 1 H),4.24 (dd, J=5.0,2.0 Hz, 1 
H), 3.78-3.72 (m, 2 H), 3.58 (dd, J = 8.0,2.0 Hz, 1 H), 3.53-3.50 (m, 1 H); I3C NMR (126 
MHz, CD30D): 6 156.4, 149.7, 148.3, 129.8, 129.7, 129.6, 129.3, 126.4, 125.2, 123.8, 
117.8, 115.5, 115.3, 72.9, 72.4, 71.9, 71.6,63.6; IR (NaCI): 3630,2820, 1793, 1598, 
1554, 1503, 1412, 1027,697 cm-'; HRMS calcd for c ~ ~ H ~ ~ F N ~ ~ +  [M+H+]: 374.1404, 
found 374.1417; [alZ2D +22.0° (c 0.5, CH30H); mp 188-189 "C. 
(1S,2S~R)-1-(2-Phenyl)quinolin-4-yl)-butane-l,2,4-tetrol ( l l l a )  
Isolated in 64% yield as a white solid: IH NMR (500 MHz, CD30D): 6 8.28 (s, 1 H), 
8.18(d,J=8.50Hz,1H),8.15(d,J=8.5Hz,3H),7.76(t,J=7.25Hz,1H),7.60(t,J= 
7.25 Hz, 1 H), 7.56 (t, J = 7.5 Hz, 2 H), 7.50 (t, J = 7.25 Hz, 1 H), 5.99 (s, 1 H), 4.00-3.95 
(m,lH),3.88(dd,J=11.5,3.5Hz,1H),3.78(d,J=9.0Hz,1H),3.70(dd,J=11.5,5.5 
Hz, 1 H); 13CNMR(126 MHz, CD30D): 6 157.6, 150.8, 148.0, 140.0, 129.3, 129.3, 
128.7, 127.7, 126.3, 124.8, 123.1, 117.7, 73.8, 72.0,67.6, 64.0; IR(NaC1): 3632,2821, 
1794,1599,1553,1505,1415,1027,697 cm-'; HRMS calcd for C19H20N04+ [M+H+]: 
326.1392, found 326.1402; [alZ2o -16.6' (c 0.5, CH30H); mp 175-176 OC. 
(1S,2S,3R)-1-[2-(4-Fluorophenyl)quinoli~)-butane-1,2,3,4-tetro ( l l l b )  
Isolated in 48% yield as a white solid: 'H NMR (500 MHz, CD30D): 6 8.25 (s, 1 H), 
8.23-8.10 (m, 4 H), 7.75 (t, J = 7.0 Hz, 1 H), 7.59 (t, J = 7.25 Hz, 1 H), 7.29 (t, J = 8.75 
Hz, 2 H), 5.98 (s, 1 H), 4.00-3.95 (m, 1 H), 3.88 (dd, J =  11.5,3.5 Hz, 1 H), 3.77 (d, J =  
9.0 Hz, 1 H), 3.69 (dd, J = 1 1.25, 5.75 Hz, 1 H); "C NMR (126 MHz, CD3OD): 6 156.3, 
151.0, 148.1, 136.3, 129.8, 129.7, 129.4, 129.3, 126.3, 123.1, 117.3, 115.5, 115.3, 73.8, 
72.0,67.5,64.0; IR (NaCI): 3632,2822, 1793, 1599, 1553, 1505, 1414, 1025,697 cm-I; 
HRMS calcd for C ~ ~ H $ N O ~ +  [M+H+]: 344.1298, found 344.1308; [a]220 -13.4" (c 0.5, 
CH30H); mp 185-187 OC. 
(5R)-5-C-(2-Phenylquinolin-4-yl)-D-arabinito (116a) 
Isolated in 60% yield as a white solid: 'H NMR (500 MHz, CD30D): 6 8.29 (s, 1 H), 
8.20(d, J=8.0Hz, 1 H),8.17-8.14(m,3H),7.76(t,J=8.25Hz, 1 H),7.62-7.54(m,3 
H), 7.52-7.48(m, 1 H),6.01 (s, 1 H),4.01-3.92(m,3H),3.74-3.70(m,2H);13CNMR 
(126MHz, CD30D): 6 157.6, 151.2, 148.0, 140.0, 129.3, 129.2, 128.7, 127.8, 126.3, 
124.8, 123.2, 117.7, 115.3,72.9,70.7,70.6,67.5,64.0;IR(NaCl): 3630,2823, 1795, 
1599, 1555, 1415, 1027,697 cm-I; HRMS calcd for C 2 0 ~ 2 2 ~ O s +  [M+H+]: 356.1492, 
found 356.1506; [a]221, -4.8' (c 0.5, CH30H); mp 158-162 OC. 
Procedure for the preparation of 2,6-Anhydro-1,3,4,5-tetra-O-benzyl-7,8,9-tndeoxyl- 
D-glycero-L-gulo-non-8-enitol(118). 
To a solution of methyl-2,3,4,6-tetra-O-benzyl-alpha-D-glucopyranoside (200 mg; 0.361 
mmol) in acetonititrile (5 mL) was added ally1 trimethylsilane (61.8 mg; 0.542 mmol) 
and trimethylsilyl trifluoromethanesulfonate (41 mg; 0.181 mmol) at room temperature 
under an atomosphere of nitrogen. The reaction was stirred overnight and quenched with 
the addition of saturated aqueous bicarbonate solution (1 mL). The mixture was 
extracted three times with ethyl acetate, and the combined organics were washed with 
brine, dried (Na2S04), and concentrated in vacuo. The crude material was purified over 
silica gel, eluting with a gradient of 5% to 100% ethyl acetate in hexane to give the olefin 
as a colorless oil (128 mg; 63% yield). The ratio of a$ anomers was -10: 1. 'H and 13c 
NMR data were consistent with literature  value^.'^' 
The NCI60 human humor cell line anticancer drug screenl2' 
The human tumor cell lines of the cancer screening panel are grown in RPMI 1640 
medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical 
screening experiment, cells are inoculated into 96 well microtiter plates in 100 pL at 
plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling time 
of individual cell lines. After cell inoculation, the microtiter plates are incubated at 37 "C, 
5% C02, 95% air and 100% relative humidity for 24 hours prior to addition of 
experimental drugs. After 24 hours, two plates of each cell line are fixed in siru with 
trichloroacetic acid (TCA), to represent a measurement of the cell population for each 
cell line at the time of drug addition (Tz). Experimental drugs are solubilized in dimethyl 
sulfoxide at 400-fold the desired final maximum test concentration (10 pM) and stored 
frozen prior to use. At the time of drug addition, an aliquot of frozen concentrate is 
thawed and diluted to twice the desired final maximum test concentration with complete 
medium containing 50 pg/mL gentamycin. Aliquots of 100 pL of this different drug 
dilution are added to the appropriate microtiter wells already containing 100 pL of 
medium, resulting in the required final drug concentrations. Following drug addition, the 
plates are incubated for an additional 48 hours at 37 "C, 5% C02, 95% air, and 100% 
relative humidity. For adherent cells, the assay is terminated by the addition of cold TCA. 
Cells are fixed in situ by the gentle addition of 50 pL of cold 50 % (wlv) TCA (final 
concentration, 10% TCA) and incubated for 60 minutes at 4 OC. The supernatant is 
discarded, and the plates are washed five times with tap water and air dried. 
Sulforhodamine B (SRB) solution (100 pL) at 0.4% (wlv) in 1 % acetic acid is added to 
each well, and plates are incubated for 10 minutes at room temperature. After staining, 
unbound dye is removed by washing five times with 1% acetic acid and the plates are air 
dried. Bound stain is subsequently solubilized with 10 mM trizma base, and the 
absorbance is read on an automated plate reader at a wavelength of 5 15 nm. For 
suspension cells, the methodology is the same except that the assay is terminated by 
fixing settled cells at the bottom of the wells by gently adding 50 pL of 80% TCA (final 
concentration, 16% TCA). Using the seven absorbance measurements [time zero, (Tz), 
control growth, (C), and test growth in the presence of drug at concentration level (Ti)], 
the percentage growth is calculated. 
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5.4. Appendix 
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